Symbol,Price,Name,Therapeutic_Area_Filter,Therapeutic_Areas,Highest_Phase,Has_Marketed_Drug,Pipeline_Count,Total_Active_Trials,All_NCTIds,Country,52W Low,52W High,Wall Street Ratings,Market Cap,EV,Shares Outstanding,Institutional Shares,Insider %,Total Debt,Total Cash,Industry,Business Summary
NVO,38.16,Novo Nordisk A/S,Cardiovascular,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
CSLLY,51.79,CSL Limited,Cardiovascular,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
UTHR,535.1,United Therapeutics Corporation,Cardiovascular,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Cardiovascular,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Cardiovascular,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
TGRNF,0.55,Tong Ren Tang Technologies Co. Ltd.,Cardiovascular,"Cardiovascular, Hematology, Metabolic/Endocrinology, Others",PHASE4,Yes,13,16,"NCT04307511, NCT04731155, NCT04967833, NCT05292404, NCT05736965, NCT05736978, NCT06064669",China,0.55,0.7,-,720322400,745837600,1280784000,113980721,0.027898537145998083,337102700,718518683.9570625,Drug Manufacturers - General,"Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China."
ILPLF,-,Island Pharmaceuticals Limited,Cardiovascular,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
INSM,148.61,Insmed Incorporated,Cardiovascular,"Cardiovascular, Dermatology, Respiratory",PHASE3,Yes,3,5,"NCT05649722, NCT05649748, NCT06685835, NCT07179380, NCT07234032",United States,60.4,212.75,4.8,34190842000,33510330000,215551900,194243386,0.006452118253281625,749536000,1430047000,Biotechnology,"Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey."
ARWR,61.615,"Arrowhead Pharmaceuticals, Inc.",Cardiovascular,"Cardiovascular, Metabolic/Endocrinology, Neurology/CNS, Respiratory, Urology/Nephrology",PHASE3,Yes,17,21,"NCT05089084, NCT05217667, NCT06131983, NCT06138743, NCT06209177, NCT06347003, NCT06347016, NCT06347133, NCT06672445, NCT06700538, NCT06822790, NCT06880770, NCT06937203, NCT07037771, NCT07221344, NCT07223658, NCT07241546",United States,9.57,76.76,4.33,8915849000,8693578000,140032200,105803368,0.03328908874452367,698163000,914710000,Biotechnology,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California."
CYTK,62.89,"Cytokinetics, Incorporated",Cardiovascular,Cardiovascular,PHASE3,No,5,6,"NCT06081894, NCT06412666, NCT06736574, NCT06793371",United States,29.31,70.98,4.35,8570771500,8972794000,122264930,139217950,0.0038797894318273792,1350253000,882221000,Biotechnology,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California."
NAMS,35.01,NewAmsterdam Pharma Company N.V.,Cardiovascular,"Cardiovascular, Metabolic/Endocrinology",PHASE3,No,3,7,"NCT05202509, NCT05972278, NCT06305559, NCT06496243, NCT06982508, NCT07219602",Netherlands,14.06,42,4.69,4140265000,3411617000,114975420,78947412,0.009102299335461366,202000,636241000,Biotechnology,"NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands."
KNSA,42.76,"Kiniksa Pharmaceuticals International, plc",Cardiovascular,"Cardiovascular, Others",PHASE3,No,1,2,"NCT07010159, NCT07288216",Bermuda,18.255,49.12,4.87,3297115400,2954731500,75795760,40652479,0.04582797389919846,9718000,414074000,Drug Manufacturers - Specialty & Generic,"Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom."
LQDA,30,Liquidia Corporation,Cardiovascular,"Cardiovascular, Respiratory",PHASE3,Yes,3,3,"NCT03992755, NCT06129240, NCT07285655",United States,11.26,46.67,4.37,2920438300,2962124300,86995480,49336935,0.09368697912741056,199182000,157496000,Biotechnology,"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina."
MLYS,29.23,"Mineralys Therapeutics, Inc.",Cardiovascular,Cardiovascular,PHASE3,No,1,1,NCT05968430,United States,8.685,47.65,4.77,2371033000,1777405000,79139950,69986237,0.007538709080704681,-,593628000,Biotechnology,"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania."
PHVS,27.63,Pharvaris N.V.,Cardiovascular,"Cardiovascular, Immunology/Autoimmune",PHASE3,Yes,2,4,"NCT05834777, NCT06669754, NCT06679881, NCT07266805",Netherlands,11.51,29.797,4.63,1815616800,1429946200,64959456,34755816,0.051404208254619145,679334.4,386576225.6398215,Biotechnology,"Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland."
GNIIF,15.5,GNI Group Ltd.,Cardiovascular,"Cardiovascular, Gastroenterology, Immunology/Autoimmune, Respiratory, Urology/Nephrology",PHASE3,Yes,20,25,"NCT05288179, NCT05689645, NCT05704166, NCT05905172, NCT06899815, NCT07262333, NCT07262346, NCT07263152, NCT07295873, NCT07343778, NCT07364448, NCT07388680, NCT07394309, NCT07412236, NCT07417553",Japan,12.02,19.88,-,1027117600,935934400,55671490,4905922,0.030491587740266182,34252916,134719624.079832,Biotechnology,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan."
LXRX,1.5,"Lexicon Pharmaceuticals, Inc.",Cardiovascular,"Cardiovascular, Hematology, Metabolic/Endocrinology",PHASE3,Yes,8,11,"NCT05696366, NCT06217302, NCT06435156, NCT06481891, NCT06933056, NCT07211802",United States,0.2836,1.83,4,632085200,581085200,427084580,92348930,0.01057365765220919,64950000,115950000,Biotechnology,"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas."
HUMA,1.16,"Humacyte, Inc.",Cardiovascular,"Cardiovascular, Urology/Nephrology",PHASE3,No,2,2,"NCT03005418, NCT05908084",United States,0.88,3.94,4.57,216156100,247639090,192996510,56679688,0.0490037822497216,50971000,19488000,Biotechnology,"Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina."
MIST,1.73,Milestone Pharmaceuticals Inc.,Cardiovascular,Cardiovascular,PHASE3,No,2,2,"NCT05763953, NCT06716021",Canada,0.6254,3.06,4.4,176753150,151376140,101582270,31349821,0.01143723222012298,57208000,82585000,Biotechnology,"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada."
CRDL,1.03,Cardiol Therapeutics Inc.,Cardiovascular,Cardiovascular,PHASE3,No,1,1,NCT06708299,Canada,0.7709,1.59,4.6,110911576,102527980,110937490,9460983,0.0307818771155834,96445.44,8352731.323439578,Drug Manufacturers - Specialty & Generic,"Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada."
GOSS,0.3801,"Gossamer Bio, Inc.",Cardiovascular,"Cardiovascular, Respiratory",PHASE3,No,2,3,"NCT04816604, NCT06274801, NCT07181382",United States,0.3312,3.87,3.75,96146930,118798930,231456240,153406014,0.03628875482457814,202876000,180224000,Biotechnology,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California."
GRCE,4.07,"Grace Therapeutics, Inc.",Cardiovascular,"Cardiovascular, Neurology/CNS",PHASE3,Yes,2,2,NCT05995405,United States,1.75,4.3,5,63752988,45080988,15474026,2242219,0.16528775381403651,-,18672000,Biotechnology,"Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey."
EWTX,30.12,"Edgewise Therapeutics, Inc.",Cardiovascular,"Cardiovascular, Musculoskeletal, Others",PHASE2,No,9,14,"NCT05291091, NCT05540860, NCT06100887, NCT06347159, NCT07034768, NCT07177066, NCT07324616",United States,10.6,31.82,4.41,3272393200,2713234200,105868430,79285500,0.004863210621796405,4181000,563340000,Biotechnology,"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado."
TECX,23.11,"Tectonic Therapeutic, Inc.",Cardiovascular,Cardiovascular,PHASE2,No,2,2,NCT06616974,United States,13.7,27.33,4.77,399592580,132395576,18716280,14505113,0.3130240903358943,1238000,268435000,Biotechnology,"Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts."
HRTDF,-,Heartseed Inc.,Cardiovascular,Cardiovascular,PHASE2,No,1,1,NCT04945018,Japan,-,-,-,275675620,228594640,22858200,899111,0.318205283005661,5775.208,47629627.46663032,,
CRVO,4.39,CervoMed Inc.,Cardiovascular,"Cardiovascular, Neurology/CNS",PHASE2,No,2,3,"NCT06815965, NCT06987643, NCT07033481",United States,1.92,16.94,5,44320524,17026436,9252719,1441459,0.3206030573283378,-,27294088,Biotechnology,"CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts."
IGC,0.2901,"IGC Pharma, Inc.",Cardiovascular,"Cardiovascular, Neurology/CNS",PHASE2,No,2,2,NCT05543681,United States,0.242,0.4985,5,26723646,25739646,95818024,18673942,0.08864803023539736,146000,1130000,Biotechnology,"IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland."
ESPR,3.33,"Esperion Therapeutics, Inc.",Cardiovascular,"Cardiovascular, Metabolic/Endocrinology",,No,2,2,NCT05103254,United States,0.6925,4.175,4,776919740,1285457700,235430220,141484121,0.008996413912646,600985000,92447000,Drug Manufacturers - Specialty & Generic,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan."
UCBJY,159.42,UCB SA,Dermatology,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
CSLLY,99.483,CSL Limited,Dermatology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,98.374,184.09,-,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
GALDY,37.97,Galderma Group AG,Dermatology,"Dermatology, Hematology, Immunology/Autoimmune",PHASE4,Yes,6,8,"NCT03989206, NCT04204616, NCT07047690, NCT07074977, NCT07186413, NCT07225348, NCT07398989",Switzerland,17.27,42.93,5,44206682000,46662803000,237406140,74821471,0,2848000000,458000000,Drug Manufacturers - Specialty & Generic,"Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland."
CONI.F,-,"Celltrion, Inc.",Dermatology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
EOLS,4.5,"Evolus, Inc.",Dermatology,"Dermatology, Musculoskeletal",PHASE4,Yes,2,2,"NCT05481931, NCT06903975",United States,4.0913,14.94,4.57,278725060,390094080,64819784,43325160,0.122150499606725,154892000,43523000,Drug Manufacturers - Specialty & Generic,"Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California."
ILPLF,-,Island Pharmaceuticals Limited,Dermatology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
HLN,10.44,Haleon plc,Dermatology,"Dermatology, Others, Pain/Analgesia",PHASE3,Yes,16,16,"NCT07215767, NCT07255040, NCT07273539, NCT07297732, NCT07345130, NCT07352956",United Kingdom,8.71,11.42,4,48773566000,59471802000,8906796000,8238496414,0.0005333885179778298,11728615000,927857691.8853629,Drug Manufacturers - Specialty & Generic,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom."
INSM,148.61,Insmed Incorporated,Dermatology,"Cardiovascular, Dermatology, Respiratory",PHASE3,Yes,3,5,"NCT05649722, NCT05649748, NCT06685835, NCT07179380, NCT07234032",United States,60.4,212.75,4.8,34190842000,33510330000,215551900,194243386,0.006452118253281625,749536000,1430047000,Biotechnology,"Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey."
ALMS,29.39,Alumis Inc.,Dermatology,"Dermatology, Immunology/Autoimmune",PHASE3,Yes,4,9,"NCT05739435, NCT05966480, NCT06586112, NCT06588738, NCT06846541, NCT06952634",United States,2.7601,30.6,4.9,3500358400,3160431400,124656640,51450693,0.005333257862022095,37797000,377724000,Biotechnology,"Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California."
BCRX,7.55,"BioCryst Pharmaceuticals, Inc.",Dermatology,"Dermatology, Immunology/Autoimmune, Metabolic/Endocrinology, Ophthalmology, Rare/Orphan Diseases",PHASE3,Yes,3,3,"NCT05453968, NCT06539507, NCT07228559",United States,6,11.31,4.7,1886086900,2356322800,247843230,179610448,0.009866350027790148,683109000,212873000,Drug Manufacturers - Specialty & Generic,"BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina."
CLDX,30.82,"Celldex Therapeutics, Inc.",Dermatology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
MANE,42.17,"Veradermics, Incorporated",Dermatology,Dermatology,PHASE3,No,3,5,"NCT06527365, NCT06724614, NCT06972264, NCT07146022",United States,32,51.56,-,1635063000,1731508000,37338732,1399062,0.03708821812931993,16000,15139000,Biotechnology,"Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut."
PVLA,128.6,"Palvella Therapeutics, Inc.",Dermatology,"Dermatology, Rare/Orphan Diseases",PHASE3,No,3,3,"NCT05643872, NCT06239480, NCT06653842",United States,18.225,129.32,5,1425231700,1377685800,11836490,8028039,0.1518170480970827,16021000,63567000,Biotechnology,"Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania"
MLTX,18.22,MoonLake Immunotherapeutics,Dermatology,"Dermatology, Immunology/Autoimmune, Musculoskeletal",PHASE3,No,2,6,"NCT06411379, NCT06411899, NCT06641076, NCT06641089, NCT06768671",Switzerland,5.95,62.75,3.81,1298999200,996531140,71373576,29553819,0.1055596497409777,75726000,393968000,Biotechnology,"MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland."
CLVLY,8.24,Clinuvel Pharmaceuticals Limited,Dermatology,Dermatology,PHASE3,No,1,1,NCT06109649,Australia,6,9,-,397692800,239832580,50200740,10643167,0.10259464302717451,347853.1,147496341.9770962,Biotechnology,"Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia."
ABEO,5.3,Abeona Therapeutics Inc.,Dermatology,"Dermatology, Rare/Orphan Diseases",PHASE3,No,5,5,"NCT02716246, NCT05725018",United States,3.9328,7.5401,5,292633340,109623350,54191360,34047878,0.12225254870421139,24107000,207117000,Biotechnology,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio."
APGE,70.89,"Apogee Therapeutics, Inc.",Dermatology,"Dermatology, Respiratory",PHASE2,Yes,3,6,"NCT06395948, NCT06920901, NCT07003425, NCT07027527",United States,26.2,84.56,4.75,4809886700,4230811000,67488240,59986671,0.01941189456261128,9853000,527289000,Biotechnology,"Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts."
ARQT,27.01,"Arcutis Biotherapeutics, Inc.",Dermatology,Dermatology,PHASE2,No,3,3,"NCT07077902, NCT07105254, NCT07340216",United States,11.86,31.77,4.5,3304839400,3227545300,122492190,102645885,0.01452951650828932,113774000,191068000,Biotechnology,"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California."
ORKA,35.28,"Oruka Therapeutics, Inc.",Dermatology,"Dermatology, Others",PHASE2,No,4,5,"NCT06698939, NCT06944379, NCT07090330, NCT07290569",United States,5.485,36.53,4.84,1721432300,1225357300,48409230,44776071,0.024656947123451508,1912000,349155000,Biotechnology,"Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California."
EVMN,29.86,"Evommune, Inc.",Dermatology,"Dermatology, Immunology/Autoimmune",PHASE2,No,3,5,"NCT06645821, NCT06873516, NCT07150845",United States,13.885,33.2,4.87,878891700,1060598700,31524092,14651548,0.171078525039693,765000,76062000,Biotechnology,"Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California."
FBRX,28.44,"Forte Biosciences, Inc.",Dermatology,"Dermatology, Immunology/Autoimmune",PHASE2,No,1,3,"NCT06905873, NCT06982963, NCT07205159",United States,4.9,35.62,5,508196220,414782200,17831446,11353422,0.02460153820391235,-,93414000,Biotechnology,"Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas."
ZURA,7,Zura Bio Limited,Dermatology,"Dermatology, Immunology/Autoimmune",PHASE2,No,3,3,"NCT06843239, NCT06993610",United States,0.97,7.19,4.83,492923940,364107940,73680710,30852662,0.060054755682802996,-,139017000,Biotechnology,"Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada."
AVTX,16.855,"Avalo Therapeutics, Inc.",Dermatology,Dermatology,PHASE2,No,2,2,NCT06603077,United States,3.39,20.7199,4.9,299906660,188844660,18512756,15244333,0.03033379407969648,555000,111617000,Biotechnology,"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland."
QTTB,4.73,Q32 Bio Inc.,Dermatology,"Dermatology, Immunology/Autoimmune",PHASE2,Yes,2,2,"NCT05509023, NCT06018428",United States,1.345,6.3699,4,62869640,30855640,13971031,2138676,0.005808447493960897,17025000,49039000,Biotechnology,"Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb  CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts."
FYBGF,-,Formycon AG,Dermatology,"Dermatology, Oncology/Hematology",PHASE1,Yes,2,2,NCT06551064,Germany,-,-,-,432717100,350747940,17664428,486624,0.1423897305018725,11622447,93331768.02066213,,
NVO,38.16,Novo Nordisk A/S,Gastroenterology,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
CSLLY,51.79,CSL Limited,Gastroenterology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
CONI.F,-,"Celltrion, Inc.",Gastroenterology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
MIRM,108.62,"Mirum Pharmaceuticals, Inc.",Gastroenterology,"Gastroenterology, Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE4,Yes,9,11,"NCT03115086, NCT04663308, NCT05050136, NCT06193928, NCT06553768, NCT07209462, NCT07290257, NCT07389031",United States,36.8801,109.28,4.72,6435898000,6379114000,59879960,54815602,0.01165946746085052,318764000,375548000,Biotechnology,"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California."
ARDX,6.56,"Ardelyx, Inc.",Gastroenterology,"Gastroenterology, Neurology/CNS",PHASE4,Yes,5,9,"NCT05643534, NCT05995899, NCT06460038, NCT06553547, NCT06810167, NCT07382167",United States,3.21,8.4,4.9,1608823200,1577964200,245247420,155639011,0.03894313231673578,233830000,264689000,Biotechnology,"Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Gastroenterology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
PHAT,12.32,"Phathom Pharmaceuticals, Inc.",Gastroenterology,Gastroenterology,PHASE4,Yes,5,6,"NCT06660342, NCT06851559, NCT07224035, NCT07224048",United States,2.21,18.31,4.54,909002100,1356981100,78294750,42881144,0.03703767848768824,583135000,135156000,Biotechnology,"Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey."
HITI,2.57,High Tide Inc.,Gastroenterology,"Gastroenterology, Neurology/CNS, Pain/Analgesia, Urology/Nephrology",PHASE4,Yes,9,10,"NCT04793932, NCT05226117, NCT05487417, NCT06222645, NCT06845306, NCT07412522, NCT07420712",Canada,1.64,4.0554,5,224996690,281240480,87839736,11283642,0.08707990751565906,78315210,34185590.53153186,Pharmaceutical Retailers,"High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products. The company also engages in data analytics; advertising; product sourcing and imports; event-based cannabis retail; medical cannabis distribution; accessories retail; and other related services. It provides its products under the Daily High Club, DankStop, FAB CBD, GC, Nuleaf Naturals, Smoke Cartel, Blessed CBD, Fastendr, Famous Brandz, Queen of Bud, Canna Cabana, Grasscity, Daily High Club, and Valiant Distribution brands. The company sells its products through a network of retail stores, e-commerce platforms, and the wholesale distribution arm. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. The company was founded in 2009 and is headquartered in Calgary, Canada."
ILPLF,-,Island Pharmaceuticals Limited,Gastroenterology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Gastroenterology,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
HLN,5.03,Haleon plc,Gastroenterology,"Dermatology, Gastroenterology, Others, Pain/Analgesia",PHASE3,Yes,16,16,"NCT07215767, NCT07255040, NCT07273539, NCT07297732, NCT07345130, NCT07352956",United Kingdom,4.25,5.8,-,48773566000,59471802000,8906796000,8238496414,0.0005333885179778298,11728615000,927857691.8853629,Drug Manufacturers - Specialty & Generic,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom."
MDGL,435.01,"Madrigal Pharmaceuticals, Inc.",Gastroenterology,"Gastroenterology, Metabolic/Endocrinology",PHASE3,No,2,4,"NCT03900429, NCT04951219, NCT05500222, NCT07335601",United States,265,615,4.56,10093586000,9457658000,22939968,16123164,0.07344268154238724,347630000,983559000,Biotechnology,"Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania."
PTCT,67.76,"PTC Therapeutics, Inc.",Gastroenterology,"Gastroenterology, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,5,5,"NCT03605550, NCT04014530, NCT05166161, NCT05515536, NCT06302348",United States,35.95,87.5,4,5709801000,6471493600,82774730,88379259,0.02122564899703586,2707064000,1945371000,Biotechnology,"PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey."
ZLDPF,57.08,Zealand Pharma A/S,Gastroenterology,"Gastroenterology, Metabolic/Endocrinology, Oncology, Others, Urology/Nephrology",PHASE3,Yes,10,14,"NCT02446405, NCT03905707, NCT03941236, NCT04419402, NCT04881825, NCT05788601, NCT06662539, NCT06682975, NCT06926842, NCT07197944, NCT07338214",Denmark,49.98,101.2925,-,4063842000,1746636300,70607140,26243554,0.003573958667636162,63846624,2377340630.084307,Biotechnology,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark."
PBH,69.38,Prestige Consumer Healthcare Inc.,Gastroenterology,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,9,"NCT03390686, NCT05108259, NCT05141149",United States,57.25,90.04,4.57,3255055400,4271972400,47318730,52198761,0.01049667581388105,1079290000,62373000,Drug Manufacturers - Specialty & Generic,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York."
YIHCF,0.55,"Sunshine Lake Pharma Co., Ltd.",Gastroenterology,"Gastroenterology, Hematology, Oncology, Others, Respiratory",PHASE3,Yes,22,23,"NCT04415853, NCT05048368, NCT05133882, NCT05139719, NCT05451602, NCT05586074, NCT07082842, NCT07099118, NCT07102251, NCT07341672, NCT07376200",China,0.55,0.55,-,3182218000,3294738200,576032260,16305667,5.9675478550075e-05,306183700,-,,
IRON,66.89,"Disc Medicine, Inc.",Gastroenterology,"Gastroenterology, Hematology, Rare/Orphan Diseases",PHASE3,No,3,6,"NCT05320198, NCT05745883, NCT06910358, NCT06985147, NCT07187973, NCT07368972",United States,30.82,99.5,4.92,2499060700,1914117800,37750160,37364585,0.01137007426023246,30977000,615920000,Biotechnology,"Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts."
CLDX,30.82,"Celldex Therapeutics, Inc.",Gastroenterology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
VIR,10,"Vir Biotechnology, Inc.",Gastroenterology,"Gastroenterology, Infectious Diseases, Oncology",PHASE3,Yes,17,30,"NCT04856085, NCT05356741, NCT05461170, NCT05484206, NCT05970289, NCT05997615, NCT06070051, NCT06491563, NCT06903338, NCT06960395, NCT07128550, NCT07142811",United States,4.155,10.94,4.6,1324019000,954855940,139517280,81306024,0.04384297119099471,97852000,467015000,Biotechnology,"Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California."
IVA,6.82,Inventiva S.A.,Gastroenterology,Gastroenterology,PHASE3,No,1,1,NCT04849728,France,2.67,7.9825,4.83,1286896400,1299009300,191032130,99992370,0.052710516897147626,156416960,144302709.0694935,Biotechnology,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France."
GNIIF,15.5,GNI Group Ltd.,Gastroenterology,"Cardiovascular, Gastroenterology, Immunology/Autoimmune, Respiratory, Urology/Nephrology",PHASE3,Yes,20,25,"NCT05288179, NCT05689645, NCT05704166, NCT05905172, NCT06899815, NCT07262333, NCT07262346, NCT07263152, NCT07295873, NCT07343778, NCT07364448, NCT07388680, NCT07394309, NCT07412236, NCT07417553",Japan,12.02,19.88,-,1027117600,935934400,55671490,4905922,0.030491587740266182,34252916,134719624.079832,Biotechnology,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan."
AMRN,14.05,Amarin Corporation plc,Gastroenterology,Gastroenterology,PHASE3,No,1,1,NCT03428477,Ireland,7.08,20.9,2,322702460,45147456,20792684,3052471,0.03675720748701803,9032000,302589000,Drug Manufacturers - General,"Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland."
ORPOF,-,OSE Immunotherapeutics SA,Gastroenterology,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,11,"NCT03806309, NCT04713514, NCT05751798, NCT06472245",France,-,-,-,112222850,121470290,22420804,710501,0.2413535999264969,41892624,32667998.12030075,,
CANSF,0.119,Atlas Energy Corp.,Gastroenterology,"Gastroenterology, Rare/Orphan Diseases",PHASE3,Yes,2,2,"NCT06226857, NCT07024316",Canada,0.0135,0.25,-,71197310,50688964,629439360,84209695,0.09432068653273307,-,20196916.88526357,Oil & Gas Midstream,"Atlas Energy Corp., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. The company was formerly known as Willow Biosciences Inc. and changed its name to Atlas Energy Corp. in June 2025. Atlas Energy Corp. was founded in 2019 and is headquartered in Calgary, Canada."
ANAB,55.11,"AnaptysBio, Inc.",Gastroenterology,"Gastroenterology, Immunology/Autoimmune",PHASE2,No,1,2,"NCT06041269, NCT06127043",United States,13.99,57.74,4.61,1534218100,1631712100,27688470,18996108,0.027726702289865002,346450000,248956000,Biotechnology,"AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California."
AGMB,16.11,AgomAb Therapeutics NV,Gastroenterology,"Gastroenterology, Respiratory",PHASE2,No,2,2,"NCT05843578, NCT06181370",Belgium,12.66,16.65,-,779301100,980431000,48736780,7871872,0.0009277798190151219,1557877.4,152130781.8736793,Biotechnology,"AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium."
ALT,4.56,"Altimmune, Inc.",Gastroenterology,Gastroenterology,PHASE2,No,1,2,"NCT06987513, NCT07009860",United States,2.9,7.73,4.1,572308030,377437020,125231520,55145278,0.006915958703909975,15905000,210776000,Biotechnology,"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland."
EPRX,8.05,Eupraxia Pharmaceuticals Inc.,Gastroenterology,Gastroenterology,PHASE2,No,1,1,NCT05608681,Canada,2.6801,9.32,5,488792100,429157060,60125816,14866002,0.1817047333446496,170603,88959281,Biotechnology,"Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada."
VXRT,0.7199,"Vaxart, Inc.",Gastroenterology,"Gastroenterology, Infectious Diseases",PHASE2,Yes,7,7,"NCT06672055, NCT06944717",United States,0.2606,0.8449,5,175185360,165350370,239979950,405725,0.010023766735908839,18958000,28793000,Biotechnology,"Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California."
BRIBF,0.1882,Brii Biosciences Limited,Gastroenterology,"Gastroenterology, Infectious Diseases",PHASE2,No,6,10,"NCT05970289, NCT06491563, NCT06650852",China,0.1346,0.3069,-,148484270,-148308530,721533060,37644312,0.05017027335226282,1031561,289609709.7949441,Biotechnology,"Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China."
PTN,20.96,"Palatin Technologies, Inc.",Gastroenterology,"Gastroenterology, Metabolic/Endocrinology",PHASE2,Yes,4,4,"NCT05466890, NCT06565611",United States,1.75,48.75,4.66,52625130,33556600,1772199,587840,0.09076576614702976,348788,14476162,Biotechnology,"Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey."
ALGS,6.94,"Aligos Therapeutics, Inc.",Gastroenterology,"Gastroenterology, Infectious Diseases, Others",PHASE2,Yes,5,7,"NCT06672900, NCT06963710, NCT07342868, NCT07342881",United States,3.76,18.6147,4.8,43628896,-49402104,6153582,1803760,0.01850856948034494,6065000,99096000,Biotechnology,"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California."
TRYPF,-,Tryp Therapeutics Inc.,Gastroenterology,Gastroenterology,PHASE2,No,1,1,NCT06206265,Canada,-,-,-,39884164,37747436,1613941100,117277153,0.2495206635956935,-,1991738.186126102,,
PALI,1.9,"Palisade Bio, Inc.",Gastroenterology,Gastroenterology,PHASE1,No,1,1,NCT07428096,United States,0.53,2.64,4.66,266715740,261701740,149003220,91935046,0.0003704551063027434,211000,5227000,Biotechnology,"Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California."
NVO,38.16,Novo Nordisk A/S,Hematology,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
ARGX,816.95,argenx SE,Hematology,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
CSLLY,51.79,CSL Limited,Hematology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
GALDY,37.97,Galderma Group AG,Hematology,"Dermatology, Hematology, Immunology/Autoimmune",PHASE4,Yes,6,8,"NCT03989206, NCT04204616, NCT07047690, NCT07074977, NCT07186413, NCT07225348, NCT07398989",Switzerland,17.27,42.93,5,44206682000,46662803000,237406140,74821471,0,2848000000,458000000,Drug Manufacturers - Specialty & Generic,"Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland."
CONI.F,-,"Celltrion, Inc.",Hematology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
UTHR,535.1,United Therapeutics Corporation,Hematology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Hematology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
TGTX,29.66,"TG Therapeutics, Inc.",Hematology,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE4,Yes,7,15,"NCT04130997, NCT04624633, NCT05877963, NCT06680037, NCT06864936, NCT07103746, NCT07211633, NCT07220252, NCT07225361, NCT07389590",United States,25.28,46.48,4.33,4460496400,4583454000,146197840,108410354,0.045637847183891835,254540000,131582000,Biotechnology,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Hematology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
TGRNF,0.55,Tong Ren Tang Technologies Co. Ltd.,Hematology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Others",PHASE4,Yes,13,16,"NCT04307511, NCT04731155, NCT04967833, NCT05292404, NCT05736965, NCT05736978, NCT06064669",China,0.55,0.7,-,720322400,745837600,1280784000,113980721,0.027898537145998083,337102700,718518683.9570625,Drug Manufacturers - General,"Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China."
ILPLF,-,Island Pharmaceuticals Limited,Hematology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
CELG.RT,0.1056,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,Hematology,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE3,Yes,18,25,"NCT06220201, NCT06313996, NCT06615479, NCT07335562",United States,0.015,0.274899,-,125446780000,161597780000,2036473700,1652787190,0.0005061538469508498,47187000000,10673000000,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Hematology,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
PTGX,87.1,"Protagonist Therapeutics, Inc.",Hematology,"Hematology, Others",PHASE3,No,4,4,"NCT05210790, NCT06033586, NCT07153146",United States,35.95,96.54,4.58,5463244300,4795173000,62515664,61085124,0.009338900796588601,10749000,576117000,Biotechnology,"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California."
YIHCF,0.55,"Sunshine Lake Pharma Co., Ltd.",Hematology,"Gastroenterology, Hematology, Oncology, Others, Respiratory",PHASE3,Yes,22,23,"NCT04415853, NCT05048368, NCT05133882, NCT05139719, NCT05451602, NCT05586074, NCT07082842, NCT07099118, NCT07102251, NCT07341672, NCT07376200",China,0.55,0.55,-,3182218000,3294738200,576032260,16305667,5.9675478550075e-05,306183700,-,,
VERA,41.68,"Vera Therapeutics, Inc.",Hematology,"Hematology, Urology/Nephrology",PHASE3,No,1,3,"NCT04716231, NCT06983028, NCT07020923",United States,18.53,56.05,4.64,3007714600,2587541500,70986890,64499175,0.007698153402152939,77216000,497389000,Biotechnology,"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California."
APLS,21.42,"Apellis Pharmaceuticals, Inc.",Hematology,"Hematology, Ophthalmology, Urology/Nephrology",PHASE3,No,4,9,"NCT03531255, NCT04572854, NCT04901936, NCT05809531, NCT06161584, NCT07020832, NCT07213960, NCT07215390",United States,16.1,30.48,4.04,2800003000,2808130000,126525220,107419884,0.02693274909537906,474360000,467786000,Biotechnology,"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts."
IRON,66.89,"Disc Medicine, Inc.",Hematology,"Gastroenterology, Hematology, Rare/Orphan Diseases",PHASE3,No,3,6,"NCT05320198, NCT05745883, NCT06910358, NCT06985147, NCT07187973, NCT07368972",United States,30.82,99.5,4.92,2499060700,1914117800,37750160,37364585,0.01137007426023246,30977000,615920000,Biotechnology,"Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts."
AGIO,29.96,"Agios Pharmaceuticals, Inc.",Hematology,"Hematology, Others, Rare/Orphan Diseases",PHASE3,No,9,18,"NCT03692052, NCT04278781, NCT04770753, NCT04770779, NCT05031780, NCT05144256, NCT05175105, NCT05490446, NCT06286046, NCT06924970, NCT07055243, NCT07075640, NCT07241234",United States,22.24,46,4.4,1780616100,656385100,58592172,53415867,0.01627295149671033,40207000,854425000,Biotechnology,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
CLDX,30.82,"Celldex Therapeutics, Inc.",Hematology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
GERNW,0.05,Geron Corporation WT EXP 123125,Hematology,"Hematology, Rare/Orphan Diseases",PHASE3,Yes,12,15,"NCT02598661, NCT04576156, NCT05371964, NCT05583552, NCT06247787, NCT07320235",United States,0.05,0.455875,-,1244792800,947113800,638355260,382515490,0.0009340691983785989,121916000,359799000,,
LXRX,1.5,"Lexicon Pharmaceuticals, Inc.",Hematology,"Cardiovascular, Hematology, Metabolic/Endocrinology",PHASE3,Yes,8,11,"NCT05696366, NCT06217302, NCT06435156, NCT06481891, NCT06933056, NCT07211802",United States,0.2836,1.83,4,632085200,581085200,427084580,92348930,0.01057365765220919,64950000,115950000,Biotechnology,"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas."
PRTC,17.54,PureTech Health plc,Hematology,"Hematology, Respiratory",PHASE3,Yes,7,8,"NCT05321420, NCT05829226, NCT07284602",United States,13.3,20,-,405813340,233739540,241684030,189705572,0.03581391254311962,163574000,331284000,Biotechnology,"PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts."
AKBA,1.21,"Akebia Therapeutics, Inc.",Hematology,"Hematology, Others, Respiratory, Urology/Nephrology",PHASE3,No,5,7,"NCT06520826, NCT06901505, NCT07086755, NCT07268638, NCT07429006",United States,1.14,4.0787,4.8,329053820,361617820,265366000,125640985,0.0211219415744805,199008000,166444000,Drug Manufacturers - Specialty & Generic,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
ALDX,5.49,"Aldeyra Therapeutics, Inc.",Hematology,"Hematology, Ophthalmology",PHASE3,No,2,2,NCT07402876,United States,1.14,7.2,4.8,313448030,253694460,60162772,32251736,0.03136351444438906,15543749,75297339,Biotechnology,"Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts."
XFORW,-,"X4 Pharmaceuticals, Inc. WT EXP A 041624",Hematology,"Hematology, Rare/Orphan Diseases",PHASE3,No,1,3,"NCT03995108, NCT06056297, NCT06858696",United States,-,-,-,296410370,251573380,87436690,55878166,0.0026751585101210612,77357000,122194000,,
IMUX,0.9104,"Immunic, Inc.",Hematology,"Hematology, Neurology/CNS",PHASE3,No,7,9,"NCT03846219, NCT05054140, NCT05134441, NCT05201638",United States,0.5062,1.35,5,117196550,82856550,130464824,60143460,0.013310399948798459,792000,35132000,Biotechnology,"Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York."
RPGLF,0.125,Regent Pacific Group Limited,Hematology,Hematology,PHASE3,No,2,2,NCT04332822,Hong Kong,0.0007,0.4333,-,36553856,38181340,291815780,-,0.6846467508738098,1769000,147000,Drug Manufacturers - Specialty & Generic,"Regent Pacific Group Limited, an investment holding company, focuses on healthcare and life sciences sectors in Europe, the United States, and the Asia Pacific. The company operates through Biopharma and Corporate Investment segments. It is involved in the research, development, manufacturing, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of AI system for the field of biological aging clocks, at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong."
BEAM,29.61,Beam Therapeutics Inc.,Hematology,"Hematology, Metabolic/Endocrinology, Oncology, Others, Respiratory",PHASE2,No,8,8,"NCT05456880, NCT05885464, NCT06389877, NCT06735755, NCT06934382, NCT07304791, NCT07373639",United States,13.525,36.44,4.7,3186798800,2095711900,98693060,95256420,0.01137591112436375,151420000,1245210000,Biotechnology,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts."
OMER,11.38,Omeros Corporation,Hematology,"Hematology, Urology/Nephrology",PHASE2,No,2,3,"NCT05855083, NCT06209736, NCT06298955",United States,2.95,17.65,4,818900300,1146254300,70900456,33206323,0.03765682250378661,363439000,36085000,Biotechnology,"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington."
FULC,8.98,"Fulcrum Therapeutics, Inc.",Hematology,Hematology,PHASE2,No,1,2,"NCT07401823, NCT07431398",United States,2.315,15.7399,4.33,566025100,220162100,65970292,45413622,0.01160951512959738,6443000,352306000,Biotechnology,"Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts."
RCKT,4.33,"Rocket Pharmaceuticals, Inc.",Hematology,"Hematology, Rare/Orphan Diseases",PHASE2,No,2,3,"NCT04069533, NCT04248439, NCT06422351",United States,2.19,9.805,3.64,459944480,262231470,108222220,75461762,0.03520737902383603,25045000,222758000,Biotechnology,"Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey."
CLYM,7.09,"Climb Bio, Inc.",Hematology,"Hematology, Immunology/Autoimmune, Others, Urology/Nephrology",PHASE2,No,3,5,"NCT07011043, NCT07043946, NCT07090655, NCT07096843, NCT07248865",United States,1.05,7.09,4.87,303654600,128403610,47744436,17264769,0.01580150650018164,580000,86901000,Biotechnology,"Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts."
SLN,5.35,Silence Therapeutics plc,Hematology,Hematology,PHASE2,No,1,1,NCT05499013,United Kingdom,1.97,7.775,4.16,251756940,149746940,47233948,12643482,0.346676787518745,182000,102192000,Biotechnology,"Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom."
ARCT,8.3,Arcturus Therapeutics Holdings Inc.,Hematology,"Hematology, Metabolic/Endocrinology, Rare/Orphan Diseases, Respiratory",PHASE2,No,4,4,"NCT06488313, NCT06747858, NCT07390968",United States,5.85,24.17,4.33,232428800,78055800,28414280,21994708,0.07529298913408994,25987000,180360000,Biotechnology,"Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California."
FPHAF,-,Faron Pharmaceuticals Oy,Hematology,Hematology,PHASE2,Yes,3,3,NCT05428969,Finland,-,-,-,81266160,91535770,115783960,4738938,0.21099156384881318,26393404,15938751.47232038,,
CBPHF,-,"Clover Biopharmaceuticals, Ltd.",Hematology,"Hematology, Infectious Diseases",PHASE1,No,6,7,"NCT05426369, NCT06843317, NCT06984094",China,-,-,-,346762270,293160930,1298037400,119574551,0.20519754473920881,1821354.2,55241418.78027332,,
SRNM.F,-,Sirnaomics Ltd.,Hematology,"Hematology, Others",PHASE1,No,2,2,"NCT05037149, NCT05844293",Hong Kong,-,-,-,97239140,83551030,106398780,-,0.20758723304254179,7211000,6872000,,
RLYB,5.82,Rallybio Corporation,Hematology,"Hematology, Immunology/Autoimmune",PHASE1,No,1,1,NCT06797375,United States,1.7608,6.4,3.5,30785144,-28335856,5280471,1017179,0.04096490635021005,198000,59319000,Biotechnology,"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut."
UCBJY,159.42,UCB SA,Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
ARGX,816.95,argenx SE,Immunology/Autoimmune,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
CSLLY,51.79,CSL Limited,Immunology/Autoimmune,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
GALDY,37.97,Galderma Group AG,Immunology/Autoimmune,"Dermatology, Hematology, Immunology/Autoimmune",PHASE4,Yes,6,8,"NCT03989206, NCT04204616, NCT07047690, NCT07074977, NCT07186413, NCT07225348, NCT07398989",Switzerland,17.27,42.93,5,44206682000,46662803000,237406140,74821471,0,2848000000,458000000,Drug Manufacturers - Specialty & Generic,"Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland."
CONI.F,-,"Celltrion, Inc.",Immunology/Autoimmune,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
TGTX,29.66,"TG Therapeutics, Inc.",Immunology/Autoimmune,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE4,Yes,7,15,"NCT04130997, NCT04624633, NCT05877963, NCT06680037, NCT06864936, NCT07103746, NCT07211633, NCT07220252, NCT07225361, NCT07389590",United States,25.28,46.48,4.33,4460496400,4583454000,146197840,108410354,0.045637847183891835,254540000,131582000,Biotechnology,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina."
TVTX,29.34,"Travere Therapeutics, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,7,13,"NCT03406611, NCT03493685, NCT03762850, NCT04663204, NCT05003986, NCT05630612, NCT06247085, NCT07219121, NCT07224776",United States,12.91,42.13,4.66,2848419000,2854356000,92241550,104986700,0.009636140446103184,328733000,322796000,Biotechnology,"Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California."
DMPHF,39.56,Dermapharm Holding SE,Immunology/Autoimmune,Immunology/Autoimmune,PHASE4,Yes,1,1,NCT06778213,Germany,39.56,42.683991,-,2495117000,3509686800,53840000,6411327,0.06786775631500742,1186807900,172077952.5710261,Drug Manufacturers - Specialty & Generic,"Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG."
CASBF,4.2575,CanSino Biologics Inc.,Immunology/Autoimmune,"Immunology/Autoimmune, Infectious Diseases",PHASE4,Yes,49,57,"NCT05951725, NCT06056050, NCT06131554, NCT06226714, NCT06389513, NCT06577298, NCT06621654, NCT06700148, NCT06708286, NCT06732583, NCT06857370, NCT07017777, NCT07203755",China,3.2,6.99,-,1627621600,1436837600,247043800,17391208,0.3138967571179817,200218770,392051092.9445311,Drug Manufacturers - Specialty & Generic,"CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China."
ANIP,76.3,"ANI Pharmaceuticals, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Ophthalmology, Others",PHASE4,Yes,8,8,"NCT04469595, NCT05322070, NCT05486468, NCT06539481, NCT07346079",United States,54.56,99.5,4.37,1603349600,1963460700,20904168,22456918,0.05961040667264109,631580000,271469000,Drug Manufacturers - Specialty & Generic,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Immunology/Autoimmune,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
AGYTF,0.11,Allergy Therapeutics plc,Immunology/Autoimmune,"Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Respiratory",PHASE4,Yes,19,19,"NCT05186025, NCT05476497, NCT06031272, NCT06205589, NCT06205602, NCT06856174, NCT07103746, NCT07412990",United Kingdom,0.052,0.11,-,1000048500,1063891100,6332529700,267020796,0.001447716418472931,82476390,17555177.33611508,Drug Manufacturers - Specialty & Generic,"Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom."
SPRY,9.24,"ARS Pharmaceuticals, Inc.",Immunology/Autoimmune,Immunology/Autoimmune,PHASE4,Yes,4,4,"NCT06834165, NCT06927999",United States,6.66,18.9,5,903476300,785072300,98848610,58762157,0.08447398807846332,169805000,288209000,Biotechnology,"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California."
CELG.RT,0.1056,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,Immunology/Autoimmune,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE3,Yes,18,25,"NCT06220201, NCT06313996, NCT06615479, NCT07335562",United States,0.015,0.274899,-,125446780000,161597780000,2036473700,1652787190,0.0005061538469508498,47187000000,10673000000,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Immunology/Autoimmune,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
ROIV,28.66,Roivant Sciences Ltd.,Immunology/Autoimmune,"Immunology/Autoimmune, Neurology/CNS, Ophthalmology",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United Kingdom,8.73,29.2,4.66,20225714000,16509644000,715701100,510791437,0.2424787260940063,108939000,4529978000,Biotechnology,"Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom."
AKBLF,35.8,ALK-Abelló A/S,Immunology/Autoimmune,"Immunology/Autoimmune, Respiratory",PHASE3,Yes,4,4,"NCT05440643, NCT07013123, NCT07060885",Denmark,19.9,36.1425,-,7507449300,7377901600,221562640,38642330,0.0003883190828785812,65771460,195111512.5233268,Biotechnology,"ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark."
IMVT,27.23,"Immunovant, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United States,12.72,29.25,4.41,5574746600,4580221400,203532180,97030092,0.005368950133802476,-,994525000,Biotechnology,"Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd."
ALMS,29.39,Alumis Inc.,Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune",PHASE3,Yes,4,9,"NCT05739435, NCT05966480, NCT06586112, NCT06588738, NCT06846541, NCT06952634",United States,2.7601,30.6,4.9,3500358400,3160431400,124656640,51450693,0.005333257862022095,37797000,377724000,Biotechnology,"Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California."
BVNRY,30.51,Bavarian Nordic A/S,Immunology/Autoimmune,"Immunology/Autoimmune, Infectious Diseases, Neurology/CNS",PHASE3,Yes,12,13,"NCT02977715, NCT06007183, NCT06549530, NCT06844487, NCT06844500, NCT06899802, NCT07003984, NCT07199569",Denmark,20.71,37.605,-,2403276300,1954995100,77505330,24958889,0.001803676792598014,21081488,468437690.696226,Biotechnology,"Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark."
DNTH,51.87,"Dianthus Therapeutics, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Neurology/CNS",PHASE3,No,1,3,"NCT06282159, NCT06537999, NCT06858579",United States,13.365,57.5,4.92,2284772600,1730570500,43223090,47222557,7.600964851276291e-05,1285000,402613000,Biotechnology,"Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York."
NPPNY,37.75,"Nippon Shinyaku Co., Ltd.",Immunology/Autoimmune,"Immunology/Autoimmune, Musculoskeletal, Rare/Orphan Diseases",PHASE3,Yes,4,5,"NCT04768062, NCT05135663, NCT05996003, NCT06046222, NCT06053814",Japan,21,41.82,-,2160164900,1788689900,67400950,34856354,0.001956945739740252,16261356,387993283.4915628,Drug Manufacturers - Specialty & Generic,"Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan."
BCRX,7.55,"BioCryst Pharmaceuticals, Inc.",Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune, Metabolic/Endocrinology, Ophthalmology, Rare/Orphan Diseases",PHASE3,Yes,3,3,"NCT05453968, NCT06539507, NCT07228559",United States,6,11.31,4.7,1886086900,2356322800,247843230,179610448,0.009866350027790148,683109000,212873000,Drug Manufacturers - Specialty & Generic,"BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina."
PHVS,27.63,Pharvaris N.V.,Immunology/Autoimmune,"Cardiovascular, Immunology/Autoimmune",PHASE3,Yes,2,4,"NCT05834777, NCT06669754, NCT06679881, NCT07266805",Netherlands,11.51,29.797,4.63,1815616800,1429946200,64959456,34755816,0.051404208254619145,679334.4,386576225.6398215,Biotechnology,"Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland."
KOD,27.62,Kodiak Sciences Inc.,Immunology/Autoimmune,"Immunology/Autoimmune, Ophthalmology",PHASE3,Yes,5,6,"NCT06270836, NCT06556368, NCT06990399, NCT06996080",United States,1.92,31.18,4.57,1733957600,1724120600,61971324,37774002,0.04587286284012365,62201000,72038000,Biotechnology,"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California."
CLDX,30.82,"Celldex Therapeutics, Inc.",Immunology/Autoimmune,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
ZBIO,26.03,"Zenas BioPharma, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Neurology/CNS",PHASE3,No,3,7,"NCT05638854, NCT05662241, NCT05786573, NCT06559163, NCT06564311, NCT07067463, NCT07299019",United States,6.11,44.6,4.75,1399415800,1109329900,53679170,33448030,0.01565360006400218,798000,290884000,Biotechnology,"Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts."
SVRA,5.84,Savara Inc.,Immunology/Autoimmune,"Immunology/Autoimmune, Respiratory",PHASE3,No,2,3,"NCT04544293, NCT06431776",United States,1.89,7.005,4.75,1393588900,1298500900,247090220,120188585,0.02029247851132077,29830000,124918000,Biotechnology,"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania."
DBVT,22.23,DBV Technologies S.A.,Immunology/Autoimmune,Immunology/Autoimmune,PHASE3,No,1,1,NCT05741476,France,3.82,26.185,4.16,1330121900,1267741700,295269660,141277243,0.0005178637573137512,7691000,69837000,Biotechnology,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France."
MLTX,18.22,MoonLake Immunotherapeutics,Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune, Musculoskeletal",PHASE3,No,2,6,"NCT06411379, NCT06411899, NCT06641076, NCT06641089, NCT06768671",Switzerland,5.95,62.75,3.81,1298999200,996531140,71373576,29553819,0.1055596497409777,75726000,393968000,Biotechnology,"MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland."
PHAR,16.8,Pharming Group N.V.,Immunology/Autoimmune,"Immunology/Autoimmune, Rare/Orphan Diseases",PHASE3,Yes,1,3,"NCT05438407, NCT05693129, NCT06990529",Netherlands,7.5018,21.34,5,1159530200,1124151400,685147600,147813721,0.02770361245437598,130922000,166168000,Biotechnology,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands."
GNIIF,15.5,GNI Group Ltd.,Immunology/Autoimmune,"Cardiovascular, Gastroenterology, Immunology/Autoimmune, Respiratory, Urology/Nephrology",PHASE3,Yes,20,25,"NCT05288179, NCT05689645, NCT05704166, NCT05905172, NCT06899815, NCT07262333, NCT07262346, NCT07263152, NCT07295873, NCT07343778, NCT07364448, NCT07388680, NCT07394309, NCT07412236, NCT07417553",Japan,12.02,19.88,-,1027117600,935934400,55671490,4905922,0.030491587740266182,34252916,134719624.079832,Biotechnology,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan."
KALV,15.76,"KalVista Pharmaceuticals, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT05505916, NCT05511922",United States,9.235,19,4.77,797115000,770536060,50546292,46091349,0.015116053338125619,138462000,191465000,Biotechnology,"KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts."
KYTX,8.09,"Kyverna Therapeutics, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Neurology/CNS",PHASE3,Yes,14,27,"NCT05938725, NCT06138132, NCT06152172, NCT06193889, NCT06342960, NCT06384976, NCT06400303, NCT06451159, NCT06475495, NCT06588491, NCT06590545, NCT07403188",United States,1.78,13.67,4.66,454179550,288065540,57129504,23246461,0.018330108700578048,5024000,171138000,Biotechnology,"Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California."
HNSBF,2.9,Hansa Biopharma AB (publ),Immunology/Autoimmune,"Immunology/Autoimmune, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,6,9,"NCT05369975, NCT05679401, NCT05714514, NCT05753930, NCT05937750, NCT06518005",Sweden,2.73,4.58,-,364459870,390170000,101763224,20913165,0.06214520212420161,101428310,76149548.26180178,Biotechnology,"Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden."
CABA,3.49,"Cabaletta Bio, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Musculoskeletal, Neurology/CNS",PHASE3,No,3,7,"NCT04422912, NCT06121297, NCT06154252, NCT06328777, NCT06359041, NCT07006805",United States,0.9857,3.78,4.5,316712500,182561520,96265200,55490177,0.01709548135378179,25780000,159931000,Biotechnology,"Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania."
DYMDF,0.73,Diamyd Medical AB (publ),Immunology/Autoimmune,"Immunology/Autoimmune, Metabolic/Endocrinology",PHASE3,Yes,2,2,"NCT05018585, NCT05683990",Sweden,0.73,0.73,-,239692620,213932590,137499730,39275209,0.1235476161650158,-,24700335.57331345,,
ATYR,1.02,"aTyr Pharma, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Respiratory",PHASE3,No,2,2,"NCT05415137, NCT05892614",United States,0.64,7.2904,3.4,96889180,18855184,97986630,54500219,0.025047691708646708,12359000,90202000,Biotechnology,"aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California."
ANAB,55.11,"AnaptysBio, Inc.",Immunology/Autoimmune,"Gastroenterology, Immunology/Autoimmune",PHASE2,No,1,2,"NCT06041269, NCT06127043",United States,13.99,57.74,4.61,1534218100,1631712100,27688470,18996108,0.027726702289865002,346450000,248956000,Biotechnology,"AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California."
EVMN,29.86,"Evommune, Inc.",Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune",PHASE2,No,3,5,"NCT06645821, NCT06873516, NCT07150845",United States,13.885,33.2,4.87,878891700,1060598700,31524092,14651548,0.171078525039693,765000,76062000,Biotechnology,"Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California."
FBRX,28.44,"Forte Biosciences, Inc.",Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune",PHASE2,No,1,3,"NCT06905873, NCT06982963, NCT07205159",United States,4.9,35.62,5,508196220,414782200,17831446,11353422,0.02460153820391235,-,93414000,Biotechnology,"Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas."
ZURA,7,Zura Bio Limited,Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune",PHASE2,No,3,3,"NCT06843239, NCT06993610",United States,0.97,7.19,4.83,492923940,364107940,73680710,30852662,0.060054755682802996,-,139017000,Biotechnology,"Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada."
CLYM,7.09,"Climb Bio, Inc.",Immunology/Autoimmune,"Hematology, Immunology/Autoimmune, Others, Urology/Nephrology",PHASE2,No,3,5,"NCT07011043, NCT07043946, NCT07090655, NCT07096843, NCT07248865",United States,1.05,7.09,4.87,303654600,128403610,47744436,17264769,0.01580150650018164,580000,86901000,Biotechnology,"Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts."
ELDN,2.47,"Eledon Pharmaceuticals, Inc.",Immunology/Autoimmune,"Immunology/Autoimmune, Urology/Nephrology",PHASE2,Yes,5,5,"NCT05027906, NCT06972069",United States,1.35,4.6,5,194413700,101734700,79352530,41048976,0.0005762260995024078,722000,93401000,Biotechnology,"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California."
QTTB,4.73,Q32 Bio Inc.,Immunology/Autoimmune,"Dermatology, Immunology/Autoimmune",PHASE2,Yes,2,2,"NCT05509023, NCT06018428",United States,1.345,6.3699,4,62869640,30855640,13971031,2138676,0.005808447493960897,17025000,49039000,Biotechnology,"Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb  CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts."
CYYNF,0.22,Cynata Therapeutics Limited,Immunology/Autoimmune,Immunology/Autoimmune,PHASE2,No,2,2,NCT05643638,Australia,0.08,0.22,-,58889540,55324092,241754370,32467806,0.08346616891957803,-,3323511.912597078,Biotechnology,"Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia."
JSPR,1.4,"Jasper Therapeutics, Inc.",Immunology/Autoimmune,Immunology/Autoimmune,PHASE2,No,1,2,"NCT06162728, NCT06736262",United States,1.11,7.19,4.16,38617972,-10578027,27984040,16003669,0.01191071810613186,1703000,50899000,Biotechnology,"Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California."
RLYB,5.82,Rallybio Corporation,Immunology/Autoimmune,"Hematology, Immunology/Autoimmune",PHASE1,No,1,1,NCT06797375,United States,1.7608,6.4,3.5,30785144,-28335856,5280471,1017179,0.04096490635021005,198000,59319000,Biotechnology,"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut."
NVO,38.16,Novo Nordisk A/S,Infectious Diseases,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
CASBF,4.2575,CanSino Biologics Inc.,Infectious Diseases,"Immunology/Autoimmune, Infectious Diseases",PHASE4,Yes,49,57,"NCT05951725, NCT06056050, NCT06131554, NCT06226714, NCT06389513, NCT06577298, NCT06621654, NCT06700148, NCT06708286, NCT06732583, NCT06857370, NCT07017777, NCT07203755",China,3.2,6.99,-,1627621600,1436837600,247043800,17391208,0.3138967571179817,200218770,392051092.9445311,Drug Manufacturers - Specialty & Generic,"CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China."
NVAX,9.53,"Novavax, Inc.",Infectious Diseases,Infectious Diseases,PHASE4,Yes,9,10,"NCT05468736, NCT06291857, NCT06633835, NCT07079670, NCT07086222",United States,5.01,10.6445,3.66,1537240400,1025486460,162498990,96496258,0.005296371217557376,251140000,762894000,Biotechnology,"Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Infectious Diseases,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
AGYTF,0.11,Allergy Therapeutics plc,Infectious Diseases,"Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Respiratory",PHASE4,Yes,19,19,"NCT05186025, NCT05476497, NCT06031272, NCT06205589, NCT06205602, NCT06856174, NCT07103746, NCT07412990",United Kingdom,0.052,0.11,-,1000048500,1063891100,6332529700,267020796,0.001447716418472931,82476390,17555177.33611508,Drug Manufacturers - Specialty & Generic,"Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom."
CRMD,7.31,CorMedix Inc.,Infectious Diseases,Infectious Diseases,PHASE4,Yes,2,3,"NCT06714864, NCT06822426",United States,5.6,17.43,4.57,557038500,650242600,78789050,37093906,0.07224576716217337,148920800,55716811,Biotechnology,"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey."
CPHRF,11.32,Cipher Pharmaceuticals Inc.,Infectious Diseases,Infectious Diseases,PHASE4,Yes,1,1,NCT05310734,Canada,6.63,12.5034,4.66,284300740,289351580,25281180,381795,0.4106255953786336,13393000,8424000,Drug Manufacturers - Specialty & Generic,"Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada."
ILPLF,-,Island Pharmaceuticals Limited,Infectious Diseases,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
PCVX,63.04,"Vaxcyte, Inc.",Infectious Diseases,Infectious Diseases,PHASE3,No,10,12,"NCT06720038, NCT07284654, NCT07365826, NCT07425392",United States,27.66,78.75,4.72,8807177000,7180300000,143556260,137761644,0.0059669599799964616,84443000,1560959000,Biotechnology,"Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California."
BVNRY,30.51,Bavarian Nordic A/S,Infectious Diseases,"Immunology/Autoimmune, Infectious Diseases, Neurology/CNS",PHASE3,Yes,12,13,"NCT02977715, NCT06007183, NCT06549530, NCT06844487, NCT06844500, NCT06899802, NCT07003984, NCT07199569",Denmark,20.71,37.605,-,2403276300,1954995100,77505330,24958889,0.001803676792598014,21081488,468437690.696226,Biotechnology,"Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark."
BIESF,32,Biotest Aktiengesellschaft Preference Shares,Infectious Diseases,Infectious Diseases,PHASE3,Yes,3,3,"NCT03334006, NCT05722938",Germany,30.48,32,-,1598517000,2336828200,39571452,123217,0.0,723466430,-,,"Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH."
BTTAY,24.23,Biotest Aktiengesellschaft,Infectious Diseases,Infectious Diseases,PHASE3,Yes,3,3,"NCT03334006, NCT05722938",Germany,22.8,24.27,-,1598517000,2336828200,39571452,123217,0.0,723466430,-,,"Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH."
VIR,10,"Vir Biotechnology, Inc.",Infectious Diseases,"Gastroenterology, Infectious Diseases, Oncology",PHASE3,Yes,17,30,"NCT04856085, NCT05356741, NCT05461170, NCT05484206, NCT05970289, NCT05997615, NCT06070051, NCT06491563, NCT06903338, NCT06960395, NCT07128550, NCT07142811",United States,4.155,10.94,4.6,1324019000,954855940,139517280,81306024,0.04384297119099471,97852000,467015000,Biotechnology,"Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California."
VALN,11.41,Valneva SE,Infectious Diseases,Infectious Diseases,PHASE3,Yes,7,8,"NCT04838444, NCT05477524, NCT06334393, NCT07163845, NCT07414524",France,5.4289,12.25,4.33,1039530940,1101221000,173753100,38929866,0.01117826975378591,229916640,168422164.8274243,Biotechnology,"Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France."
BPMUF,71,Basilea Pharmaceutica AG,Infectious Diseases,"Infectious Diseases, Others",PHASE3,Yes,10,10,"NCT05421858, NCT06733675, NCT06925321",Switzerland,47.5,74,-,848166200,756963500,12291580,4336174,0.002691435926056699,112622130,201716781.5395491,Biotechnology,"Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland."
IVVD,1.71,"Invivyd, Inc.",Infectious Diseases,Infectious Diseases,PHASE3,No,3,3,"NCT06523153, NCT07298434",United States,0.46,3.0699,4.5,476558080,394268100,281987040,164310569,0.002439381671851556,2677000,84967000,Biotechnology,"Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts."
AVIR,4.62,"Atea Pharmaceuticals, Inc.",Infectious Diseases,"Infectious Diseases, Others",PHASE3,Yes,10,10,"NCT06868264, NCT06911320, NCT07037277, NCT07272889, NCT07314346",United States,2.455,4.8,4.33,363289600,35025600,78126800,51095589,0.1622032599416978,1045000,329309000,Biotechnology,"Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts."
SYMQY,-,SymBio Pharmaceuticals Limited,Infectious Diseases,Infectious Diseases,PHASE3,Yes,3,3,"NCT04706923, NCT07387367",Japan,-,-,-,76689580,70909624,59476016,-1385380,0.042557071115137755,12657298,18409764.47528874,,
MBGPF,0.99,Moberg Pharma AB (publ),Infectious Diseases,Infectious Diseases,PHASE3,No,2,2,NCT05279846,Sweden,0.6916,1.135,-,52025616,26793960,47000628,26814703,0.0949841371265111,276647.56,25084992.82041479,Drug Manufacturers - Specialty & Generic,"Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden."
INVA,24.24,"Innoviva, Inc.",Infectious Diseases,Infectious Diseases,PHASE2,Yes,6,6,"NCT06794541, NCT06801223",United States,16.52,24.245,4.2,1751091500,1541219500,74769064,73262212,0.007657878876832478,323230000,533102000,Biotechnology,"Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California."
ABUS,4.6,Arbutus Biopharma Corporation,Infectious Diseases,Infectious Diseases,PHASE2,No,3,3,"NCT05960240, NCT06154278",United States,2.705,5.1,4.66,857765100,768669100,192324020,96226583,0.01567711119511403,4606000,93702000,Biotechnology,"Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania."
SIGA,6.8,"SIGA Technologies, Inc.",Infectious Diseases,Infectious Diseases,PHASE2,No,2,2,NCT04957485,United States,4.95,9.62,-,484092400,313051360,71611304,36629183,0.09597007466782269,914548,171955584,Drug Manufacturers - Specialty & Generic,"SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York."
VXRT,0.7199,"Vaxart, Inc.",Infectious Diseases,"Gastroenterology, Infectious Diseases",PHASE2,Yes,7,7,"NCT06672055, NCT06944717",United States,0.2606,0.8449,5,175185360,165350370,239979950,405725,0.010023766735908839,18958000,28793000,Biotechnology,"Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California."
BRIBF,0.1882,Brii Biosciences Limited,Infectious Diseases,"Gastroenterology, Infectious Diseases",PHASE2,No,6,10,"NCT05970289, NCT06491563, NCT06650852",China,0.1346,0.3069,-,148484270,-148308530,721533060,37644312,0.05017027335226282,1031561,289609709.7949441,Biotechnology,"Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China."
ALGS,6.94,"Aligos Therapeutics, Inc.",Infectious Diseases,"Gastroenterology, Infectious Diseases, Others",PHASE2,Yes,5,7,"NCT06672900, NCT06963710, NCT07342868, NCT07342881",United States,3.76,18.6147,4.8,43628896,-49402104,6153582,1803760,0.01850856948034494,6065000,99096000,Biotechnology,"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California."
ASMB,29.34,"Assembly Biosciences, Inc.",Infectious Diseases,Infectious Diseases,PHASE1,No,4,4,"NCT06385327, NCT06698575",United States,7.75,39.705,5,468820030,239018030,15817140,6352024,0.03828277425628147,2755000,232557000,Biotechnology,"Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California."
CBPHF,-,"Clover Biopharmaceuticals, Ltd.",Infectious Diseases,"Hematology, Infectious Diseases",PHASE1,No,6,7,"NCT05426369, NCT06843317, NCT06984094",China,-,-,-,346762270,293160930,1298037400,119574551,0.20519754473920881,1821354.2,55241418.78027332,,
NVO,38.16,Novo Nordisk A/S,Metabolic/Endocrinology,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
CONI.F,-,"Celltrion, Inc.",Metabolic/Endocrinology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
UTHR,535.1,United Therapeutics Corporation,Metabolic/Endocrinology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
NBIX,131.15,"Neurocrine Biosciences, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,8,21,"NCT04400331, NCT04490915, NCT04806451, NCT05206513, NCT05207085, NCT05226780, NCT06786624, NCT06911112, NCT06963021, NCT06963034, NCT06966401, NCT07105098, NCT07105111, NCT07111988, NCT07114874, NCT07187375, NCT07196501, NCT07227818, NCT07288320, NCT07288333, NCT07365462",United States,84.23,160.18,4.55,13143599000,12134499000,100363464,100888222,0.011908118863493009,471300000,1480400000,Drug Manufacturers - Specialty & Generic,"Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Metabolic/Endocrinology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
MIRM,108.62,"Mirum Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Gastroenterology, Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE4,Yes,9,11,"NCT03115086, NCT04663308, NCT05050136, NCT06193928, NCT06553768, NCT07209462, NCT07290257, NCT07389031",United States,36.8801,109.28,4.72,6435898000,6379114000,59879960,54815602,0.01165946746085052,318764000,375548000,Biotechnology,"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California."
HLBBF,6.2075,H. Lundbeck A/S,Metabolic/Endocrinology,"Metabolic/Endocrinology, Neurology/CNS, Ophthalmology, Pain/Analgesia, Psychiatry",PHASE4,Yes,8,14,"NCT04291859, NCT04789915, NCT04965675, NCT05104476, NCT05164172, NCT05669950, NCT05897320, NCT06323928, NCT06428838, NCT06471829, NCT06557850, NCT06701526, NCT06706622, NCT07035197",Denmark,4.415,7.55,-,6014970400,7310604000,991227460,96604633,0.0015551334439047229,1833733500,540175663.3004686,Drug Manufacturers - Specialty & Generic,"H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark."
ACAD,24.97,ACADIA Pharmaceuticals Inc.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,5,7,"NCT05357612, NCT05895513, NCT05999240, NCT06159673, NCT06173531, NCT07029581, NCT07284667",United States,13.4,28.35,4.14,4160181000,3367970800,169181820,124523308,0.005264892030329713,54809000,847019000,Biotechnology,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California."
ANIP,76.3,"ANI Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Ophthalmology, Others",PHASE4,Yes,8,8,"NCT04469595, NCT05322070, NCT05486468, NCT06539481, NCT07346079",United States,54.56,99.5,4.37,1603349600,1963460700,20904168,22456918,0.05961040667264109,631580000,271469000,Drug Manufacturers - Specialty & Generic,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Metabolic/Endocrinology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
AGYTF,0.11,Allergy Therapeutics plc,Metabolic/Endocrinology,"Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Respiratory",PHASE4,Yes,19,19,"NCT05186025, NCT05476497, NCT06031272, NCT06205589, NCT06205602, NCT06856174, NCT07103746, NCT07412990",United Kingdom,0.052,0.11,-,1000048500,1063891100,6332529700,267020796,0.001447716418472931,82476390,17555177.33611508,Drug Manufacturers - Specialty & Generic,"Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom."
TGRNF,0.55,Tong Ren Tang Technologies Co. Ltd.,Metabolic/Endocrinology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Others",PHASE4,Yes,13,16,"NCT04307511, NCT04731155, NCT04967833, NCT05292404, NCT05736965, NCT05736978, NCT06064669",China,0.55,0.7,-,720322400,745837600,1280784000,113980721,0.027898537145998083,337102700,718518683.9570625,Drug Manufacturers - General,"Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China."
HUMDF,0.4107,Hua Medicine (Shanghai) Ltd.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Neurology/CNS",PHASE4,Yes,3,3,"NCT06263348, NCT07203248",China,0.15,0.4107,-,401591940,296301920,988005800,7154755,0.05550269475540292,37835816,142769720.4036907,Drug Manufacturers - Specialty & Generic,"Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China."
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Metabolic/Endocrinology,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
MDGL,435.01,"Madrigal Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Gastroenterology, Metabolic/Endocrinology",PHASE3,No,2,4,"NCT03900429, NCT04951219, NCT05500222, NCT07335601",United States,265,615,4.56,10093586000,9457658000,22939968,16123164,0.07344268154238724,347630000,983559000,Biotechnology,"Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania."
ARWR,61.615,"Arrowhead Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Cardiovascular, Metabolic/Endocrinology, Neurology/CNS, Respiratory, Urology/Nephrology",PHASE3,Yes,17,21,"NCT05089084, NCT05217667, NCT06131983, NCT06138743, NCT06209177, NCT06347003, NCT06347016, NCT06347133, NCT06672445, NCT06700538, NCT06822790, NCT06880770, NCT06937203, NCT07037771, NCT07221344, NCT07223658, NCT07241546",United States,9.57,76.76,4.33,8915849000,8693578000,140032200,105803368,0.03328908874452367,698163000,914710000,Biotechnology,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California."
RYTM,99.15,"Rhythm Pharmaceuticals, Inc.",Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE3,Yes,5,8,"NCT05093634, NCT05774756, NCT06239116, NCT06760546, NCT06772597",United States,45.905,122.2,4.62,6583512000,6427430000,66736056,61118994,0.007253538150701839,113104000,416052000,Biotechnology,"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts."
PTCT,67.76,"PTC Therapeutics, Inc.",Metabolic/Endocrinology,"Gastroenterology, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,5,5,"NCT03605550, NCT04014530, NCT05166161, NCT05515536, NCT06302348",United States,35.95,87.5,4,5709801000,6471493600,82774730,88379259,0.02122564899703586,2707064000,1945371000,Biotechnology,"PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey."
IMVT,27.23,"Immunovant, Inc.",Metabolic/Endocrinology,"Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United States,12.72,29.25,4.41,5574746600,4580221400,203532180,97030092,0.005368950133802476,-,994525000,Biotechnology,"Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd."
FOLD,14.34,"Amicus Therapeutics, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE3,Yes,8,12,"NCT03911505, NCT04020055, NCT04252066, NCT04808505, NCT06121011, NCT06904261, NCT06906367",United States,5.51,14.38,3,4509050400,4657877000,314000700,326652839,0.007861989842338477,442363000,293536000,Biotechnology,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey."
NAMS,35.01,NewAmsterdam Pharma Company N.V.,Metabolic/Endocrinology,"Cardiovascular, Metabolic/Endocrinology",PHASE3,No,3,7,"NCT05202509, NCT05972278, NCT06305559, NCT06496243, NCT06982508, NCT07219602",Netherlands,14.06,42,4.69,4140265000,3411617000,114975420,78947412,0.009102299335461366,202000,636241000,Biotechnology,"NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands."
ZLDPF,57.08,Zealand Pharma A/S,Metabolic/Endocrinology,"Gastroenterology, Metabolic/Endocrinology, Oncology, Others, Urology/Nephrology",PHASE3,Yes,10,14,"NCT02446405, NCT03905707, NCT03941236, NCT04419402, NCT04881825, NCT05788601, NCT06662539, NCT06682975, NCT06926842, NCT07197944, NCT07338214",Denmark,49.98,101.2925,-,4063842000,1746636300,70607140,26243554,0.003573958667636162,63846624,2377340630.084307,Biotechnology,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark."
VKTX,33.12,"Viking Therapeutics, Inc.",Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE3,No,1,2,"NCT07104383, NCT07104500",United States,18.92,43.15,4.61,3899957500,3194355500,115554296,72793421,0.02400720804016848,137000,705739000,Biotechnology,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California."
BCRX,7.55,"BioCryst Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Dermatology, Immunology/Autoimmune, Metabolic/Endocrinology, Ophthalmology, Rare/Orphan Diseases",PHASE3,Yes,3,3,"NCT05453968, NCT06539507, NCT07228559",United States,6,11.31,4.7,1886086900,2356322800,247843230,179610448,0.009866350027790148,683109000,212873000,Drug Manufacturers - Specialty & Generic,"BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina."
OCS,29.56,Oculis Holding AG,Metabolic/Endocrinology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,No,3,5,"NCT05066997, NCT05608837, NCT06172257",Switzerland,14,30.68,4.7,1712818700,1533840000,57806908,18427287,0.03497438342534454,3098028.8,182389225.9953015,Biotechnology,"Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland."
MNKD,3.5,MannKind Corporation,Metabolic/Endocrinology,"Metabolic/Endocrinology, Others, Respiratory",PHASE3,No,6,6,"NCT06532942, NCT06535789, NCT07224321, NCT07344558",United States,3.29,6.51,4.88,1701169400,1666565400,307070270,181097310,0.01777247860726711,225431000,260035000,Biotechnology,"MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut."
AMLX,14.37,"Amylyx Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,3,5,"NCT05021536, NCT05676034, NCT06122662, NCT06665165, NCT06747468",United States,2.6,17.49,4.81,1615445900,1277390800,109819570,94600578,0.060628053924481985,5935000,343990000,Drug Manufacturers - Specialty & Generic,"Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts."
PROK,2.26,ProKidney Corp.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Urology/Nephrology",PHASE3,No,1,2,"NCT05099770, NCT05918523",United States,0.4603,7.13,4,673869000,1375930800,141545440,30598687,0.1780790930132914,4236000,271725000,Biotechnology,"ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina."
LXRX,1.5,"Lexicon Pharmaceuticals, Inc.",Metabolic/Endocrinology,"Cardiovascular, Hematology, Metabolic/Endocrinology",PHASE3,Yes,8,11,"NCT05696366, NCT06217302, NCT06435156, NCT06481891, NCT06933056, NCT07211802",United States,0.2836,1.83,4,632085200,581085200,427084580,92348930,0.01057365765220919,64950000,115950000,Biotechnology,"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas."
OCGN,1.86,"Ocugen, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,No,6,6,"NCT05203939, NCT05802329, NCT05956626",United States,0.515,1.96,4.8,583641300,584040300,327888400,61070010,0.014222337142090919,32964000,32565000,Biotechnology,"Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania."
VTVT,38.515,vTv Therapeutics Inc.,Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE3,No,2,2,NCT06334133,United States,14,44,5,494245820,396092220,12408642,1283932,0.0098726355390058,360000,98504000,Biotechnology,"vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina."
RGNX,8.53,REGENXBIO Inc.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,Yes,7,8,"NCT04514653, NCT04567550, NCT04704921, NCT05407636, NCT06942520",United States,5.035,16.19,4.45,409034530,375131520,50623090,36986665,0.08386564975513347,268140000,274205000,Biotechnology,"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland."
AARD,12.38,"Aardvark Therapeutics, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT06828861, NCT07197034",United States,4.88,17.94,4.81,276085100,150280100,21773272,5602607,0.1473812020536004,545000,126350000,Biotechnology,"Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California."
DYMDF,0.73,Diamyd Medical AB (publ),Metabolic/Endocrinology,"Immunology/Autoimmune, Metabolic/Endocrinology",PHASE3,Yes,2,2,"NCT05018585, NCT05683990",Sweden,0.73,0.73,-,239692620,213932590,137499730,39275209,0.1235476161650158,-,24700335.57331345,,
ORMP,3.73,Oramed Pharmaceuticals Inc.,Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE3,No,1,1,NCT06731075,United States,1.82,3.76,-,137716500,2937494,39802456,6180948,0.1879177050762321,860000,134687000,Biotechnology,"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York."
GPCR,66.53,Structure Therapeutics Inc.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Others",PHASE2,No,6,8,"NCT06139055, NCT06693843, NCT06703021, NCT07169942, NCT07400588",United States,13.22,94.9,4.73,4764381700,3972428500,69139190,53702972,0.03404625307566325,7090000,799043000,Biotechnology,"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California."
BEAM,29.61,Beam Therapeutics Inc.,Metabolic/Endocrinology,"Hematology, Metabolic/Endocrinology, Oncology, Others, Respiratory",PHASE2,No,8,8,"NCT05456880, NCT05885464, NCT06389877, NCT06735755, NCT06934382, NCT07304791, NCT07373639",United States,13.525,36.44,4.7,3186798800,2095711900,98693060,95256420,0.01137591112436375,151420000,1245210000,Biotechnology,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts."
WVE,14.54,Wave Life Sciences Ltd.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE2,No,3,4,"NCT04906460, NCT06405633, NCT06842186, NCT07209332",Singapore,5.28,21.73,4.87,2565614300,2397042400,182996750,128054661,0.030099107859328077,19772000,196218000,Biotechnology,"Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore."
MBX,35.64,"MBX Biosciences, Inc.",Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE2,No,4,4,"NCT06531941, NCT07029412, NCT07142707",United States,4.8069,44.89,4.45,1731940200,1340890200,47153290,31000655,0.0258718659459044,623000,391673000,Biotechnology,"MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana."
ZVRA,8.93,"Zevra Therapeutics, Inc.",Metabolic/Endocrinology,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE2,No,1,1,NCT06773026,United States,6.19,13.16,4.75,504988900,368196900,56297536,34941093,0.01372962421889342,62717000,199509000,Biotechnology,"Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida."
ARCT,8.3,Arcturus Therapeutics Holdings Inc.,Metabolic/Endocrinology,"Hematology, Metabolic/Endocrinology, Rare/Orphan Diseases, Respiratory",PHASE2,No,4,4,"NCT06488313, NCT06747858, NCT07390968",United States,5.85,24.17,4.33,232428800,78055800,28414280,21994708,0.07529298913408994,25987000,180360000,Biotechnology,"Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California."
TNXP,14.84,Tonix Pharmaceuticals Holding Corp.,Metabolic/Endocrinology,"Metabolic/Endocrinology, Others, Psychiatry, Urology/Nephrology",PHASE2,Yes,4,4,"NCT04789148, NCT06636786, NCT07204080, NCT07413367",United States,6.76,69.97,5,182825570,-6804426,12793952,3780812,0.0004202767057434638,425000,190055000,Biotechnology,"Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey."
PTN,20.96,"Palatin Technologies, Inc.",Metabolic/Endocrinology,"Gastroenterology, Metabolic/Endocrinology",PHASE2,Yes,4,4,"NCT05466890, NCT06565611",United States,1.75,48.75,4.66,52625130,33556600,1772199,587840,0.09076576614702976,348788,14476162,Biotechnology,"Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey."
RANI,1.35,"Rani Therapeutics Holdings, Inc.",Metabolic/Endocrinology,Metabolic/Endocrinology,PHASE1,No,1,1,NCT06891287,United States,0.387,3.87,4.66,159192960,137088780,97550984,19822807,0.030572670509587188,17554000,4144000,Biotechnology,"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California."
PGBIF,-,"PegBio Co., Ltd.",Metabolic/Endocrinology,Metabolic/Endocrinology,EARLY_PHASE1,No,1,1,NCT07347080,China,-,-,-,2282103800,-,284300350,89328488,0.2420436937509555,11729086,46443138.51393794,,
ESPR,3.33,"Esperion Therapeutics, Inc.",Metabolic/Endocrinology,"Cardiovascular, Metabolic/Endocrinology",,No,2,2,NCT05103254,United States,0.6925,4.175,4,776919740,1285457700,235430220,141484121,0.008996413912646,600985000,92447000,Drug Manufacturers - Specialty & Generic,"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan."
NVO,38.16,Novo Nordisk A/S,Musculoskeletal,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
UCBJY,159.42,UCB SA,Musculoskeletal,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
ARGX,816.95,argenx SE,Musculoskeletal,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Musculoskeletal,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
AXSM,164.22,"Axsome Therapeutics, Inc.",Musculoskeletal,"Musculoskeletal, Neurology/CNS, Pain/Analgesia, Psychiatry",PHASE4,Yes,6,9,"NCT05838430, NCT06170970, NCT06223880, NCT06413420, NCT06413433, NCT06568367, NCT07398417",United States,86.99,191.5,4.76,8693502000,8588681000,51153290,38732733,0.01124811348885113,218113000,322933000,Biotechnology,"Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York."
ANIP,76.3,"ANI Pharmaceuticals, Inc.",Musculoskeletal,"Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Ophthalmology, Others",PHASE4,Yes,8,8,"NCT04469595, NCT05322070, NCT05486468, NCT06539481, NCT07346079",United States,54.56,99.5,4.37,1603349600,1963460700,20904168,22456918,0.05961040667264109,631580000,271469000,Drug Manufacturers - Specialty & Generic,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Musculoskeletal,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
EOLS,4.5,"Evolus, Inc.",Musculoskeletal,"Dermatology, Musculoskeletal",PHASE4,Yes,2,2,"NCT05481931, NCT06903975",United States,4.0913,14.94,4.57,278725060,390094080,64819784,43325160,0.122150499606725,154892000,43523000,Drug Manufacturers - Specialty & Generic,"Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California."
ILPLF,-,Island Pharmaceuticals Limited,Musculoskeletal,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Musculoskeletal,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
RNA,72.8,"Avidity Biosciences, Inc.",Musculoskeletal,Musculoskeletal,PHASE3,No,4,4,"NCT05747924, NCT06244082, NCT06411288, NCT07038200",United States,21.51,73.06,3.28,11287136000,9639519000,155149650,132692599,0.059041352885372274,49251000,1696869000,Biotechnology,"Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California."
NPPNY,37.75,"Nippon Shinyaku Co., Ltd.",Musculoskeletal,"Immunology/Autoimmune, Musculoskeletal, Rare/Orphan Diseases",PHASE3,Yes,4,5,"NCT04768062, NCT05135663, NCT05996003, NCT06046222, NCT06053814",Japan,21,41.82,-,2160164900,1788689900,67400950,34856354,0.001956945739740252,16261356,387993283.4915628,Drug Manufacturers - Specialty & Generic,"Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan."
MESO,16.91,Mesoblast Limited,Musculoskeletal,Musculoskeletal,PHASE3,No,1,1,NCT06325566,Australia,9.61,21.5,4.33,2096145300,2060181200,1290769800,347285955,0.32658105934393733,128157000,161551000,Biotechnology,"Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia."
SRPT,18.97,"Sarepta Therapeutics, Inc.",Musculoskeletal,Musculoskeletal,PHASE3,Yes,3,3,"NCT03992430, NCT06246513",United States,10.415,109.495,3.23,1974190600,2383553500,104787180,85997618,0.05204295635877696,1260356000,850993000,Biotechnology,"Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts."
VCEL,37.09,Vericel Corporation,Musculoskeletal,Musculoskeletal,PHASE3,Yes,2,2,"NCT03588975, NCT06915233",United States,29.24,55.41,4.75,1934456400,1897741400,50574024,54497706,0.009715063200633553,98665000,135380000,Biotechnology,"Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts."
MLTX,18.22,MoonLake Immunotherapeutics,Musculoskeletal,"Dermatology, Immunology/Autoimmune, Musculoskeletal",PHASE3,No,2,6,"NCT06411379, NCT06411899, NCT06641076, NCT06641089, NCT06768671",Switzerland,5.95,62.75,3.81,1298999200,996531140,71373576,29553819,0.1055596497409777,75726000,393968000,Biotechnology,"MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland."
PCRX,23.46,"Pacira BioSciences, Inc.",Musculoskeletal,"Musculoskeletal, Pain/Analgesia",PHASE3,Yes,8,9,"NCT03739021, NCT04119687, NCT06269705, NCT06271265, NCT06884865, NCT07212114",United States,18.8,27.64,3.85,1007128060,1186102000,43021276,46553714,0.01606792538629515,425308000,246334000,Drug Manufacturers - Specialty & Generic,"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California."
CABA,3.49,"Cabaletta Bio, Inc.",Musculoskeletal,"Immunology/Autoimmune, Musculoskeletal, Neurology/CNS",PHASE3,No,3,7,"NCT04422912, NCT06121297, NCT06154252, NCT06328777, NCT06359041, NCT07006805",United States,0.9857,3.78,4.5,316712500,182561520,96265200,55490177,0.01709548135378179,25780000,159931000,Biotechnology,"Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania."
PBIGF,0.2,Paradigm Biopharmaceuticals Limited,Musculoskeletal,Musculoskeletal,PHASE3,No,5,6,"NCT04809376, NCT06917404",Australia,0.1338,0.3807,-,83738400,71867576,439254430,57848471,0.1062643818269018,3609.3196,11068927.866263,Biotechnology,"Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia."
EWTX,30.12,"Edgewise Therapeutics, Inc.",Musculoskeletal,"Cardiovascular, Musculoskeletal, Others",PHASE2,No,9,14,"NCT05291091, NCT05540860, NCT06100887, NCT06347159, NCT07034768, NCT07177066, NCT07324616",United States,10.6,31.82,4.41,3272393200,2713234200,105868430,79285500,0.004863210621796405,4181000,563340000,Biotechnology,"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado."
WVE,14.54,Wave Life Sciences Ltd.,Musculoskeletal,"Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE2,No,3,4,"NCT04906460, NCT06405633, NCT06842186, NCT07209332",Singapore,5.28,21.73,4.87,2565614300,2397042400,182996750,128054661,0.030099107859328077,19772000,196218000,Biotechnology,"Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore."
DYN,16.09,"Dyne Therapeutics, Inc.",Musculoskeletal,"Musculoskeletal, Neurology/CNS",PHASE2,No,2,2,"NCT05481879, NCT05524883",United States,6.36,25,4.56,2558695700,1887274800,164652240,169174642,0.0045046965933351005,120466000,791887000,Biotechnology,"Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts."
PEPG,6.4,PepGen Inc.,Musculoskeletal,Musculoskeletal,PHASE2,No,1,2,"NCT06667453, NCT07220603",United States,0.8801,7.8,4.5,434488770,288261760,68748220,35066895,0.0009992112668976002,17438000,163665000,Biotechnology,"PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts."
TRDA,11.98,"Entrada Therapeutics, Inc.",Musculoskeletal,Musculoskeletal,PHASE2,No,4,4,"NCT07037862, NCT07038824",United States,4.93,12.505,5,411690700,137252670,35861556,15158459,0.010899917145259478,52400000,326838000,Biotechnology,"Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts."
ENLV,1.1,Enlivex Ltd.,Musculoskeletal,Musculoskeletal,PHASE2,No,2,3,"NCT06208241, NCT06233474, NCT06522035",Israel,0.66,2.1,4,272988740,255486720,237381500,1688993,0.005050212464326095,701000,18203000,Biotechnology,"Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel."
PLX,3.03,"Protalix BioTherapeutics, Inc.",Musculoskeletal,Musculoskeletal,PHASE2,Yes,2,2,NCT07280156,Israel,1.32,3.19,5,241263540,220070540,80421180,15330620,0.10563243282885891,8177000,29370000,Biotechnology,"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey."
NVO,38.16,Novo Nordisk A/S,Neurology/CNS,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
UCBJY,159.42,UCB SA,Neurology/CNS,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
ARGX,816.95,argenx SE,Neurology/CNS,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
CSLLY,51.79,CSL Limited,Neurology/CNS,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
CONI.F,-,"Celltrion, Inc.",Neurology/CNS,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
UTHR,535.1,United Therapeutics Corporation,Neurology/CNS,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
NBIX,131.15,"Neurocrine Biosciences, Inc.",Neurology/CNS,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,8,21,"NCT04400331, NCT04490915, NCT04806451, NCT05206513, NCT05207085, NCT05226780, NCT06786624, NCT06911112, NCT06963021, NCT06963034, NCT06966401, NCT07105098, NCT07105111, NCT07111988, NCT07114874, NCT07187375, NCT07196501, NCT07227818, NCT07288320, NCT07288333, NCT07365462",United States,84.23,160.18,4.55,13143599000,12134499000,100363464,100888222,0.011908118863493009,471300000,1480400000,Drug Manufacturers - Specialty & Generic,"Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."
AXSM,164.22,"Axsome Therapeutics, Inc.",Neurology/CNS,"Musculoskeletal, Neurology/CNS, Pain/Analgesia, Psychiatry",PHASE4,Yes,6,9,"NCT05838430, NCT06170970, NCT06223880, NCT06413420, NCT06413433, NCT06568367, NCT07398417",United States,86.99,191.5,4.76,8693502000,8588681000,51153290,38732733,0.01124811348885113,218113000,322933000,Biotechnology,"Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York."
HLBBF,6.2075,H. Lundbeck A/S,Neurology/CNS,"Metabolic/Endocrinology, Neurology/CNS, Ophthalmology, Pain/Analgesia, Psychiatry",PHASE4,Yes,8,14,"NCT04291859, NCT04789915, NCT04965675, NCT05104476, NCT05164172, NCT05669950, NCT05897320, NCT06323928, NCT06428838, NCT06471829, NCT06557850, NCT06701526, NCT06706622, NCT07035197",Denmark,4.415,7.55,-,6014970400,7310604000,991227460,96604633,0.0015551334439047229,1833733500,540175663.3004686,Drug Manufacturers - Specialty & Generic,"H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark."
ALKS,31.04,Alkermes plc,Neurology/CNS,"Neurology/CNS, Others, Psychiatry",PHASE4,Yes,6,8,"NCT05028062, NCT05303064, NCT06555783, NCT06767683, NCT06843590",Ireland,25.165,36.3164,4.5,5513274000,4473757700,165117500,172817486,0.01340967260697474,71598000,1319421000,Drug Manufacturers - Specialty & Generic,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland."
TGTX,29.66,"TG Therapeutics, Inc.",Neurology/CNS,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE4,Yes,7,15,"NCT04130997, NCT04624633, NCT05877963, NCT06680037, NCT06864936, NCT07103746, NCT07211633, NCT07220252, NCT07225361, NCT07389590",United States,25.28,46.48,4.33,4460496400,4583454000,146197840,108410354,0.045637847183891835,254540000,131582000,Biotechnology,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina."
ACAD,24.97,ACADIA Pharmaceuticals Inc.,Neurology/CNS,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,5,7,"NCT05357612, NCT05895513, NCT05999240, NCT06159673, NCT06173531, NCT07029581, NCT07284667",United States,13.4,28.35,4.14,4160181000,3367970800,169181820,124523308,0.005264892030329713,54809000,847019000,Biotechnology,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California."
SUPN,56.32,"Supernus Pharmaceuticals, Inc.",Neurology/CNS,"Neurology/CNS, Psychiatry",PHASE4,Yes,7,9,"NCT02339064, NCT02736656, NCT03474770, NCT04781140, NCT06185985, NCT06798896, NCT07125222, NCT07141329, NCT07226661",United States,29.16,59.68,4.5,3056187400,2777882400,57339350,55117613,0.040673221224828505,42212000,308670000,Drug Manufacturers - Specialty & Generic,"Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland."
ARDX,6.56,"Ardelyx, Inc.",Neurology/CNS,"Gastroenterology, Neurology/CNS",PHASE4,Yes,5,9,"NCT05643534, NCT05995899, NCT06460038, NCT06553547, NCT06810167, NCT07382167",United States,3.21,8.4,4.9,1608823200,1577964200,245247420,155639011,0.03894313231673578,233830000,264689000,Biotechnology,"Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Neurology/CNS,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
IDRSF,5.14,Idorsia Ltd,Neurology/CNS,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,12,23,"NCT03737214, NCT05422612, NCT05423717, NCT05924425, NCT05948540, NCT05948553, NCT05948579, NCT06393504, NCT06498128, NCT06816433",Switzerland,1,5.82,-,1176495100,2719101700,251506690,23033434,0.24521416020356832,1589192100,89453385.09277755,Biotechnology,"Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat immune-mediated disorders; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and optional license and/or research and development collaboration agreement with Neurocrine Biosciences, Inc, to to develop and commercialize ACT-709478, and/or to collaborate in a research program to discover, identify and develop novel calcium channel blocker compounds for follow-on compounds to ACT-709478. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland."
TBPH,19.06,"Theravance Biopharma, Inc.",Neurology/CNS,"Neurology/CNS, Respiratory",PHASE4,Yes,6,6,"NCT05696717, NCT07133880",United States,7.9,21.03,4.42,965816500,677702500,50672430,26158733,0.06249226999959969,44595000,329680000,Biotechnology,"Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California."
HUMDF,0.4107,Hua Medicine (Shanghai) Ltd.,Neurology/CNS,"Metabolic/Endocrinology, Neurology/CNS",PHASE4,Yes,3,3,"NCT06263348, NCT07203248",China,0.15,0.4107,-,401591940,296301920,988005800,7154755,0.05550269475540292,37835816,142769720.4036907,Drug Manufacturers - Specialty & Generic,"Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China."
HITI,2.57,High Tide Inc.,Neurology/CNS,"Gastroenterology, Neurology/CNS, Pain/Analgesia, Urology/Nephrology",PHASE4,Yes,9,10,"NCT04793932, NCT05226117, NCT05487417, NCT06222645, NCT06845306, NCT07412522, NCT07420712",Canada,1.64,4.0554,5,224996690,281240480,87839736,11283642,0.08707990751565906,78315210,34185590.53153186,Pharmaceutical Retailers,"High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products. The company also engages in data analytics; advertising; product sourcing and imports; event-based cannabis retail; medical cannabis distribution; accessories retail; and other related services. It provides its products under the Daily High Club, DankStop, FAB CBD, GC, Nuleaf Naturals, Smoke Cartel, Blessed CBD, Fastendr, Famous Brandz, Queen of Bud, Canna Cabana, Grasscity, Daily High Club, and Valiant Distribution brands. The company sells its products through a network of retail stores, e-commerce platforms, and the wholesale distribution arm. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. The company was founded in 2009 and is headquartered in Calgary, Canada."
ILPLF,-,Island Pharmaceuticals Limited,Neurology/CNS,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
CELG.RT,0.1056,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,Neurology/CNS,"Hematology, Immunology/Autoimmune, Neurology/CNS",PHASE3,Yes,18,25,"NCT06220201, NCT06313996, NCT06615479, NCT07335562",United States,0.015,0.274899,-,125446780000,161597780000,2036473700,1652787190,0.0005061538469508498,47187000000,10673000000,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Neurology/CNS,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
ROIV,28.66,Roivant Sciences Ltd.,Neurology/CNS,"Immunology/Autoimmune, Neurology/CNS, Ophthalmology",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United Kingdom,8.73,29.2,4.66,20225714000,16509644000,715701100,510791437,0.2424787260940063,108939000,4529978000,Biotechnology,"Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom."
PRAX,347.55,"Praxis Precision Medicines, Inc.",Neurology/CNS,"Neurology/CNS, Others",PHASE3,No,12,12,"NCT05737784, NCT05818553, NCT06840925, NCT06908356, NCT06999902, NCT07010471, NCT07019922",United States,26.7,355.9999,4.52,9544759000,8618781000,27850832,27605084,0.002565403398514227,110000,599331000,Biotechnology,"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts."
ARWR,61.615,"Arrowhead Pharmaceuticals, Inc.",Neurology/CNS,"Cardiovascular, Metabolic/Endocrinology, Neurology/CNS, Respiratory, Urology/Nephrology",PHASE3,Yes,17,21,"NCT05089084, NCT05217667, NCT06131983, NCT06138743, NCT06209177, NCT06347003, NCT06347016, NCT06347133, NCT06672445, NCT06700538, NCT06822790, NCT06880770, NCT06937203, NCT07037771, NCT07221344, NCT07223658, NCT07241546",United States,9.57,76.76,4.33,8915849000,8693578000,140032200,105803368,0.03328908874452367,698163000,914710000,Biotechnology,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California."
PTCT,67.76,"PTC Therapeutics, Inc.",Neurology/CNS,"Gastroenterology, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,5,5,"NCT03605550, NCT04014530, NCT05166161, NCT05515536, NCT06302348",United States,35.95,87.5,4,5709801000,6471493600,82774730,88379259,0.02122564899703586,2707064000,1945371000,Biotechnology,"PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey."
IMVT,27.23,"Immunovant, Inc.",Neurology/CNS,"Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United States,12.72,29.25,4.41,5574746600,4580221400,203532180,97030092,0.005368950133802476,-,994525000,Biotechnology,"Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd."
XENE,44.575,Xenon Pharmaceuticals Inc.,Neurology/CNS,"Neurology/CNS, Psychiatry",PHASE3,No,2,7,"NCT03796962, NCT05614063, NCT05667142, NCT05716100, NCT06775379, NCT07076407, NCT07172516",Canada,26.74,46.6,4.85,3461147400,2914218500,77275010,79942801,0.000993725600456143,8327000,462268000,Biotechnology,"Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada."
DNLI,22.29,Denali Therapeutics Inc.,Neurology/CNS,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,Yes,8,10,"NCT04251026, NCT05262023, NCT05348785, NCT05371613, NCT06181136, NCT06602193, NCT07328451, NCT07354724",United States,10.57,23.77,4.84,3346473700,2518046700,156158370,152521608,0.04243453945803113,44480000,848204000,Biotechnology,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California."
BVNRY,30.51,Bavarian Nordic A/S,Neurology/CNS,"Immunology/Autoimmune, Infectious Diseases, Neurology/CNS",PHASE3,Yes,12,13,"NCT02977715, NCT06007183, NCT06549530, NCT06844487, NCT06844500, NCT06899802, NCT07003984, NCT07199569",Denmark,20.71,37.605,-,2403276300,1954995100,77505330,24958889,0.001803676792598014,21081488,468437690.696226,Biotechnology,"Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark."
DNTH,51.87,"Dianthus Therapeutics, Inc.",Neurology/CNS,"Immunology/Autoimmune, Neurology/CNS",PHASE3,No,1,3,"NCT06282159, NCT06537999, NCT06858579",United States,13.365,57.5,4.92,2284772600,1730570500,43223090,47222557,7.600964851276291e-05,1285000,402613000,Biotechnology,"Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York."
STOK,35.5,"Stoke Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE3,No,2,2,"NCT04740476, NCT06872125",United States,5.35,38.693,4.91,2027658900,1703815800,57117150,59670364,0.031180878047275228,4782000,248310000,Biotechnology,"Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts."
CLDX,30.82,"Celldex Therapeutics, Inc.",Neurology/CNS,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
HRMY,28.19,"Harmony Biosciences Holdings, Inc.",Neurology/CNS,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE3,Yes,6,7,"NCT04257929, NCT04462770, NCT05066217, NCT05536011, NCT06366464",United States,25.52,40.87,3.81,1623641300,1011964350,57596360,52300102,0.014374406977469669,163663000,775340000,Biotechnology,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania."
AMLX,14.37,"Amylyx Pharmaceuticals, Inc.",Neurology/CNS,"Metabolic/Endocrinology, Neurology/CNS",PHASE3,No,3,5,"NCT05021536, NCT05676034, NCT06122662, NCT06665165, NCT06747468",United States,2.6,17.49,4.81,1615445900,1277390800,109819570,94600578,0.060628053924481985,5935000,343990000,Drug Manufacturers - Specialty & Generic,"Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts."
CAPR,28.35,"Capricor Therapeutics, Inc.",Neurology/CNS,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT04428476, NCT05126758",United States,4.3,40.37,4.8,1443462700,1359439500,51718476,27207591,0.01141006187827464,14542789,98565971,Biotechnology,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California."
ZBIO,26.03,"Zenas BioPharma, Inc.",Neurology/CNS,"Immunology/Autoimmune, Neurology/CNS",PHASE3,No,3,7,"NCT05638854, NCT05662241, NCT05786573, NCT06559163, NCT06564311, NCT07067463, NCT07299019",United States,6.11,44.6,4.75,1399415800,1109329900,53679170,33448030,0.01565360006400218,798000,290884000,Biotechnology,"Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts."
DAWN,10.93,"Day One Biopharmaceuticals, Inc.",Neurology/CNS,"Neurology/CNS, Oncology/Hematology, Rare/Orphan Diseases",PHASE3,No,3,5,"NCT04775485, NCT05465174, NCT05566795, NCT06752681",United States,5.635,13.2,4.44,1234159500,785472500,102675500,70282943,0.043363469506095036,2893000,441113000,Biotechnology,"Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California."
ANNX,5.09,"Annexon, Inc.",Neurology/CNS,"Neurology/CNS, Ophthalmology",PHASE3,No,2,2,"NCT06510816, NCT07020819",United States,1.285,7.18,4.77,739317200,577534140,149055870,118060210,0.010106599015795949,26938000,188721000,Biotechnology,"Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California."
PRTA,8.88,Prothena Corporation plc,Neurology/CNS,"Neurology/CNS, Others",PHASE3,No,3,4,"NCT03100149, NCT04777331, NCT06699680, NCT07174310",Ireland,4.32,16.16,3.71,482854940,183696940,53829984,44459418,0.1782047046638872,8373000,307531000,Biotechnology,"Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland."
DMAC,8.5,DiaMedica Therapeutics Inc.,Neurology/CNS,Neurology/CNS,PHASE3,No,1,1,NCT05065216,United States,3.19,10.4195,5,458095650,403043650,53578440,13169777,0.4751309757270084,266000,55318000,Biotechnology,"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota."
KYTX,8.09,"Kyverna Therapeutics, Inc.",Neurology/CNS,"Immunology/Autoimmune, Neurology/CNS",PHASE3,Yes,14,27,"NCT05938725, NCT06138132, NCT06152172, NCT06193889, NCT06342960, NCT06384976, NCT06400303, NCT06451159, NCT06475495, NCT06588491, NCT06590545, NCT07403188",United States,1.78,13.67,4.66,454179550,288065540,57129504,23246461,0.018330108700578048,5024000,171138000,Biotechnology,"Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California."
CABA,3.49,"Cabaletta Bio, Inc.",Neurology/CNS,"Immunology/Autoimmune, Musculoskeletal, Neurology/CNS",PHASE3,No,3,7,"NCT04422912, NCT06121297, NCT06154252, NCT06328777, NCT06359041, NCT07006805",United States,0.9857,3.78,4.5,316712500,182561520,96265200,55490177,0.01709548135378179,25780000,159931000,Biotechnology,"Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania."
ACB,3.83,Aurora Cannabis Inc.,Neurology/CNS,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,Yes,2,2,"NCT03936361, NCT06513533",Canada,3.28,6.665,4.2,215197180,232719360,56709424,6802276,0.005165931503730315,73580940,79012363.66815536,Drug Manufacturers - Specialty & Generic,"Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants. It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada."
PRQR,1.54,ProQR Therapeutics N.V.,Neurology/CNS,"Neurology/CNS, Ophthalmology",PHASE3,No,2,2,"NCT03913143, NCT04123626",Netherlands,1.07,3.1,4.87,159071230,53014690,105345190,29793823,0.01737522107321234,19360178,125478985.6773891,Biotechnology,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands."
PLYX,2.77,"Polaryx Therapeutics, Inc.",Neurology/CNS,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,No,1,1,NCT04637282,United States,2.201,48.91,-,132561230,126816230,47343296,85281,0.2164571470381541,-,5745000,Biotechnology,"Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey."
IMUX,0.9104,"Immunic, Inc.",Neurology/CNS,"Hematology, Neurology/CNS",PHASE3,No,7,9,"NCT03846219, NCT05054140, NCT05134441, NCT05201638",United States,0.5062,1.35,5,117196550,82856550,130464824,60143460,0.013310399948798459,792000,35132000,Biotechnology,"Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York."
ATGGF,0.0311,Actinogen Medical Limited,Neurology/CNS,Neurology/CNS,PHASE3,No,1,1,NCT06125951,Australia,0.01,0.04,-,105106424,95758270,3461912300,147557022,0.15024869456575002,2148511.2,10862333.81597999,Biotechnology,"Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia."
ANVS,2.88,"Annovis Bio, Inc.",Neurology/CNS,Neurology/CNS,PHASE3,No,1,2,"NCT06709014, NCT07284784",United States,1.11,5.5,4.75,71027740,55741344,26502888,5281086,0.1545037976803208,-,15286399,Biotechnology,"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania."
GRCE,4.07,"Grace Therapeutics, Inc.",Neurology/CNS,"Cardiovascular, Neurology/CNS",PHASE3,Yes,2,2,NCT05995405,United States,1.75,4.3,5,63752988,45080988,15474026,2242219,0.16528775381403651,-,18672000,Biotechnology,"Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey."
BRCTF,38.06,BioArctic AB (publ),Neurology/CNS,Neurology/CNS,PHASE2,No,2,2,NCT06671938,Sweden,15.49,40,-,3135481300,2898372000,88641490,38629838,0.31980811242049934,4786752,237917985.458353,Biotechnology,"BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden."
DYN,16.09,"Dyne Therapeutics, Inc.",Neurology/CNS,"Musculoskeletal, Neurology/CNS",PHASE2,No,2,2,"NCT05481879, NCT05524883",United States,6.36,25,4.56,2558695700,1887274800,164652240,169174642,0.0045046965933351005,120466000,791887000,Biotechnology,"Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts."
QURE,24.87,uniQure N.V.,Neurology/CNS,"Neurology/CNS, Rare/Orphan Diseases",PHASE2,No,2,2,"NCT06100276, NCT06270316",Netherlands,7.76,71.5,4.35,1496868600,1334285700,62291664,52981848,0.01586907176217855,531662000,694245000,Biotechnology,"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands."
RAPP,30.2,"Rapport Therapeutics, Inc.",Neurology/CNS,"Neurology/CNS, Psychiatry",PHASE2,No,1,2,"NCT07046494, NCT07219407",United States,6.43,42.2685,4.9,1381696400,880542400,47661136,36681098,0.04061799753882662,11872000,513026000,Biotechnology,"Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts."
DRUG,90,Bright Minds Biosciences Inc.,Neurology/CNS,Neurology/CNS,PHASE2,No,1,2,"NCT06401538, NCT07266324",United States,23.175,123.75,4.85,857283650,792376960,9787161,5026573,0.16310746293026138,76425.98,64876739.98411739,Biotechnology,"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York."
MPLT,17.63,"MapLight Therapeutics, Inc.",Neurology/CNS,"Neurology/CNS, Psychiatry",PHASE2,No,5,5,"NCT05081245, NCT06887192, NCT07038876",United States,12.24,21.55,4.75,786418400,1072949440,43641424,15253918,0.023903705186571172,6006000,227168000,Biotechnology,"MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California."
DSGN,10.97,"Design Therapeutics, Inc.",Neurology/CNS,"Neurology/CNS, Ophthalmology",PHASE2,No,2,3,"NCT06772870, NCT06874010, NCT07024693",United States,2.6,11.14,4.6,603815800,399588830,56963756,26303000,0.1503369728442869,1743000,205970000,Biotechnology,"Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California."
ANRO,18.99,"Alto Neuroscience, Inc.",Neurology/CNS,"Neurology/CNS, Psychiatry",PHASE2,No,3,3,"NCT05922878, NCT06502964, NCT06656416",United States,1.6,20.9075,4.8,600201600,487783580,31066336,11779732,0.04263956466058838,25398000,137816000,Biotechnology,"Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California."
NGEN,4.15,NervGen Pharma Corp.,Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT05965700,Canada,1.5,6.3,4.25,328403800,320135070,79649256,-45000,0.027803360425571827,23877.969,8167059.542204175,Biotechnology,"NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada."
ALEC,2.39,"Alector, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,1,2,"NCT06079190, NCT07105709",United States,0.87,3.3999,2.87,239041730,-14191277,109151470,75749603,0.06516551604544554,37875000,291108000,Biotechnology,"Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California."
VYGR,4.09,"Voyager Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,2,2,NCT06874621,United States,2.645,5.55,5,210168320,19525316,55600084,24158594,0.014496722702793039,38368000,208930000,Biotechnology,"Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts."
ABOS,2.78,"Acumen Pharmaceuticals, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT06335173,United States,0.8551,3.0499,5,167182660,61966652,60573424,18197128,0.1166088098865138,30836000,126609000,Biotechnology,"Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts."
CNTB,2.59,Connect Biopharma Holdings Limited,Neurology/CNS,"Neurology/CNS, Respiratory",PHASE2,Yes,2,3,"NCT04937062, NCT06940141, NCT06940154",United States,0.51,3.28,5,136963600,82963610,55903510,7037949,0.2045582895658096,781000,54781000,Biotechnology,"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California."
COYA,5.05,"Coya Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT07161999,United States,3.9401,8.29,5,114891200,86761330,23447184,5946921,0.05645313554297759,-,28129866,Biotechnology,"Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas."
GANX,2.52,"Gain Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,3,3,"NCT06732180, NCT07280299",United States,1.41,4.34,4.8,105386110,97184040,38462084,8164395,0.03480079148075306,605278,8807353,Biotechnology,"Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland."
CGTX,1.12,"Cognition Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT05531656,United States,0.222301,3.83,5,91805230,52851228,88274260,15466135,0.009377501649461613,380000,39334000,Biotechnology,"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York."
CLNN,4.96,Clene Inc.,Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT05299658,United States,2.2801,13.5,4.83,59362668,72749660,11778307,2103952,0.1324783774102679,21312000,7925000,Packaged Foods,"Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah."
CRVO,4.39,CervoMed Inc.,Neurology/CNS,"Cardiovascular, Neurology/CNS",PHASE2,No,2,3,"NCT06815965, NCT06987643, NCT07033481",United States,1.92,16.94,5,44320524,17026436,9252719,1441459,0.3206030573283378,-,27294088,Biotechnology,"CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts."
PASG,9.32,"Passage Bio, Inc.",Neurology/CNS,Neurology/CNS,PHASE2,No,1,1,NCT04747431,United States,5.1239,20,5,29498428,1062428,3178710,1359351,0.005032230055588588,24337000,52773000,Biotechnology,"Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania."
IGC,0.2901,"IGC Pharma, Inc.",Neurology/CNS,"Cardiovascular, Neurology/CNS",PHASE2,No,2,2,NCT05543681,United States,0.242,0.4985,5,26723646,25739646,95818024,18673942,0.08864803023539736,146000,1130000,Biotechnology,"IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland."
LXEO,6.89,"Lexeo Therapeutics, Inc.",Neurology/CNS,Neurology/CNS,PHASE1,No,1,1,NCT05400330,United States,1.45,10.99,4.81,488285220,373978200,72987330,57924846,0.002460346263803061,8457000,122764000,Biotechnology,"Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York."
PMN,19.86,"ProMIS Neurosciences, Inc.",Neurology/CNS,Neurology/CNS,PHASE1,No,1,1,NCT06750432,Canada,6.27,39.75,4.5,161059760,145627550,8967693,28381,0.1144437036370447,-,15432216,Biotechnology,"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada."
ALPS,1.05,Alps Group Inc,Neurology/CNS,Neurology/CNS,PHASE1,No,1,1,NCT03570450,Malaysia,0.5622,2.9,-,154935340,154801420,166400320,631221,0.5668032946041224,779231,643252,,
ELAN,26.84,Elanco Animal Health Incorporated,No Trials,,No Trials,No,0,0,,United States,8.02,27.72,4.35,13107258000,16926258000,496863500,541292206,0.006412904109186144,4324000000,545000000,Drug Manufacturers - Specialty & Generic,"Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana."
RGC,26.51,Regencell Bioscience Holdings Limited,No Trials,,No Trials,No,0,0,,Hong Kong,0.105,83.6,-,12792429000,12788076000,494488900,839342,0.8855529596631518,544415,4897015,Drug Manufacturers - Specialty & Generic,"Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong."
KRKA.F,-,"Krka, d. d.",No Trials,,No Trials,No,0,0,,Slovenia,-,-,-,8682602000,8020361700,30464456,8052582,0.1008232380983018,22357360,704199342.5686781,Conglomerates,"Koç Holding A.S., through its subsidiaries, engages in the energy, automotive, consumer durables, finance, and other businesses in Turkey and internationally. The company's energy business produces and trades in petroleum products; operates petroleum refineries; distributes fuel and liquefied petroleum gases, as well as water products; ships petroleum; and generates electricity through hydroelectric, natural gas, coal, wind, thermal, solar power and other renewable plants. Its automotive business provides light commercial vehicles, passenger cars, tractors, buses, and trucks, as well as armored vehicles for the defense industry; and automotive retailing, car rental, and insurance services. The company's consumer durables business offers white goods, televisions, and air conditioners; and distributes information and communication technologies. Its finance business provides various banking and financial products and services that include private banking, factoring, leasing, asset and portfolio management, investment, and credit cards; and consumer finance, custody, brokerage, and financial consulting services. The company's other business offers home improvement retailing, ship construction, tourism, marina operation, catering, purchasing and supply chain management, payment, electric vehicle charging station, and information technology services, as well as healthcare technologies; operates hotels, restaurants, pubs, cafeterias, patisseries, cafés, banquet units, bakeries, stadiums, residences, and production facilities; and manufactures and exports electric motors. Koç Holding A.S. was founded in 1926 and is based in Istanbul, Turkey."
DESNF,-,Dottikon ES Holding AG,No Trials,,No Trials,No,0,0,,Switzerland,-,-,-,6259199500,6127552000,13819705,892476,0.2089097415610536,163318640,291307679.7447204,,
DUTBF,45.0165,"Duality Biotherapeutics, Inc.",No Trials,,No Trials,No,0,0,,China,43.6948,45.0512,-,3912664300,3402902500,90137710,24726807,0.1275965685129312,9477100,517514621.9238124,,
ADMA,15.68,"ADMA Biologics, Inc.",No Trials,,No Trials,No,0,0,,United States,13.5,25.67,5,3693725200,3715463400,237997760,223632128,0.01958268809793235,83123000,61385000,Biotechnology,"ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey."
VRBCF,436.32,Virbac SA,No Trials,,No Trials,No,0,0,,France,324,436.32,-,3640816000,3861259000,8377824,1560253,0.5018078680096407,383538270,163136631.3309776,Drug Manufacturers - General,"Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France."
APNHY,8.2,Aspen Pharmacare Holdings Limited,No Trials,,No Trials,No,0,0,,South Africa,6.23,12.245,-,3611712000,5472441000,444022560,327066759,0.1754881176046929,2040274600,362018809.8398622,Drug Manufacturers - Specialty & Generic,"Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa."
HYPMY,4.5,Hypera S.A.,No Trials,,No Trials,No,0,0,,Brazil,3.1,5.5,-,2958873000,4410969000,632941000,231220409,0.27451154326526717,1756548500,350179809.4808635,Drug Manufacturers - Specialty & Generic,"Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex  A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil."
HAWPY,14.17,Haw Par Corporation Limited,No Trials,,No Trials,No,0,0,,Singapore,8.37,14.17,-,2954347800,2429101000,221368180,57656628,0.007651113423608551,26729792,550125831.6686852,Drug Manufacturers - General,"Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, The Association of Southeast Asian Nations countries, other Asian countries, and internationally. It manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands; and invests in quoted securities. The company also owns and leases various investment properties. In addition, it provides family and tourist oriented leisure activities primarily in the form of oceanariums. Further, the company is involved in the property development; and owning and letting properties; letting out of office spaces; and management support services. Haw Par Corporation Limited was incorporated in 1969 and is based in Singapore."
GENSY,37.25,Genus plc,No Trials,,No Trials,No,0,0,,United Kingdom,21,37.25,-,2849504500,3143483100,66913228,53998025,0.0034135402943047373,364966500,65883386.40606127,Biotechnology,"Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom."
HTSUF,28.5916,"Hisamitsu Pharmaceutical Co., Inc.",No Trials,,No Trials,No,0,0,,Japan,24.559,32.3,-,2710159600,2032110700,70073070,30060641,0.0074393914809212725,15100865,709420429.0746077,Drug Manufacturers - Specialty & Generic,"Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd."
PAHC,53.1,Phibro Animal Health Corporation,No Trials,,No Trials,No,0,0,,United States,16.16,56.3,3,2085916500,2785631500,40534716,20113348,0.4895168872035516,774536000,74821000,Drug Manufacturers - Specialty & Generic,"Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey."
BORAY,3.8,"Bora Pharmaceuticals Co., Ltd.",No Trials,,No Trials,No,0,0,,Taiwan,3.792,5,-,2054155600,2600190700,124023600,15423862,0.07862403226014915,641443700,146519011.8434435,,"Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan."
PRGO,14.41,Perrigo Company plc,No Trials,,No Trials,No,0,0,,Ireland,12.17,30.93,3.8,2010686700,5438987000,137624020,155587275,0.004220784211843884,3860400000,432100000,Drug Manufacturers - Specialty & Generic,"Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland."
TSMRF,22.7404,Tsumura & Co.,No Trials,,No Trials,No,0,0,,Japan,22.7404,28.15,-,1970215300,2606810400,74544910,31397958,0.0009242750196016059,864495100,443583244.482184,Drug Manufacturers - Specialty & Generic,"Tsumura & Co. engages in the production and sale of Kampo extract intermediates and granular Kampo formulations in Japan and internationally. The company offers products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation and hemorrhoids, as well as body aches, children's sickness, stress, urinary problems, and cold, cough, and nasal and throat inflammation symptoms. It also offers over-the-counter Kampo medicines. The company was founded in 1893 and is headquartered in Tokyo, Japan."
AUPH,14.43,Aurinia Pharmaceuticals Inc.,No Trials,,No Trials,No,0,0,,Canada,6.55,16.54,4.14,1923553800,1650257800,131840560,78192374,0.02242763548962198,78212000,351508000,Biotechnology,"Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada."
CURLF,2.4801,"Curaleaf Holdings, Inc.",No Trials,,No Trials,No,0,0,,United States,0.675,5.05,4.87,1909968100,2925444600,774339500,23776227,0.059117844756342276,1035104000,107488000,Drug Manufacturers - Specialty & Generic,"Curaleaf Holdings, Inc. produces and distributes cannabis products in the United States and internationally. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of hemp-derived THC products through wholesale channels. The company is headquartered in Stamford, Connecticut."
SMNR,8,"Semnur Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,4.5,23,-,1841673100,1851402100,230209140,-,0.0,9813000,85000,Biotechnology,"Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company."
MMDCF,-,Mind Medicine (MindMed) Inc. WT EXP 010724,No Trials,,No Trials,No,0,0,,United States,-,-,-,1718986900,1550901900,98509280,65195533,0.00975997398174034,40985000,209070000,,
VETOF,87.51,Vetoquinol SA,No Trials,,No Trials,No,0,0,,France,72.0407,87.51,-,1190542000,997759040,11795673,1100147,0.0401949087601869,20891638,213795053.0035336,Drug Manufacturers - Specialty & Generic,"Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA."
XERS,6.66,"Xeris Biopharma Holdings, Inc.",No Trials,,No Trials,No,0,0,,United States,3.59,10.08,4.57,1108374300,1274430200,165924290,101646647,0.05182751152243901,257654000,91598000,Biotechnology,"Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois."
TCNNF,6.4,Trulieve Cannabis Corp.,No Trials,,No Trials,No,0,0,,United States,3.02,11.83,5,1081126300,1434922100,169313020,18238073,0.03421040467873758,814787000,449198000,Drug Manufacturers - Specialty & Generic,"Trulieve Cannabis Corp. operates as a cannabis retailer. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida."
CRON,2.77,Cronos Group Inc.,No Trials,,No Trials,No,0,0,,Canada,1.6,3.43,4.5,1045026560,259413730,382893280,57036656,0.06262143544038866,1742000,824170000,Drug Manufacturers - Specialty & Generic,"Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. The company is based in Stayner, Canada."
VTYX,13.97,"Ventyx Biosciences, Inc.",No Trials,,No Trials,No,0,0,,United States,0.783,25,3.25,1001780500,819166460,71760776,42679744,0.04219519470650109,10024000,192638000,Biotechnology,"Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California."
GNMLF,1,"Genomma Lab Internacional, S.A.B. de C.V.",No Trials,,No Trials,No,0,0,,Mexico,0.9348,1.43,-,997299300,1296984200,976727900,268371832,0.30959849255538613,404715000,123658990.6533892,Drug Manufacturers - Specialty & Generic,"Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico."
BJTRF,0.5645,Beijing Tong Ren Tang Chinese Medicine Company Limited,No Trials,,No Trials,No,0,0,,Hong Kong,0.5645,0.6484,-,939442500,723879550,837100000,31128078,7.287062477601242e-05,18179584,257692523.274004,Drug Manufacturers - Specialty & Generic,"Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals. It operates through three segments: Hong Kong, Mainland China, and Overseas. The company offers Chinese medical consultation and treatment services. It also operates retail outlets in Hong Kong and in other countries and regions in Asia, Oceania, North America, and Europe. It markets its products under the Tong Ren Tang brand name. Beijing Tong Ren Tang Chinese Medicine Company Limited was founded in 1669 and is based in Wan Chai, Hong Kong."
TLRY,7.83,"Tilray Brands, Inc.",No Trials,,No Trials,No,0,0,,Canada,3.507,23.2,3.5,922734800,917494800,116506910,9562244,0.007860314489828227,319629000,291551000,Drug Manufacturers - Specialty & Generic,"Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada."
BIOA,22.14,"BioAge Labs, Inc.",No Trials,,No Trials,No,0,0,,United States,2.88,24,4,900183300,611460300,41752470,23162735,0.02584989458827731,7133000,285778000,Drug Manufacturers - Specialty & Generic,"BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California."
GYRE,8.65,"Gyre Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,6.11,13.75,5,763479200,740090200,90890380,3373094,0.06999046466754276,1165000,60049000,Biotechnology,"Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc."
PEXXF,-,PT Tempo Scan Pacific Tbk,No Trials,,No Trials,No,0,0,,Indonesia,-,-,-,739937340,536402940,4509864400,29991125,0.001188904952195568,61614876,297008475.6296607,,
DHTRF,11.99,DRI Healthcare Trust,No Trials,,No Trials,No,0,0,,Canada,7.65,12.25,4,672791300,1090176500,55074036,32488391,0.009022690837475575,452320000,49546751.6,,
IRWD,3.36,"Ironwood Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,0.5271,5.78,3.75,616552060,1074385000,162678640,115832369,0.0238661008780089,598240000,215456000,Drug Manufacturers - Specialty & Generic,"Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts."
OPTEY,0.0183,Opthea Limited,No Trials,,No Trials,No,0,0,,Australia,0.0059,5.54,3,579528960,793359600,1367978100,240439774,0.01283018058797639,246993000,48443000,Biotechnology,"Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia."
BOIRF,30,Boiron SA,No Trials,,No Trials,No,0,0,,France,24,32.2779,-,552092100,499885100,17362276,484109,0.0,21318022,73553592.46171968,Drug Manufacturers - Specialty & Generic,"Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France."
VREOF,0.4838,Vireo Growth Inc.,No Trials,,No Trials,No,0,0,,United States,0.308,0.8,-,545242200,652552260,1082835200,197642148,0.1503850153499683,203735440,98164196,Drug Manufacturers - Specialty & Generic,"Vireo Growth Inc. operates as a cannabis company that cultivates, manufactures, processes, and distributes medical and adult-use cannabis products in Maryland, Minnesota, and New York. It sells cannabis products through a network of retail dispensaries and distributors. The company was formerly known as Goodness Growth Holdings, Inc. and changed its name to Vireo Growth Inc. in July 2024. Vireo Growth Inc. was incorporated in 2004 and is headquartered in Minneapolis, Minnesota."
AQST,4.14,"Aquestive Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,2.12,7.55,4.77,498992740,411305730,122003110,69064785,0.03154115419989324,41376000,129063000,Drug Manufacturers - Specialty & Generic,"Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey."
ETON,17.65,"Eton Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,11.0867,23,5,490224540,483980540,26817536,11115137,0.15309524160218302,30877000,37121000,Drug Manufacturers - Specialty & Generic,"Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois."
PURR,4.14,Hyperliquid Strategies Inc.,No Trials,,No Trials,No,0,0,,United States,3.01,5.78,5,489671650,207747650,123967500,24733708,0.007217310523012208,-,-,Capital Markets,"Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York."
KROS,15.22,"Keros Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,9.12,22.55,4.11,472833380,-203209620,30466068,20703867,0.01824485462827515,17429000,693472000,Biotechnology,"Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts."
CRLBF,1.029,Cresco Labs Inc.,No Trials,,No Trials,No,0,0,,United States,0.4256,2.3,5,462598140,827318600,362280800,13680779,0.027224368271715413,580760000,45413000,Drug Manufacturers - Specialty & Generic,"Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy's Edibles brand, as well as licenses the Kiva brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois."
ASKPF,-,"ASKA Pharmaceutical Holdings Co.,Ltd.",No Trials,,No Trials,No,0,0,,Japan,-,-,-,448482600,532763200,28396124,7813524,0.03592039406785256,87576376,42035638.35560465,,
ELTP,0.40371,"Elite Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,0.27,0.8194,-,436143070,421105120,1076896400,500,0.2238388108631155,6056957,21094904,Drug Manufacturers - Specialty & Generic,"Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey."
ARMP,10.63,"Armata Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,0.8981,16.34,5,431785900,594711900,36406904,1249580,0.007648411750463271,177682000,14756000,Biotechnology,"Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc."
ENTA,14.64,"Enanta Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,4.09,17.15,4.42,428035330,379314340,29019344,18980820,0.04564224470408428,193183000,185849000,Biotechnology,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts."
VRNO,1.18,Verano Holdings Corp.,No Trials,,No Trials,No,0,0,,United States,0.41,1.95,5,424129280,852032900,363245500,17491909,0.09202882844694629,505370000,82623000,Drug Manufacturers - Specialty & Generic,"Verano Holdings Corp. operates as a vertically integrated multi-state cannabis operator in the United States. The company engages in the cultivation, processing, wholesale, and retail distribution of cannabis in Arizona, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Virginia and West Virginia, and Pennsylvania. It offers cannabis products under the Encore, Avexia, MUV, Savvy, BITS, Verano, and Essence brands for medical and adult-use markets. The company is headquartered in Chicago, Illinois."
SWDCF,2.776,Swedencare AB (publ),No Trials,,No Trials,No,0,0,,Sweden,2.5899,4.84,-,412307100,600228300,159840960,31072278,0.0061660165975731965,195955970,11187553.3581125,Packaged Foods,"Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in North America, Europe, and internationally. The company offers animal nutritional supplements, treats, and grooming products under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and support and solutions for the veterinary community under the Stratford Animal Health name. It also provides pet health supplements under the NaturVet, VETCLASSICS, and NutriScience name; pet supplements, vitamins, dental care products, ear cleaners, pilling agents, and topicals under the Pet MD name; and vet-formulated pet care products under the VetWELL name. In addition, the company offers dental product for dogs and cats under the ProDen PlaqueOff name; pharmaceutical grade health products for dogs, cats, and horses under the nutravet name; range of products to improve the health and life of pets under the Animal Pharmaceuticals name; premium dog treat offerings, such as jerky and baked biscuit, as well as nutritional supplements for skin and coat health, ear care, and liver support under the Riley's Organics name; and Rx Vitamins for Pets. Further, it provides animal wellness and healthy aging neutraceuticals under the MedVant name; VetWorthy, a solution for specific animal needs and conditions; and Healthy Solutions for Pets, a solution to address a range of pet issues and needs. The company distributes its products through veterinarians and pet stores, as well as online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in Malmö, Sweden."
LENZ,13.22,"LENZ Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,11.48,50.4,4.85,401137400,199919410,31289968,25170824,0.02169853999159488,954000,202172000,Biotechnology,"LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California."
SNDL,1.55,SNDL Inc.,No Trials,,No Trials,No,0,0,,Canada,1.15,2.89,5,399125000,337249340,257500000,56802033,0.013095254368932042,111487300,173427000.6108736,Beverages - Wineries & Distilleries,"SNDL Inc. engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada. The company operates through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sale of wines, beers, and spirits through liquor stores under the Wine and Beyond, Ace Liquor, and Liquor Depot retail banners; and private sale of adult-use cannabis products and accessories through its owned and franchised retail cannabis stores. The company also produces and distributes flower, pre-rolls, and vapes, as well as offers financial services. It offers its products under the Top Leaf, Contraband, Palmetto, Bon Jak, La Logue, Versus, Grasslands, Pearls by Grön, No Future, and Bhang Chocolate brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada."
BNTC,11,Benitec Biopharma Inc.,No Trials,,No Trials,No,0,0,,United States,9.85,17.15,4.85,380914560,193111570,34254908,17356995,0.028086662153250043,987000,188790000,Biotechnology,"Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California."
DUPBF,-,Duopharma Biotech Berhad,No Trials,,No Trials,No,0,0,,Malaysia,-,-,-,368039800,425844860,961942460,693999284,0.0030188022131481963,117335500,63842169.04688354,,
XOMA,26.74,XOMA Royalty Corporation,No Trials,,No Trials,No,0,0,,United States,18.352,39.92,4.6,334839100,442086100,12383103,6160926,0.01634703353432496,133889000,46710000,Biotechnology,"XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California."
XOMAO,25.3202,XOMA Royalty Corporation 8.375% DP PFD B,No Trials,,No Trials,No,0,0,,United States,23.32,25.76,-,334839100,442086100,12383103,6160926,0.01634703353432496,133889000,46710000,Biotechnology,"XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California."
XOMAP,25.89,XOMA Royalty Corporation 8.625% CUM PERP PFD SER A,No Trials,,No Trials,No,0,0,,United States,24.96,30,-,334839100,442086100,12383103,6160926,0.01634703353432496,133889000,46710000,Biotechnology,"XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California."
LRMR,5.95,"Larimar Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,1.61,6.42,4.9,315828540,144740540,85590390,30115661,0.01177865852045636,4347000,175435000,Biotechnology,"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania."
RAONF,1.22,Racura Oncology Ltd,No Trials,,No Trials,No,0,0,,Australia,1.22,1.22,-,300148480,290499550,181666800,4754746,0.27887510938225857,-,8994205.607476635,,
NGNE,20.09,Neurogene Inc.,No Trials,,No Trials,No,0,0,,United States,6.875,37.265899,5,292757220,37555220,15489800,8406763,0.08264783530835115,10208000,265410000,Biotechnology,"Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York."
DERM,8.725,Journey Medical Corporation,No Trials,,No Trials,No,0,0,,United States,4.97,9.555,5,289332320,289685300,33256588,11196248,0.09400230715189424,25301000,24948000,Drug Manufacturers - Specialty & Generic,"Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona."
DXNH.F,-,Eurobio Scientific Société anonyme,No Trials,,No Trials,No,0,0,,France,-,-,-,274503200,262597650,10068279,-64154,0,19726738,31633686.69022379,,
CBUS,3.73,"Cibus, Inc.",No Trials,,No Trials,No,0,0,,United States,1.09,3.8,4.33,249282960,480677400,65980870,14566722,0.2359050719338997,259466000,23886000,Biotechnology,"Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California."
WDBG,0.7503,Woodbrook Group Holdings Inc.,No Trials,,No Trials,No,0,0,,Cyprus,0.0003,0.7503,-,248553000,-,331271500,-,-,-,-,Capital Markets,"Woodbrook Group Holdings Inc. provides investment and strategic planning advisory services. It offers services in the areas of portfolio management, mid and long term investment management, alternative investments, lump sum investments, education fee planning, wealth planning, retirement planning, structured product building, and qualifying recognized overseas pension scheme and financial review. The company is headquartered in Limassol, Cyprus."
TSNDF,0.6985,TerrAscend Corp.,No Trials,,No Trials,No,0,0,,Canada,0.227301,1.45,5,246225090,426387900,307285060,62902382,0.05167182741206286,254616000,37507000,Drug Manufacturers - Specialty & Generic,"TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, GAGE Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, Cookies, and Lemonnade. The company also operates retail dispensaries under the Apothecarium, TerrAscend, Pinnacle Emporium, GAGE Cannabis, and State Flower brand names. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in King Of Prussia, Pennsylvania."
EAPIF,2.54,Euroapi S.A.,No Trials,,No Trials,No,0,0,,France,2.46,3.741,-,239519680,259423100,95213550,20524223,8.736150974132297e-05,80565370,60659599.52885748,Drug Manufacturers - Specialty & Generic,"Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France."
SRZN,27.03,"Surrozen, Inc.",No Trials,,No Trials,No,0,0,,United States,5.9,27.96,5,231428370,157175360,8571421,4266605,0.004735468357956148,7082000,81335000,Biotechnology,"Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California."
EDIT,2.13,"Editas Medicine, Inc.",No Trials,,No Trials,No,0,0,,United States,0.9101,4.5372,3.71,205975380,59979372,97618660,50813454,0.0036315085660876723,19652000,165648000,Biotechnology,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts."
OVID,1.62,Ovid Therapeutics Inc.,No Trials,,No Trials,No,0,0,,United States,0.2425,2.01,5,196578370,184738370,130184350,44332831,0.03070928193651659,13763000,25603000,Biotechnology,"Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York."
OGI,1.42,Organigram Global Inc.,No Trials,,No Trials,No,0,0,,Canada,0.85,2.24,5,192310400,232511230,135141950,8431202,0.002262583998347693,6157791.5,6106063.807310374,Drug Manufacturers - Specialty & Generic,"Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada."
HTTIF,0.36,"HighTide Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,China,0.3358,0.4883,-,186948530,145799710,571325700,27795654,0.02745303226950413,13885453,62196289.73045408,Biotechnology,"HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China."
CNTN,5.13,"Canton Strategic Holdings, Inc.",No Trials,,No Trials,No,0,0,,United States,0.952,9.08,-,186185580,178770740,39529850,9776446,0.15150817558185842,195493,7610340,Biotechnology,"Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey."
BGM,1.02,BGM Group Ltd.,No Trials,,No Trials,No,0,0,,British Virgin Islands,0.96,17.17,-,182120340,170729390,183959940,16789886,0.7294147658709439,-,-,Drug Manufacturers - Specialty & Generic,"BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China."
BBIXF,0.135,Bonus BioGroup Ltd.,No Trials,,No Trials,No,0,0,,Israel,0.0001,0.15,-,177772700,180477780,1167925200,3365468,0.45545159265753765,2851162.5,355393.2484189899,Biotechnology,"Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel."
CNBRF,-,CANbridge Pharmaceuticals Inc.,No Trials,,No Trials,No,0,0,,China,-,-,-,172511140,177134030,511228220,70367980,0.08329258473623348,4880861,372665.1125783442,,
DVYSF,-,Devyser Diagnostics AB (publ),No Trials,,No Trials,No,0,0,,Sweden,-,-,-,168335820,165507790,16653657,8225842,0.2962409397527522,5637223.5,8417819.274307946,,
ADOCY,11.8,Adocia SA,No Trials,,No Trials,No,0,0,,France,11.8,11.8,-,158297340,162269780,19593334,2989851,0.13441500053028238,12330978,8358068.315665489,Biotechnology,"Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France."
ANIK,10.94,"Anika Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,7.8701,17.74,4.5,156470220,122987224,14421219,10926039,0.03555073950405996,24507000,57990000,Drug Manufacturers - Specialty & Generic,"Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts."
AMGXF,0.3602,"AnGes, Inc.",No Trials,,No Trials,No,0,0,,Japan,0.3602,0.3602,-,154728080,143001400,389026300,23400107,0.02075874969076642,344763.75,12015654.82765005,Biotechnology,"AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan."
RLFTY,0.9456,MindMaze Therapeutics Holding SA,No Trials,,No Trials,No,0,0,,Switzerland,0.94,4.88,-,150850910,-,152600000,26585838,0.046472477064220176,-,-,,"MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland."
CAVG,0.3,ACC Aviation Holdings Ltd.,No Trials,,No Trials,No,0,0,,United States,0.0152,2.5,-,149683220,-,498944060,-,-,-,-,Shell Companies,"ACC Aviation Holdings Ltd. engages in the development of cannabis powder products. It offers cannabis nanometric powders. The company was formerly known as Elfato Inc. The company is based in Los Angeles, California."
UNCY,6.71,"Unicycive Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,3.71,11,4.75,148075710,105645720,21491396,5420421,0.029291489487234798,265000,42695000,Biotechnology,"Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California."
MAYNF,1.8,Mayne Pharma Group Limited,No Trials,,No Trials,No,0,0,,Australia,1.8,4.6,-,145706700,128067784,81245820,27294105,0.08624945131028083,28334556,45003669.84720091,Medical Distribution,"Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia."
SHIEF,0.1413,Shield Therapeutics plc,No Trials,,No Trials,No,0,0,,United Kingdom,0.0331,0.1512,-,140550580,156544210,1067997000,345077917,0.0170285503868861,27048000,10814000,Drug Manufacturers - Specialty & Generic,"Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom."
TNYA,0.602,"Tenaya Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,0.36,2.35,4.71,132393340,87608350,216505890,59386470,0.004224970605302484,11527000,56312000,Biotechnology,"Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California."
BIOYF,11.56,BioSyent Inc.,No Trials,,No Trials,No,0,0,,Canada,6.49,11.57,-,129867060,113445670,11263255,2212332,0.1396304176723336,641688.9,16813708.00244349,Drug Manufacturers - Specialty & Generic,"BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was founded in 2006 and is headquartered in Mississauga, Canada."
SPRO,2.22,"Spero Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,0.5052,3.22,3,125636620,80371624,56339296,11932715,0.02432060962069192,3351000,48616000,Biotechnology,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts."
CBWTF,0.0885,Auxly Cannabis Group Inc.,No Trials,,No Trials,No,0,0,,Canada,0.0442,0.1357,-,124700690,150511460,1367038800,73600,0.053746839023501775,47425348,22006539.94035,Drug Manufacturers - Specialty & Generic,"Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. The company offers cannabis products under various forms, including milled and dried flowers, vape cartridges, infused pre-rolls, pre-rolled, all- in-one vapes, edibles, concentrates, oils, and softgels under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Toronto, Canada."
SRIMF,-,StemRIM,No Trials,,No Trials,No,0,0,,Japan,-,-,-,117011330,76027230,62681080,2697243,0.47197177317257094,-,41456682.69449149,,
SENOF,-,Sensorion SA,No Trials,,No Trials,No,0,0,,France,-,-,-,116728990,51347996,300347230,34830515,0,1824499.4,67213191.99057715,,
RECEF,0.22,Recce Pharmaceuticals Ltd,No Trials,,No Trials,No,0,0,,Australia,0.22,0.6,-,116383920,116442390,289183420,42919822,0.2479885102127328,7087170,7032670.132947216,Biotechnology,"Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia."
FBSBF,-,4basebio PLC,No Trials,,No Trials,No,0,0,,United Kingdom,-,-,-,114899610,100489520,15477395,6288909,0.1378721585233633,21189744,35843307.34599759,,
JUSHF,0.533,Jushi Holdings Inc.,No Trials,,No Trials,No,0,0,,United States,0.2326,0.98,5,106438290,357631300,199696590,21608590,0.1149265202551248,274366000,23173000,Drug Manufacturers - Specialty & Generic,"Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for the medical and adult-use markets in the United States. The company offers flowers, extracts, concentrates, edibles, pre-rolls, infused blunts, cannabis-infused gummies and chocolates, tinctures, capsules, softgels, and topical products, as well as vaporization devices and cartridges under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, and Sèche brands. It also engages in the sale of bulk raw materials to third parties. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida."
HLTRF,3.362,HLS Therapeutics Inc.,No Trials,,No Trials,No,0,0,,Canada,2.7325,4.02,-,102699784,146725150,31273680,121140,0.006911530497481252,54090000,10778000,Drug Manufacturers - Specialty & Generic,"HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada."
TTRX,3.48,Turn Therapeutics Inc.,No Trials,,No Trials,No,0,0,,United States,2.5701,26.5,5,98641360,95626376,29445184,483602,0.5947439348568491,91173,3106157,Biotechnology,"Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California."
BSEM,5.65,"BioStem Technologies, Inc.",No Trials,,No Trials,No,0,0,,United States,3.0932,15.74,-,97443000,73672040,16800516,-,-,3387156,27158117,Biotechnology,"BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida."
EAHGF,-,ECO Animal Health Group plc,No Trials,,No Trials,No,0,0,,United Kingdom,-,-,-,93288780,85271180,67759670,61105535,0.09945832116174212,6807881,25062201.60043037,,
GRUSF,0.35,Grown Rogue International Inc.,No Trials,,No Trials,No,0,0,,United States,0.281,0.62067,-,93021250,98957830,249938980,-,0.1460598142794693,17369540,13094093,Drug Manufacturers - Specialty & Generic,"Grown Rogue International Inc., a craft cannabis company, focuses on premium flower and flower-derived products. It produces a range of cultivars for consumers, which are classified as indicas, sativas, and hybrids. The company sells its products through dispensaries. Grown Rogue International Inc. was incorporated in 1978 and is headquartered in Medford, Oregon."
HSTC,0.625,"HST Global, Inc.",No Trials,,No Trials,No,0,0,,United States,0.0001,1.05,-,88193900,88774400,141110260,-,0,609297,-,Biotechnology,"HST Global, Inc. operates in the healthcare, software and media, and transportation industries. It offers Qwyit, a cryptographic protocol. HST Global, Inc. is based in Virginia Beach, Virginia."
BXPHF,0.04515,Botanix Pharmaceuticals Limited,No Trials,,No Trials,No,0,0,,Australia,0.03,0.34,-,87702780,42691964,2218097400,438511773,0.08240147290960154,801473.6,42758049.88811373,Biotechnology,"Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia."
OKYO,1.7,OKYO Pharma Limited,No Trials,,No Trials,No,0,0,,United Kingdom,1.03,3.349,4.75,85788220,81753650,51370196,677383,0.3106490714839968,185795,4220378,Biotechnology,"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom."
OXNXF,-,Valerio Therapeutics Société anonyme,No Trials,,No Trials,No,0,0,,France,-,-,-,84919390,109481870,488847870,396987,0,26888104,3107184.92343934,,
UNBSF,0.0036,Uni-Bio Science Group Limited,No Trials,,No Trials,No,0,0,,Hong Kong,0.0036,0.004,-,83956580,73563930,5971228000,5739300,0.47866935103392555,14530775,24888407.07468573,Biotechnology,"Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, an oral medication for the treatment of diabetes. It also develops prescription drugs, such as UOS003(oral PTH) for the treatment of osteoporosis; Uni-GLP-1, a non-insulin treatment candidate that stimulates the incretin pathway for the treatment of type 2 diabetes and obesity; and pre-clinical stage biopharmaceutical products for wound care and ophthalmology. In addition, the company offers contract manufacture organization services. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong."
TXTM,0.008,"ProText Mobility, Inc.",No Trials,,No Trials,No,0,0,,United States,0.0001,0.0092,-,78637480,-,8791221000,-,-,-,-,Biotechnology,"ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Fort Lauderdale, Florida."
MCRB,8.89,"Seres Therapeutics, Inc.",No Trials,,No Trials,No,0,0,,United States,6.53,29.98,3.66,78252390,115867390,9046519,1125658,0.005393787378327509,85253000,47638000,Biotechnology,"Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts."
EXOZ,9,"eXoZymes, Inc.",No Trials,,No Trials,No,0,0,,United States,8.05,20.33,-,75602320,71823760,8400258,3996100,0.2553822751634533,1320124,5098687,Biotechnology,"eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California."
PTHS,23,Pelthos Therapeutics Inc.,No Trials,,No Trials,No,0,0,,United States,9,54.29,5,75194020,64471020,3235543,857108,0.05569667904274491,3480000,14203000,Biotechnology,"Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina."
MVRBF,-,Medivir AB (publ),No Trials,,No Trials,No,0,0,,Sweden,-,-,-,73907960,61645748,538671200,26410520,0.2019649184153555,890659.56,12947149.12900009,,
ENTX,1.58,Entera Bio Ltd.,No Trials,,No Trials,No,0,0,,Israel,1,3.22,5,72454440,64091440,45857240,5544994,0.025804953555645577,211000,8574000,Biotechnology,"Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel."
HRPMF,-,Herantis Pharma Oyj,No Trials,,No Trials,No,0,0,,Finland,-,-,-,66884852,61545080,25932388,9333758,0.1207445685295161,29446.408,5369846.878680801,,
CING,6.81,Cingulate Inc.,No Trials,,No Trials,No,0,0,,United States,3.2,7.92,4.66,66053070,64513172,10418466,1381773,0.001103521382130536,4578809,6118710,Biotechnology,"Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas."
CINGW,0.0434,Cingulate Inc. WT EXP 121026,No Trials,,No Trials,No,0,0,,United States,0.0202,0.175001,-,66053070,64513172,10418466,1381773,0.001103521382130536,4578809,6118710,,"Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas."
ETHZ,3.91,ETHZilla Corporation,No Trials,,No Trials,No,0,0,,United States,2.99,174.6,-,65592196,550218430,19012232,4875665,0.2667729526324396,546762300,53309509,Biotechnology,"ETHZilla Corporation operates a technology company focused on Ethereum-based infrastructure for the tokenization of real-world assets. The company develops platforms that enable the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments using Ethereum Layer 2 protocols. It bridges traditional finance and blockchain technology by supporting regulated access, scalability, and efficiency in asset tokenization. The company was formerly known as 180 Life Sciences Corp. and changed its name to ETHZilla Corporation in August 2025. ETHZilla Corporation is headquartered in Palm Beach, Florida."
SPRB,58.73,"Spruce Biosciences, Inc.",No Trials,,No Trials,No,0,0,,United States,4.275,240,4.75,62316940,52995940,1070370,507254,0.09235311154086905,1348000,10669000,Biotechnology,"Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California."
NSRX,5.0606,Nasus Pharma Ltd.,No Trials,,No Trials,No,0,0,,Israel,4.9,9.9899,4,61831610,64191610,11755059,577507,0.3370393121803982,2563000,203000,Drug Manufacturers - General,"Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel."
ATHE,3.43,Alterity Therapeutics Limited,No Trials,,No Trials,No,0,0,,Australia,2.5209,7,4.5,61430016,32832130,10875417000,3508648083,0.04729750286693599,102314.73,26759669.60642359,Biotechnology,"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia."
NRXP,1.91,"NRx Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,1.58,3.84,5,60079360,63151360,31872340,2217031,0.05592827511252704,10256000,7184000,Biotechnology,"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware."
CLDGF,-,Cleo Diagnostics Ltd,No Trials,,No Trials,No,0,0,,Australia,-,-,-,59912796,55351252,136862080,-,0.2991332478969614,-,6289657.703342897,,
HOFBF,0.1666,Hofseth BioCare ASA,No Trials,,No Trials,No,0,0,,Norway,0.1,0.1666,-,57152956,81513360,411081020,84971791,0.33482626040904884,29840084,6652029.886017642,Packaged Foods,"Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway."
IMMPF,-,ImmuPharma plc,No Trials,,No Trials,No,0,0,,United Kingdom,-,-,-,56252532,55717150,502723940,416837419,0.007454240312553889,-,544427.3635664873,,
ONPPF,0.265,Oncopeptides AB (publ),No Trials,,No Trials,No,0,0,,Sweden,0.265,0.265,-,56215070,63613604,272706370,37925854,0.007027679959803797,16208701,8934293.218170324,,
LONA,5.81,"LeonaBio, Inc.",No Trials,,No Trials,No,0,0,,United States,2.19549,8.36,4,55455324,31141324,9335913,3792829,0.053295590907927265,912000,25226000,Biotechnology,"LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington."
NTRB,4.46,Nutriband Inc.,No Trials,,No Trials,No,0,0,,United States,3.60808,9.34232,5,53851004,48799860,12155983,372666,0.4387139238348721,258025,5312177,Biotechnology,"Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida."
EZYMF,-,Enzymatica AB (publ),No Trials,,No Trials,No,0,0,,Sweden,-,-,-,53630080,50082770,242735100,34939445,0.0700806741149286,111115.21,3598916.436579606,,
LPCN,9.48,Lipocine Inc.,No Trials,,No Trials,No,0,0,,United States,2.52,12.37,5,52354708,37380840,5551931,1102924,0.02842488496344785,157200,15131071,Biotechnology,"Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah."
MIRA,1.27,"MIRA Pharmaceuticals, Inc.",No Trials,,No Trials,No,0,0,,United States,0.73,2.45,-,52345108,44809204,41876090,2225011,0.1063635912304796,-,7535905,Drug Manufacturers - General,"MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida."
NICXF,0.3,Nicox S.A.,No Trials,,No Trials,No,0,0,,France,0.24,0.3,-,51637060,62403130,88130700,3645309,0,17487286,6719945.81861013,Biotechnology,"Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France."
VIVRF,-,Vivoryon Therapeutics N.V.,No Trials,,No Trials,No,0,0,,Germany,-,-,-,50641876,45030052,29614336,3017018,0.08320149122365966,84805.66,5697290.930506478,,
SCLX,8.23,Scilex Holding Company,No Trials,,No Trials,No,0,0,,United States,3.6,34.27,3,49997812,114003816,6127183,666784,0.05414021418978346,67666000,878000,Drug Manufacturers - General,"Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California."
KZR,6.76,"Kezar Life Sciences, Inc.",No Trials,,No Trials,No,0,0,,United States,3.5334,6.86,3,49650996,-30653004,7323156,3108077,0.021718368419299,9912000,90216000,Biotechnology,"Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California."
INCR,0.8302,InterCure Ltd.,No Trials,,No Trials,No,0,0,,Israel,0.68,1.7698,-,47405150,88870640,54681336,1437917,0.2604509381491875,53246936,15315459.75475788,Drug Manufacturers - Specialty & Generic,"InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, development, and commercialization of evidence-based cannabis therapeutics. The company was incorporated in 1994 and is headquartered in Herzliya, Israel."
MTRLF,1.9,Matricelf Ltd,No Trials,,No Trials,No,0,0,,Israel,1.9,1.9,-,47299812,45928292,29244760,43638,0.2338879774055941,306701.1,1572102.966063953,Biotechnology,"Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. Matricelf Ltd was incorporated in 2019 and is based in Ness Ziona, Israel."
VEXTF,0.1774,Vext Science Inc.,No Trials,,No Trials,No,0,0,,United States,0.072,0.3176,5,45798404,77676950,251033870,87681419,0.2212900806418264,35064000,3702000,Drug Manufacturers - Specialty & Generic,"Vext Science, Inc., through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, and Revibe brands. In addition, it provides management, advisory, cultivation, non-cannabis products, and dispensary services to entities in the cannabis field through operations agreements and direct sales. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona."
NRXBF,0.4735,NUREXONE BIOLOGIC INC,No Trials,,No Trials,No,0,0,,Canada,0.3776,0.8,-,43046812,42127920,90750620,-,0.051495777009846734,79000,983000,Biotechnology,"NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada."
TSUBF,-,Tsubota Laboratory Incorporated,No Trials,,No Trials,No,0,0,,Japan,-,-,-,42195136,35090024,25794300,305400,0.8215458453999527,477465.84,7548780.877104496,,
TLPH,0.9598,"Talphera, Inc.",No Trials,,No Trials,No,0,0,,United States,0.38,1.57,4.5,41049090,26259090,46609616,8287472,0.009701602789364204,6499000,21289000,Drug Manufacturers - Specialty & Generic,"Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California."
FRPRQ,-,4D Pharma PLC.,No Trials,,No Trials,No,0,0,,United Kingdom,-,-,-,40552650,32409560,180337580,128844,0,-,-,,
TYPTF,0.0122,Entropy Neurodynamics Limited,No Trials,,No Trials,No,0,0,,Canada,0.0061,0.03425,-,39884164,37747436,1613941100,117277153,0.2495206635956935,-,1991738.186126102,Biotechnology,"Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia."
CXXIF,0.29944,C21 Investments Inc.,No Trials,,No Trials,No,0,0,,Canada,0.123,0.537,-,38755380,47288550,118016170,11469210,0.1206957941618287,10946750,2418561,Drug Manufacturers - Specialty & Generic,"C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. The company offers CO2, live resin, distillate, CBD cured resin, and CBD CO2 vaporizer pens; live, cured, and CBD cured resin extracts; bulk and packaged flowers; edibles; pre-rolls; tinctures; and topicals. It also provides payroll and benefits services. The company was formerly known as Curlew Lake Resources Inc. and changed its name to C21 Investments Inc. in November 2017. C21 Investments Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada."
ZYBT,0.8876,Zhengye Biotechnology Holding Limited,No Trials,,No Trials,No,0,0,,China,0.720101,14.3,-,38164276,52724144,47391376,259751,0.00018990796975382188,11971552,6648334.008012395,Drug Manufacturers - Specialty & Generic,"Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited."
MDDVF,0.3706,Medical Developments International Limited,No Trials,,No Trials,No,0,0,,Australia,0.3038,0.5076,-,35794850,25172806,112658320,20758076,0.16708387211583228,1223060,11261092.94722093,Drug Manufacturers - Specialty & Generic,"Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia."
SEOVF,0.1013,Sernova Biotherapeutics Inc,No Trials,,No Trials,No,0,0,,Canada,0.0867,0.165,-,34644980,37935204,339105060,150000,0.04053825666730465,3403562,188944.4226587288,Biotechnology,"Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada."
MRMD,0.08168,MariMed Inc.,No Trials,,No Trials,No,0,0,,United States,0.067,0.23,5,34641450,127340450,397264320,971168,0.1069172354162347,86399000,6596000,Drug Manufacturers - Specialty & Generic,"MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States and internationally. The company sells cannabis flower, vapes, and concentrates under the Nature's Heritage brand; cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty's Eddies brand; and cannabis-infused ice creams under Emack & Bolio's brand. It offers soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under InHouse brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts."
SCYX,0.71,"SCYNEXIS, Inc.",No Trials,,No Trials,No,0,0,,United States,0.565,1.31,4.66,33022304,-2621696,41965056,10503363,0.024077078601916862,2284000,37928000,Drug Manufacturers - Specialty & Generic,"SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey."
AEON,1.15,"AEON Biopharma, Inc.",No Trials,,No Trials,No,0,0,,United States,0.375,1.45,5,31375792,43703790,25303058,2757192,0.13540659789026288,18255000,5927000,Biotechnology,"AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California."
EMYRF,-,Emyria Limited,No Trials,,No Trials,No,0,0,,Australia,-,-,-,30182516,28095002,806556540,15356518,0.2336137619933643,403777.16,2349641.305778597,,
DYAI,0.8396,"Dyadic International, Inc.",No Trials,,No Trials,No,0,0,,United States,0.711,1.55,5,29601618,25730646,36187800,5573072,0.1653273017606653,5062378,8933350,Biotechnology,"Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida."
DVHGF,10.65,Devonian Health Group Inc.,No Trials,,No Trials,No,0,0,,Canada,0.0711,10.8,-,28236140,23471862,2765729,-,0.0065346243250875265,81439.52,4736236.141314035,Biotechnology,"Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada."
NRSN,0.8799,NeuroSense Therapeutics Ltd.,No Trials,,No Trials,No,0,0,,Israel,0.6801,2.6,5,27351820,26685820,33396608,362003,0.3295229563433508,-,666000,Biotechnology,"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel."
LEAS,-,"Anew Medical, Inc.",No Trials,,No Trials,No,0,0,,United States,-,-,-,26377622,19029588,73536720,6085519,0.08769267686422029,-,7348034,,
TXMD,2.25,"TherapeuticsMD, Inc.",No Trials,,No Trials,No,0,0,,United States,0.72,2.95,-,26042314,25410314,11574362,1557657,0.01621402544693176,6483000,7115000,Drug Manufacturers - Specialty & Generic,"TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida."
ITHUF,0.005,"iAnthus Capital Holdings, Inc.",No Trials,,No Trials,No,0,0,,Canada,0.003,0.01332,-,25441326,232550260,6972551700,75,0.04114737011721637,220962000,17209000,Drug Manufacturers - Specialty & Generic,"iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. The company also develops, produces, and distributors of branded cannabis products under the MPX, Anthologie, Black Label, Cheetah, Frutful, Last Resort, Moodz, Sunshine State, and The Vault brand names. It offers cannabis flower and trims, such as packaged flowers and pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures. The company was formerly known as Ianthus Capital Management LLC and changed its name to iAnthus Capital Holdings, Inc. in August 2016. iAnthus Capital Holdings, Inc. was founded in 2014 and is headquartered in Toronto, Canada."
HYPD,3.22,"Hyperion DeFi, Inc.",No Trials,,No Trials,No,0,0,,United States,0.85,17.18,5,25109000,25378804,8397659,2201635,0.205476192829454,8492439,8223180,Biotechnology,"Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York."
UTHR,535.1,United Therapeutics Corporation,Oncology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Oncology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
ILPLF,-,Island Pharmaceuticals Limited,Oncology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
ZLDPF,57.08,Zealand Pharma A/S,Oncology,"Gastroenterology, Metabolic/Endocrinology, Oncology, Others, Urology/Nephrology",PHASE3,Yes,10,14,"NCT02446405, NCT03905707, NCT03941236, NCT04419402, NCT04881825, NCT05788601, NCT06662539, NCT06682975, NCT06926842, NCT07197944, NCT07338214",Denmark,49.98,101.2925,-,4063842000,1746636300,70607140,26243554,0.003573958667636162,63846624,2377340630.084307,Biotechnology,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark."
PBH,69.38,Prestige Consumer Healthcare Inc.,Oncology,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,9,"NCT03390686, NCT05108259, NCT05141149",United States,57.25,90.04,4.57,3255055400,4271972400,47318730,52198761,0.01049667581388105,1079290000,62373000,Drug Manufacturers - Specialty & Generic,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York."
YIHCF,0.55,"Sunshine Lake Pharma Co., Ltd.",Oncology,"Gastroenterology, Hematology, Oncology, Others, Respiratory",PHASE3,Yes,22,23,"NCT04415853, NCT05048368, NCT05133882, NCT05139719, NCT05451602, NCT05586074, NCT07082842, NCT07099118, NCT07102251, NCT07341672, NCT07376200",China,0.55,0.55,-,3182218000,3294738200,576032260,16305667,5.9675478550075e-05,306183700,-,,
CLDX,30.82,"Celldex Therapeutics, Inc.",Oncology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
VIR,10,"Vir Biotechnology, Inc.",Oncology,"Gastroenterology, Infectious Diseases, Oncology",PHASE3,Yes,17,30,"NCT04856085, NCT05356741, NCT05461170, NCT05484206, NCT05970289, NCT05997615, NCT06070051, NCT06491563, NCT06903338, NCT06960395, NCT07128550, NCT07142811",United States,4.155,10.94,4.6,1324019000,954855940,139517280,81306024,0.04384297119099471,97852000,467015000,Biotechnology,"Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California."
ORPOF,-,OSE Immunotherapeutics SA,Oncology,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,11,"NCT03806309, NCT04713514, NCT05751798, NCT06472245",France,-,-,-,112222850,121470290,22420804,710501,0.2413535999264969,41892624,32667998.12030075,,
BEAM,29.61,Beam Therapeutics Inc.,Oncology,"Hematology, Metabolic/Endocrinology, Oncology, Others, Respiratory",PHASE2,No,8,8,"NCT05456880, NCT05885464, NCT06389877, NCT06735755, NCT06934382, NCT07304791, NCT07373639",United States,13.525,36.44,4.7,3186798800,2095711900,98693060,95256420,0.01137591112436375,151420000,1245210000,Biotechnology,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Oncology/Hematology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
CLDX,30.82,"Celldex Therapeutics, Inc.",Oncology/Hematology,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
DAWN,10.93,"Day One Biopharmaceuticals, Inc.",Oncology/Hematology,"Neurology/CNS, Oncology/Hematology, Rare/Orphan Diseases",PHASE3,No,3,5,"NCT04775485, NCT05465174, NCT05566795, NCT06752681",United States,5.635,13.2,4.44,1234159500,785472500,102675500,70282943,0.043363469506095036,2893000,441113000,Biotechnology,"Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California."
FYBGF,-,Formycon AG,Oncology/Hematology,"Dermatology, Oncology/Hematology",PHASE1,Yes,2,2,NCT06551064,Germany,-,-,-,432717100,350747940,17664428,486624,0.1423897305018725,11622447,93331768.02066213,,
ARGX,814.94,argenx SE,Ophthalmology,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Ophthalmology, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,532.4,872.27,-,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
HLBBF,6.2075,H. Lundbeck A/S,Ophthalmology,"Metabolic/Endocrinology, Neurology/CNS, Ophthalmology, Pain/Analgesia, Psychiatry",PHASE4,Yes,8,14,"NCT04291859, NCT04789915, NCT04965675, NCT05104476, NCT05164172, NCT05669950, NCT05897320, NCT06323928, NCT06428838, NCT06471829, NCT06557850, NCT06701526, NCT06706622, NCT07035197",Denmark,4.415,7.55,-,6014970400,7310604000,991227460,96604633,0.0015551334439047229,1833733500,540175663.3004686,Drug Manufacturers - Specialty & Generic,"H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark."
HROW,53.44,"Harrow, Inc.",Ophthalmology,Ophthalmology,PHASE4,Yes,3,3,"NCT07224529, NCT07368595",United States,20.85,54.85,5,1954836700,2128897800,37037452,18528920,0.16203238921423668,251872000,77456000,Drug Manufacturers - Specialty & Generic,"Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee."
ANIP,76.3,"ANI Pharmaceuticals, Inc.",Ophthalmology,"Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Ophthalmology, Others",PHASE4,Yes,8,8,"NCT04469595, NCT05322070, NCT05486468, NCT06539481, NCT07346079",United States,54.56,99.5,4.37,1603349600,1963460700,20904168,22456918,0.05961040667264109,631580000,271469000,Drug Manufacturers - Specialty & Generic,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota."
EYPT,17.76,"EyePoint, Inc.",Ophthalmology,Ophthalmology,PHASE4,Yes,4,6,"NCT05191706, NCT06668064, NCT06683742",United States,3.91,19.11,4.76,1411522000,1230762100,82787220,63627024,0.00943249509114731,23262000,204022000,Biotechnology,"EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts."
ROIV,28.66,Roivant Sciences Ltd.,Ophthalmology,"Immunology/Autoimmune, Neurology/CNS, Ophthalmology",PHASE3,No,7,16,"NCT05403541, NCT05517447, NCT05524571, NCT05581199, NCT06727604, NCT06754462, NCT06979531, NCT06980805, NCT07018323, NCT07032662, NCT07039916, NCT07286006",United Kingdom,8.73,29.2,4.66,20225714000,16509644000,715701100,510791437,0.2424787260940063,108939000,4529978000,Biotechnology,"Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom."
BLTE,188.04,"Belite Bio, Inc",Ophthalmology,"Ophthalmology, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT05949593, NCT06388083",United States,49,200,4.75,6983348000,6708244500,37514630,4227803,0.01214851379315216,510000,275614000,Biotechnology,"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd."
SNPHY,9.508,"Santen Pharmaceutical Co., Ltd.",Ophthalmology,Ophthalmology,PHASE3,Yes,5,5,"NCT06666855, NCT06683651",Japan,8.88,11.45,-,3557528800,3156653800,321671580,194770632,0.001206199177357239,-,392928512.5998378,Drug Manufacturers - General,"Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan."
VRDN,28.94,"Viridian Therapeutics, Inc.",Ophthalmology,Ophthalmology,PHASE3,No,1,4,"NCT06625398, NCT06625411, NCT06812325, NCT07155668",United States,9.9,34.29,4.76,2805995000,2528181000,95442010,108470009,0.0003142553857431406,24202000,490901000,Biotechnology,"Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts."
APLS,21.42,"Apellis Pharmaceuticals, Inc.",Ophthalmology,"Hematology, Ophthalmology, Urology/Nephrology",PHASE3,No,4,9,"NCT03531255, NCT04572854, NCT04901936, NCT05809531, NCT06161584, NCT07020832, NCT07213960, NCT07215390",United States,16.1,30.48,4.04,2800003000,2808130000,126525220,107419884,0.02693274909537906,474360000,467786000,Biotechnology,"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts."
BCRX,7.55,"BioCryst Pharmaceuticals, Inc.",Ophthalmology,"Dermatology, Immunology/Autoimmune, Metabolic/Endocrinology, Ophthalmology, Rare/Orphan Diseases",PHASE3,Yes,3,3,"NCT05453968, NCT06539507, NCT07228559",United States,6,11.31,4.7,1886086900,2356322800,247843230,179610448,0.009866350027790148,683109000,212873000,Drug Manufacturers - Specialty & Generic,"BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina."
KOD,27.62,Kodiak Sciences Inc.,Ophthalmology,"Immunology/Autoimmune, Ophthalmology",PHASE3,Yes,5,6,"NCT06270836, NCT06556368, NCT06990399, NCT06996080",United States,1.92,31.18,4.57,1733957600,1724120600,61971324,37774002,0.04587286284012365,62201000,72038000,Biotechnology,"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California."
OCS,29.56,Oculis Holding AG,Ophthalmology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,No,3,5,"NCT05066997, NCT05608837, NCT06172257",Switzerland,14,30.68,4.7,1712818700,1533840000,57806908,18427287,0.03497438342534454,3098028.8,182389225.9953015,Biotechnology,"Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland."
SGP,29.13,"SpyGlass Pharma, Inc.",Ophthalmology,Ophthalmology,PHASE3,Yes,5,10,"NCT06120842, NCT07218783, NCT07218796",United States,16,32.44,-,975867100,1065934140,33317414,-,0.042921398401448554,-,-,,
OCUTF,-,Ocumension Therapeutics,Ophthalmology,Ophthalmology,PHASE3,No,2,2,NCT04770610,China,-,-,-,757694460,688356800,815382400,64552461,0.1642752893613425,11616996,80720138.4720613,,
ANNX,5.09,"Annexon, Inc.",Ophthalmology,"Neurology/CNS, Ophthalmology",PHASE3,No,2,2,"NCT06510816, NCT07020819",United States,1.285,7.18,4.77,739317200,577534140,149055870,118060210,0.010106599015795949,26938000,188721000,Biotechnology,"Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California."
OCGN,1.86,"Ocugen, Inc.",Ophthalmology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,No,6,6,"NCT05203939, NCT05802329, NCT05956626",United States,0.515,1.96,4.8,583641300,584040300,327888400,61070010,0.014222337142090919,32964000,32565000,Biotechnology,"Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania."
FDMT,9.92,"4D Molecular Therapeutics, Inc.",Ophthalmology,"Ophthalmology, Rare/Orphan Diseases, Respiratory",PHASE3,Yes,8,13,"NCT04483440, NCT04517149, NCT04519749, NCT05197270, NCT05248230, NCT05629559, NCT05930561, NCT06864988, NCT07064759",United States,2.235,12.34,4.45,513649280,163684290,51007870,39882063,0.03335125256430374,22263000,305063000,Biotechnology,"4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California."
RGNX,8.53,REGENXBIO Inc.,Ophthalmology,"Metabolic/Endocrinology, Ophthalmology",PHASE3,Yes,7,8,"NCT04514653, NCT04567550, NCT04704921, NCT05407636, NCT06942520",United States,5.035,16.19,4.45,409034530,375131520,50623090,36986665,0.08386564975513347,268140000,274205000,Biotechnology,"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland."
ALDX,5.49,"Aldeyra Therapeutics, Inc.",Ophthalmology,"Hematology, Ophthalmology",PHASE3,No,2,2,NCT07402876,United States,1.14,7.2,4.8,313448030,253694460,60162772,32251736,0.03136351444438906,15543749,75297339,Biotechnology,"Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts."
CDBKF,-,Cloudbreak Pharma Inc.,Ophthalmology,Ophthalmology,PHASE3,No,2,2,NCT05456425,United States,-,-,-,247694770,581813100,838892860,-,0.44133529497593504,348083000,15090000,,
PRQR,1.54,ProQR Therapeutics N.V.,Ophthalmology,"Neurology/CNS, Ophthalmology",PHASE3,No,2,2,"NCT03913143, NCT04123626",Netherlands,1.07,3.1,4.87,159071230,53014690,105345190,29793823,0.01737522107321234,19360178,125478985.6773891,Biotechnology,"ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands."
OTLK,0.4397,"Outlook Therapeutics, Inc.",Ophthalmology,Ophthalmology,PHASE3,Yes,1,1,NCT05112861,United States,0.3801,3.39,4,34140616,62356304,83067190,8282353,0.0009174741555600953,36893110,8677424,Biotechnology,"Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey."
TARS,72.65,"Tarsus Pharmaceuticals, Inc.",Ophthalmology,Ophthalmology,PHASE2,No,1,1,NCT06054217,United States,38.51,85.25,4.87,3192237600,2858006500,42557492,36926498,0.02827130488592367,83037000,417268000,Biotechnology,"Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California."
DSGN,10.97,"Design Therapeutics, Inc.",Ophthalmology,"Neurology/CNS, Ophthalmology",PHASE2,No,2,3,"NCT06772870, NCT06874010, NCT07024693",United States,2.6,11.14,4.6,603815800,399588830,56963756,26303000,0.1503369728442869,1743000,205970000,Biotechnology,"Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California."
IRD,3.5,"Opus Genetics, Inc.",Ophthalmology,Ophthalmology,PHASE2,No,1,1,NCT05616793,United States,0.65,3.965,4.91,251029710,221282720,68964210,24244739,0.152467044934381,1068000,30815000,Biotechnology,"Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina."
OXBDF,8.4,Oxford Biomedica plc,Ophthalmology,Ophthalmology,PHASE1,No,1,1,NCT01678872,United Kingdom,3.15,12.61,-,1113948000,1183524400,120833190,53883455,0.0183948797511677,144701870,73949983.52915339,Biotechnology,"Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom."
KBBTF,-,"Kubota Pharmaceutical Holdings Co., Ltd.",Ophthalmology,Ophthalmology,,Yes,1,1,NCT06034379,Japan,-,-,-,158428560,146263260,115404104,3717019,0.3818924424531499,134074.78,12249423.79763645,,
NVO,38.16,Novo Nordisk A/S,Others,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
UCBJY,159.42,UCB SA,Others,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
ARGX,816.95,argenx SE,Others,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
CSLLY,51.79,CSL Limited,Others,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
CONI.F,-,"Celltrion, Inc.",Others,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
UTHR,535.1,United Therapeutics Corporation,Others,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
ALKS,31.04,Alkermes plc,Others,"Neurology/CNS, Others, Psychiatry",PHASE4,Yes,6,8,"NCT05028062, NCT05303064, NCT06555783, NCT06767683, NCT06843590",Ireland,25.165,36.3164,4.5,5513274000,4473757700,165117500,172817486,0.01340967260697474,71598000,1319421000,Drug Manufacturers - Specialty & Generic,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland."
ANIP,76.3,"ANI Pharmaceuticals, Inc.",Others,"Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Ophthalmology, Others",PHASE4,Yes,8,8,"NCT04469595, NCT05322070, NCT05486468, NCT06539481, NCT07346079",United States,54.56,99.5,4.37,1603349600,1963460700,20904168,22456918,0.05961040667264109,631580000,271469000,Drug Manufacturers - Specialty & Generic,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Others,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
TGRNF,0.55,Tong Ren Tang Technologies Co. Ltd.,Others,"Cardiovascular, Hematology, Metabolic/Endocrinology, Others",PHASE4,Yes,13,16,"NCT04307511, NCT04731155, NCT04967833, NCT05292404, NCT05736965, NCT05736978, NCT06064669",China,0.55,0.7,-,720322400,745837600,1280784000,113980721,0.027898537145998083,337102700,718518683.9570625,Drug Manufacturers - General,"Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China."
ILPLF,-,Island Pharmaceuticals Limited,Others,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
HLN,10.44,Haleon plc,Others,"Dermatology, Others, Pain/Analgesia",PHASE3,Yes,16,16,"NCT07215767, NCT07255040, NCT07273539, NCT07297732, NCT07345130, NCT07352956",United Kingdom,8.71,11.42,4,48773566000,59471802000,8906796000,8238496414,0.0005333885179778298,11728615000,927857691.8853629,Drug Manufacturers - Specialty & Generic,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom."
PRAX,347.55,"Praxis Precision Medicines, Inc.",Others,"Neurology/CNS, Others",PHASE3,No,12,12,"NCT05737784, NCT05818553, NCT06840925, NCT06908356, NCT06999902, NCT07010471, NCT07019922",United States,26.7,355.9999,4.52,9544759000,8618781000,27850832,27605084,0.002565403398514227,110000,599331000,Biotechnology,"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts."
PTGX,87.1,"Protagonist Therapeutics, Inc.",Others,"Hematology, Others",PHASE3,No,4,4,"NCT05210790, NCT06033586, NCT07153146",United States,35.95,96.54,4.58,5463244300,4795173000,62515664,61085124,0.009338900796588601,10749000,576117000,Biotechnology,"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California."
ZLDPF,57.08,Zealand Pharma A/S,Others,"Gastroenterology, Metabolic/Endocrinology, Oncology, Others, Urology/Nephrology",PHASE3,Yes,10,14,"NCT02446405, NCT03905707, NCT03941236, NCT04419402, NCT04881825, NCT05788601, NCT06662539, NCT06682975, NCT06926842, NCT07197944, NCT07338214",Denmark,49.98,101.2925,-,4063842000,1746636300,70607140,26243554,0.003573958667636162,63846624,2377340630.084307,Biotechnology,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark."
KNSA,42.76,"Kiniksa Pharmaceuticals International, plc",Others,"Cardiovascular, Others",PHASE3,No,1,2,"NCT07010159, NCT07288216",Bermuda,18.255,49.12,4.87,3297115400,2954731500,75795760,40652479,0.04582797389919846,9718000,414074000,Drug Manufacturers - Specialty & Generic,"Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom."
PBH,69.38,Prestige Consumer Healthcare Inc.,Others,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,9,"NCT03390686, NCT05108259, NCT05141149",United States,57.25,90.04,4.57,3255055400,4271972400,47318730,52198761,0.01049667581388105,1079290000,62373000,Drug Manufacturers - Specialty & Generic,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York."
YIHCF,0.55,"Sunshine Lake Pharma Co., Ltd.",Others,"Gastroenterology, Hematology, Oncology, Others, Respiratory",PHASE3,Yes,22,23,"NCT04415853, NCT05048368, NCT05133882, NCT05139719, NCT05451602, NCT05586074, NCT07082842, NCT07099118, NCT07102251, NCT07341672, NCT07376200",China,0.55,0.55,-,3182218000,3294738200,576032260,16305667,5.9675478550075e-05,306183700,-,,
AGIO,29.96,"Agios Pharmaceuticals, Inc.",Others,"Hematology, Others, Rare/Orphan Diseases",PHASE3,No,9,18,"NCT03692052, NCT04278781, NCT04770753, NCT04770779, NCT05031780, NCT05144256, NCT05175105, NCT05490446, NCT06286046, NCT06924970, NCT07055243, NCT07075640, NCT07241234",United States,22.24,46,4.4,1780616100,656385100,58592172,53415867,0.01627295149671033,40207000,854425000,Biotechnology,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
MNKD,3.5,MannKind Corporation,Others,"Metabolic/Endocrinology, Others, Respiratory",PHASE3,No,6,6,"NCT06532942, NCT06535789, NCT07224321, NCT07344558",United States,3.29,6.51,4.88,1701169400,1666565400,307070270,181097310,0.01777247860726711,225431000,260035000,Biotechnology,"MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut."
CLDX,30.82,"Celldex Therapeutics, Inc.",Others,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
BPMUF,71,Basilea Pharmaceutica AG,Others,"Infectious Diseases, Others",PHASE3,Yes,10,10,"NCT05421858, NCT06733675, NCT06925321",Switzerland,47.5,74,-,848166200,756963500,12291580,4336174,0.002691435926056699,112622130,201716781.5395491,Biotechnology,"Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland."
PRTA,8.88,Prothena Corporation plc,Others,"Neurology/CNS, Others",PHASE3,No,3,4,"NCT03100149, NCT04777331, NCT06699680, NCT07174310",Ireland,4.32,16.16,3.71,482854940,183696940,53829984,44459418,0.1782047046638872,8373000,307531000,Biotechnology,"Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland."
HNSBF,2.9,Hansa Biopharma AB (publ),Others,"Immunology/Autoimmune, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,6,9,"NCT05369975, NCT05679401, NCT05714514, NCT05753930, NCT05937750, NCT06518005",Sweden,2.73,4.58,-,364459870,390170000,101763224,20913165,0.06214520212420161,101428310,76149548.26180178,Biotechnology,"Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden."
AVIR,4.62,"Atea Pharmaceuticals, Inc.",Others,"Infectious Diseases, Others",PHASE3,Yes,10,10,"NCT06868264, NCT06911320, NCT07037277, NCT07272889, NCT07314346",United States,2.455,4.8,4.33,363289600,35025600,78126800,51095589,0.1622032599416978,1045000,329309000,Biotechnology,"Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts."
AKBA,1.21,"Akebia Therapeutics, Inc.",Others,"Hematology, Others, Respiratory, Urology/Nephrology",PHASE3,No,5,7,"NCT06520826, NCT06901505, NCT07086755, NCT07268638, NCT07429006",United States,1.14,4.0787,4.8,329053820,361617820,265366000,125640985,0.0211219415744805,199008000,166444000,Drug Manufacturers - Specialty & Generic,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
ACHV,4.62,"Achieve Life Sciences, Inc.",Others,Others,PHASE3,No,1,1,NCT07392125,Canada,1.84,6.025,4.71,233697200,195541200,53233988,24955682,0.049140184650453014,9958000,48114000,Biotechnology,"Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington."
ORPOF,-,OSE Immunotherapeutics SA,Others,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,11,"NCT03806309, NCT04713514, NCT05751798, NCT06472245",France,-,-,-,112222850,121470290,22420804,710501,0.2413535999264969,41892624,32667998.12030075,,
GPCR,66.53,Structure Therapeutics Inc.,Others,"Metabolic/Endocrinology, Others",PHASE2,No,6,8,"NCT06139055, NCT06693843, NCT06703021, NCT07169942, NCT07400588",United States,13.22,94.9,4.73,4764381700,3972428500,69139190,53702972,0.03404625307566325,7090000,799043000,Biotechnology,"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California."
EWTX,30.12,"Edgewise Therapeutics, Inc.",Others,"Cardiovascular, Musculoskeletal, Others",PHASE2,No,9,14,"NCT05291091, NCT05540860, NCT06100887, NCT06347159, NCT07034768, NCT07177066, NCT07324616",United States,10.6,31.82,4.41,3272393200,2713234200,105868430,79285500,0.004863210621796405,4181000,563340000,Biotechnology,"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado."
BEAM,29.61,Beam Therapeutics Inc.,Others,"Hematology, Metabolic/Endocrinology, Oncology, Others, Respiratory",PHASE2,No,8,8,"NCT05456880, NCT05885464, NCT06389877, NCT06735755, NCT06934382, NCT07304791, NCT07373639",United States,13.525,36.44,4.7,3186798800,2095711900,98693060,95256420,0.01137591112436375,151420000,1245210000,Biotechnology,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts."
ORKA,35.28,"Oruka Therapeutics, Inc.",Others,"Dermatology, Others",PHASE2,No,4,5,"NCT06698939, NCT06944379, NCT07090330, NCT07290569",United States,5.485,36.53,4.84,1721432300,1225357300,48409230,44776071,0.024656947123451508,1912000,349155000,Biotechnology,"Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California."
HLOSF,2.1,Healios K.K.,Others,Others,PHASE2,No,1,1,NCT04533464,Japan,1.9,4.45,-,312640700,293023580,135001900,1543932,0.21420439267891792,16676350,36257653.43582606,Biotechnology,"Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of solid tumors. It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan."
CLYM,7.09,"Climb Bio, Inc.",Others,"Hematology, Immunology/Autoimmune, Others, Urology/Nephrology",PHASE2,No,3,5,"NCT07011043, NCT07043946, NCT07090655, NCT07096843, NCT07248865",United States,1.05,7.09,4.87,303654600,128403610,47744436,17264769,0.01580150650018164,580000,86901000,Biotechnology,"Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts."
TNXP,14.84,Tonix Pharmaceuticals Holding Corp.,Others,"Metabolic/Endocrinology, Others, Psychiatry, Urology/Nephrology",PHASE2,Yes,4,4,"NCT04789148, NCT06636786, NCT07204080, NCT07413367",United States,6.76,69.97,5,182825570,-6804426,12793952,3780812,0.0004202767057434638,425000,190055000,Biotechnology,"Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey."
BTMD,2.12,biote Corp.,Others,Others,PHASE2,No,2,2,NCT06348264,United States,2.015,4.7498,4.6,94065016,152115020,32268460,13739326,0.1253917912413545,106406000,28048000,Medical Care Facilities,"biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas."
ALGS,6.94,"Aligos Therapeutics, Inc.",Others,"Gastroenterology, Infectious Diseases, Others",PHASE2,Yes,5,7,"NCT06672900, NCT06963710, NCT07342868, NCT07342881",United States,3.76,18.6147,4.8,43628896,-49402104,6153582,1803760,0.01850856948034494,6065000,99096000,Biotechnology,"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California."
SEPN,29.99,"Septerna, Inc.",Others,Others,PHASE1,No,2,2,"NCT07069036, NCT07433179",United States,4.66,32.63,4.87,1381731600,844283600,44774190,25902917,0.02999338247906035,24110000,474346000,Biotechnology,"Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California."
GHRS,15.75,GH Research PLC,Others,Others,PHASE1,No,2,2,NCT06511947,Ireland,7.98,19.51,4.66,948429440,655126460,62029396,24166677,0.2627391681275604,582000,288507000,Biotechnology,"GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland."
JBIO,14.5,"Jade Biosciences, Inc.",Others,Others,PHASE1,No,1,1,NCT07059312,United States,6.565,100.1,5,638538400,440500350,46004204,38803549,0.007874032150177462,107600000,-,Biotechnology,"Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts."
NERV,6.23,"Minerva Neurosciences, Inc.",Others,Others,PHASE1,No,2,2,NCT04020575,United States,1.15,12.46,3,270465000,318178340,43274400,12399388,0.006502435920656827,60000000,12286646,Biotechnology,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts."
CAMP,4.45,Camp4 Therapeutics Corporation,Others,Others,PHASE1,No,1,1,NCT06247670,United States,1.305,7.305,4.5,243841330,174932340,51881136,27335392,0.01467849565508726,6346000,75255000,Biotechnology,"Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts."
SRNM.F,-,Sirnaomics Ltd.,Others,"Hematology, Others",PHASE1,No,2,2,"NCT05037149, NCT05844293",Hong Kong,-,-,-,97239140,83551030,106398780,-,0.20758723304254179,7211000,6872000,,
AXSM,164.22,"Axsome Therapeutics, Inc.",Pain/Analgesia,"Musculoskeletal, Neurology/CNS, Pain/Analgesia, Psychiatry",PHASE4,Yes,6,9,"NCT05838430, NCT06170970, NCT06223880, NCT06413420, NCT06413433, NCT06568367, NCT07398417",United States,86.99,191.5,4.76,8693502000,8588681000,51153290,38732733,0.01124811348885113,218113000,322933000,Biotechnology,"Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York."
HLBBF,6.2075,H. Lundbeck A/S,Pain/Analgesia,"Metabolic/Endocrinology, Neurology/CNS, Ophthalmology, Pain/Analgesia, Psychiatry",PHASE4,Yes,8,14,"NCT04291859, NCT04789915, NCT04965675, NCT05104476, NCT05164172, NCT05669950, NCT05897320, NCT06323928, NCT06428838, NCT06471829, NCT06557850, NCT06701526, NCT06706622, NCT07035197",Denmark,4.415,7.55,-,6014970400,7310604000,991227460,96604633,0.0015551334439047229,1833733500,540175663.3004686,Drug Manufacturers - Specialty & Generic,"H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Pain/Analgesia,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
HITI,2.57,High Tide Inc.,Pain/Analgesia,"Gastroenterology, Neurology/CNS, Pain/Analgesia, Urology/Nephrology",PHASE4,Yes,9,10,"NCT04793932, NCT05226117, NCT05487417, NCT06222645, NCT06845306, NCT07412522, NCT07420712",Canada,1.64,4.0554,5,224996690,281240480,87839736,11283642,0.08707990751565906,78315210,34185590.53153186,Pharmaceutical Retailers,"High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products. The company also engages in data analytics; advertising; product sourcing and imports; event-based cannabis retail; medical cannabis distribution; accessories retail; and other related services. It provides its products under the Daily High Club, DankStop, FAB CBD, GC, Nuleaf Naturals, Smoke Cartel, Blessed CBD, Fastendr, Famous Brandz, Queen of Bud, Canna Cabana, Grasscity, Daily High Club, and Valiant Distribution brands. The company sells its products through a network of retail stores, e-commerce platforms, and the wholesale distribution arm. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. The company was founded in 2009 and is headquartered in Calgary, Canada."
ILPLF,-,Island Pharmaceuticals Limited,Pain/Analgesia,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Pain/Analgesia,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
HLN,10.44,Haleon plc,Pain/Analgesia,"Dermatology, Others, Pain/Analgesia",PHASE3,Yes,16,16,"NCT07215767, NCT07255040, NCT07273539, NCT07297732, NCT07345130, NCT07352956",United Kingdom,8.71,11.42,4,48773566000,59471802000,8906796000,8238496414,0.0005333885179778298,11728615000,927857691.8853629,Drug Manufacturers - Specialty & Generic,"Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom."
CLBPF,-,"Caliway Biopharmaceuticals Co., Ltd.",Pain/Analgesia,"Pain/Analgesia, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,3,3,"NCT06303570, NCT07140939",Taiwan,-,-,-,8071872500,7864480000,1549997000,110195912,0.243680529704251,171713.53,213790033.1353958,,
PCRX,23.46,"Pacira BioSciences, Inc.",Pain/Analgesia,"Musculoskeletal, Pain/Analgesia",PHASE3,Yes,8,9,"NCT03739021, NCT04119687, NCT06269705, NCT06271265, NCT06884865, NCT07212114",United States,18.8,27.64,3.85,1007128060,1186102000,43021276,46553714,0.01606792538629515,425308000,246334000,Drug Manufacturers - Specialty & Generic,"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California."
INDV,33.63,"Indivior Pharmaceuticals, Inc.",Pain/Analgesia,"Pain/Analgesia, Psychiatry",PHASE2,Yes,3,3,NCT06576843,United States,8.34,38,4.71,4127669800,4038669800,124853896,115309875,0.03492954725891099,356000000,445000000,Drug Manufacturers - Specialty & Generic,"Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia."
CTNM,15.78,"Contineum Therapeutics, Inc.",Pain/Analgesia,"Pain/Analgesia, Respiratory",PHASE2,No,3,3,"NCT06810245, NCT07284459",United States,3.35,16.33,4.57,581914100,405000130,36529450,20804204,0.0087932615682213,5493000,182407000,Biotechnology,"Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California."
ASRT,11.85,"Assertio Holdings, Inc.",Pain/Analgesia,Pain/Analgesia,PHASE2,Yes,2,2,NCT06158620,United States,7.7055,15.15,4.75,76616696,23544700,6416809,1418384,0.01972039373464287,40355000,93427000,Drug Manufacturers - Specialty & Generic,"Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois."
UTHR,535.1,United Therapeutics Corporation,Psychiatry,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
NBIX,131.15,"Neurocrine Biosciences, Inc.",Psychiatry,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,8,21,"NCT04400331, NCT04490915, NCT04806451, NCT05206513, NCT05207085, NCT05226780, NCT06786624, NCT06911112, NCT06963021, NCT06963034, NCT06966401, NCT07105098, NCT07105111, NCT07111988, NCT07114874, NCT07187375, NCT07196501, NCT07227818, NCT07288320, NCT07288333, NCT07365462",United States,84.23,160.18,4.55,13143599000,12134499000,100363464,100888222,0.011908118863493009,471300000,1480400000,Drug Manufacturers - Specialty & Generic,"Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."
AXSM,164.22,"Axsome Therapeutics, Inc.",Psychiatry,"Musculoskeletal, Neurology/CNS, Pain/Analgesia, Psychiatry",PHASE4,Yes,6,9,"NCT05838430, NCT06170970, NCT06223880, NCT06413420, NCT06413433, NCT06568367, NCT07398417",United States,86.99,191.5,4.76,8693502000,8588681000,51153290,38732733,0.01124811348885113,218113000,322933000,Biotechnology,"Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York."
HLBBF,6.2075,H. Lundbeck A/S,Psychiatry,"Metabolic/Endocrinology, Neurology/CNS, Ophthalmology, Pain/Analgesia, Psychiatry",PHASE4,Yes,8,14,"NCT04291859, NCT04789915, NCT04965675, NCT05104476, NCT05164172, NCT05669950, NCT05897320, NCT06323928, NCT06428838, NCT06471829, NCT06557850, NCT06701526, NCT06706622, NCT07035197",Denmark,4.415,7.55,-,6014970400,7310604000,991227460,96604633,0.0015551334439047229,1833733500,540175663.3004686,Drug Manufacturers - Specialty & Generic,"H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark."
ALKS,31.04,Alkermes plc,Psychiatry,"Neurology/CNS, Others, Psychiatry",PHASE4,Yes,6,8,"NCT05028062, NCT05303064, NCT06555783, NCT06767683, NCT06843590",Ireland,25.165,36.3164,4.5,5513274000,4473757700,165117500,172817486,0.01340967260697474,71598000,1319421000,Drug Manufacturers - Specialty & Generic,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland."
ACAD,24.97,ACADIA Pharmaceuticals Inc.,Psychiatry,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,5,7,"NCT05357612, NCT05895513, NCT05999240, NCT06159673, NCT06173531, NCT07029581, NCT07284667",United States,13.4,28.35,4.14,4160181000,3367970800,169181820,124523308,0.005264892030329713,54809000,847019000,Biotechnology,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California."
SUPN,56.32,"Supernus Pharmaceuticals, Inc.",Psychiatry,"Neurology/CNS, Psychiatry",PHASE4,Yes,7,9,"NCT02339064, NCT02736656, NCT03474770, NCT04781140, NCT06185985, NCT06798896, NCT07125222, NCT07141329, NCT07226661",United States,29.16,59.68,4.5,3056187400,2777882400,57339350,55117613,0.040673221224828505,42212000,308670000,Drug Manufacturers - Specialty & Generic,"Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland."
IDRSF,5.14,Idorsia Ltd,Psychiatry,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,12,23,"NCT03737214, NCT05422612, NCT05423717, NCT05924425, NCT05948540, NCT05948553, NCT05948579, NCT06393504, NCT06498128, NCT06816433",Switzerland,1,5.82,-,1176495100,2719101700,251506690,23033434,0.24521416020356832,1589192100,89453385.09277755,Biotechnology,"Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat immune-mediated disorders; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and optional license and/or research and development collaboration agreement with Neurocrine Biosciences, Inc, to to develop and commercialize ACT-709478, and/or to collaborate in a research program to discover, identify and develop novel calcium channel blocker compounds for follow-on compounds to ACT-709478. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland."
ILPLF,-,Island Pharmaceuticals Limited,Psychiatry,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
XENE,44.575,Xenon Pharmaceuticals Inc.,Psychiatry,"Neurology/CNS, Psychiatry",PHASE3,No,2,7,"NCT03796962, NCT05614063, NCT05667142, NCT05716100, NCT06775379, NCT07076407, NCT07172516",Canada,26.74,46.6,4.85,3461147400,2914218500,77275010,79942801,0.000993725600456143,8327000,462268000,Biotechnology,"Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada."
DFTX,17.62,"Definium Therapeutics, Inc.",Psychiatry,Psychiatry,PHASE3,No,3,5,"NCT06741228, NCT06809595, NCT06941844, NCT07303907",United States,4.7,18.7,4.8,1718986900,1550901900,98509280,65195533,0.00975997398174034,40985000,209070000,Biotechnology,"Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York."
HRMY,28.19,"Harmony Biosciences Holdings, Inc.",Psychiatry,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE3,Yes,6,7,"NCT04257929, NCT04462770, NCT05066217, NCT05536011, NCT06366464",United States,25.52,40.87,3.81,1623641300,1011964350,57596360,52300102,0.014374406977469669,163663000,775340000,Biotechnology,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania."
CMPS,7.44,COMPASS Pathways plc,Psychiatry,Psychiatry,PHASE3,No,1,5,"NCT04433858, NCT05624268, NCT05711940, NCT05733546, NCT06247839",United Kingdom,2.25,8.9,4.58,907001150,756248200,113517040,41120434,0.03773715249315336,35184000,185937000,Medical Care Facilities,"COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom."
LBRX,25.14,LB Pharmaceuticals Inc,Psychiatry,Psychiatry,PHASE3,No,3,3,"NCT07363577, NCT07369154",United States,13.36,25.6,4.75,626152770,315339780,25299102,15536642,0.005666230616849541,3666000,314479000,Biotechnology,"LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York."
NMRA,3.46,"Neumora Therapeutics, Inc.",Psychiatry,Psychiatry,PHASE3,No,1,3,"NCT06029439, NCT06058013, NCT06058039",United States,0.611,3.65,4.22,582888800,431449860,169938450,57941288,0.048900542755950085,20086000,171525000,Biotechnology,"Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts."
NWPHF,9.36,Newron Pharmaceuticals S.p.A.,Psychiatry,Psychiatry,PHASE3,No,1,1,NCT07184619,Italy,9.36,9.36,-,488810340,500120100,20014584,2890499,0.10539673942777229,61915196,50877502.94464076,,"Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy."
HELP,7.69,Cybin Inc.,Psychiatry,Psychiatry,PHASE3,No,2,4,"NCT06051721, NCT06564818, NCT06605105, NCT06793397",Canada,4.81,9.83,5,368763800,173635800,50035796,18055739,0.0166254978061206,-,195128000,Biotechnology,"Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada."
RVPH,0.2205,"Reviva Pharmaceuticals Holdings, Inc.",Psychiatry,Psychiatry,PHASE3,No,1,1,NCT05184335,United States,0.2153,1.5,4.83,26863800,13680540,116849940,12784451,0.03008385148225846,-,13183259,Biotechnology,"Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California."
INDV,33.63,"Indivior Pharmaceuticals, Inc.",Psychiatry,"Pain/Analgesia, Psychiatry",PHASE2,Yes,3,3,NCT06576843,United States,8.34,38,4.71,4127669800,4038669800,124853896,115309875,0.03492954725891099,356000000,445000000,Drug Manufacturers - Specialty & Generic,"Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia."
ATAI,4.34,AtaiBeckley Inc.,Psychiatry,Psychiatry,PHASE2,No,3,3,"NCT05434156, NCT05660642",Germany,1.15,6.75,4.84,1587142500,1478151600,363190530,62524267,0.02335694211755889,5458000,114606000,Biotechnology,"AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York."
RAPP,30.2,"Rapport Therapeutics, Inc.",Psychiatry,"Neurology/CNS, Psychiatry",PHASE2,No,1,2,"NCT07046494, NCT07219407",United States,6.43,42.2685,4.9,1381696400,880542400,47661136,36681098,0.04061799753882662,11872000,513026000,Biotechnology,"Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts."
MPLT,17.63,"MapLight Therapeutics, Inc.",Psychiatry,"Neurology/CNS, Psychiatry",PHASE2,No,5,5,"NCT05081245, NCT06887192, NCT07038876",United States,12.24,21.55,4.75,786418400,1072949440,43641424,15253918,0.023903705186571172,6006000,227168000,Biotechnology,"MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California."
ANRO,18.99,"Alto Neuroscience, Inc.",Psychiatry,"Neurology/CNS, Psychiatry",PHASE2,No,3,3,"NCT05922878, NCT06502964, NCT06656416",United States,1.6,20.9075,4.8,600201600,487783580,31066336,11779732,0.04263956466058838,25398000,137816000,Biotechnology,"Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California."
TNXP,14.84,Tonix Pharmaceuticals Holding Corp.,Psychiatry,"Metabolic/Endocrinology, Others, Psychiatry, Urology/Nephrology",PHASE2,Yes,4,4,"NCT04789148, NCT06636786, NCT07204080, NCT07413367",United States,6.76,69.97,5,182825570,-6804426,12793952,3780812,0.0004202767057434638,425000,190055000,Biotechnology,"Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey."
CGC,1.17,Canopy Growth Corporation,Psychiatry,Psychiatry,PHASE1,No,2,2,NCT05324982,Canada,0.77,2.38,3,443953860,359039400,377862620,38961652,0.0006279054308397162,185873950,270649220.0762074,Drug Manufacturers - Specialty & Generic,"Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada."
CWBHF,0.725,"Charlotte's Web Holdings, Inc.",Psychiatry,Psychiatry,PHASE1,Yes,1,1,NCT05015439,United States,0.052,0.97,-,114199800,168036140,159683950,2476274,0.1015821107584931,62774000,9810000,Drug Manufacturers - Specialty & Generic,"Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte's Web, CBD CLINIC, and CBD MEDIC brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through retail outlets, health care practitioners, and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado."
NVO,38.16,Novo Nordisk A/S,Rare/Orphan Diseases,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
UCBJY,159.42,UCB SA,Rare/Orphan Diseases,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,71.155,168.76,5,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
ARGX,816.95,argenx SE,Rare/Orphan Diseases,"Hematology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases",PHASE4,Yes,24,44,"NCT04023526, NCT04150887, NCT04225156, NCT04280718, NCT04812925, NCT04833894, NCT05405361, NCT05523167, NCT05701189, NCT05907096, NCT06284954, NCT06298552, NCT06298565, NCT06299748, NCT06392386, NCT06436742, NCT06441682, NCT06453694, NCT06544499, NCT06637072, NCT06684847, NCT06688253, NCT06742190, NCT06765161, NCT06860633, NCT06909214, NCT06920004, NCT06968338, NCT07011589, NCT07091630, NCT07194850, NCT07264426, NCT07284420, NCT07287982, NCT07294170, NCT07377396",Netherlands,510.055,934.6199,4.54,51116440000,47216775000,61199904,49027025,0.001403923816740752,43152000,3928176000,Biotechnology,"argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands."
CSLLY,51.79,CSL Limited,Rare/Orphan Diseases,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
UTHR,535.1,United Therapeutics Corporation,Rare/Orphan Diseases,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
NBIX,131.15,"Neurocrine Biosciences, Inc.",Rare/Orphan Diseases,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,8,21,"NCT04400331, NCT04490915, NCT04806451, NCT05206513, NCT05207085, NCT05226780, NCT06786624, NCT06911112, NCT06963021, NCT06963034, NCT06966401, NCT07105098, NCT07105111, NCT07111988, NCT07114874, NCT07187375, NCT07196501, NCT07227818, NCT07288320, NCT07288333, NCT07365462",United States,84.23,160.18,4.55,13143599000,12134499000,100363464,100888222,0.011908118863493009,471300000,1480400000,Drug Manufacturers - Specialty & Generic,"Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Rare/Orphan Diseases,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
MIRM,108.62,"Mirum Pharmaceuticals, Inc.",Rare/Orphan Diseases,"Gastroenterology, Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE4,Yes,9,11,"NCT03115086, NCT04663308, NCT05050136, NCT06193928, NCT06553768, NCT07209462, NCT07290257, NCT07389031",United States,36.8801,109.28,4.72,6435898000,6379114000,59879960,54815602,0.01165946746085052,318764000,375548000,Biotechnology,"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California."
ACAD,24.97,ACADIA Pharmaceuticals Inc.,Rare/Orphan Diseases,"Metabolic/Endocrinology, Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,5,7,"NCT05357612, NCT05895513, NCT05999240, NCT06159673, NCT06173531, NCT07029581, NCT07284667",United States,13.4,28.35,4.14,4160181000,3367970800,169181820,124523308,0.005264892030329713,54809000,847019000,Biotechnology,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California."
TVTX,29.34,"Travere Therapeutics, Inc.",Rare/Orphan Diseases,"Immunology/Autoimmune, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,7,13,"NCT03406611, NCT03493685, NCT03762850, NCT04663204, NCT05003986, NCT05630612, NCT06247085, NCT07219121, NCT07224776",United States,12.91,42.13,4.66,2848419000,2854356000,92241550,104986700,0.009636140446103184,328733000,322796000,Biotechnology,"Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Rare/Orphan Diseases,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
IDRSF,5.14,Idorsia Ltd,Rare/Orphan Diseases,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE4,Yes,12,23,"NCT03737214, NCT05422612, NCT05423717, NCT05924425, NCT05948540, NCT05948553, NCT05948579, NCT06393504, NCT06498128, NCT06816433",Switzerland,1,5.82,-,1176495100,2719101700,251506690,23033434,0.24521416020356832,1589192100,89453385.09277755,Biotechnology,"Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat immune-mediated disorders; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and optional license and/or research and development collaboration agreement with Neurocrine Biosciences, Inc, to to develop and commercialize ACT-709478, and/or to collaborate in a research program to discover, identify and develop novel calcium channel blocker compounds for follow-on compounds to ACT-709478. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland."
SPHDF,21.15,Santhera Pharmaceuticals Holding AG,Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE4,Yes,1,1,NCT06713135,Switzerland,9.42,22.04,-,290094430,319589060,13926512,440957,0.02339027891549585,51956140,23187547.26493572,Biotechnology,"Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland."
ILPLF,-,Island Pharmaceuticals Limited,Rare/Orphan Diseases,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Rare/Orphan Diseases,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
CLBPF,-,"Caliway Biopharmaceuticals Co., Ltd.",Rare/Orphan Diseases,"Pain/Analgesia, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,3,3,"NCT06303570, NCT07140939",Taiwan,-,-,-,8071872500,7864480000,1549997000,110195912,0.243680529704251,171713.53,213790033.1353958,,
BLTE,188.04,"Belite Bio, Inc",Rare/Orphan Diseases,"Ophthalmology, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT05949593, NCT06388083",United States,49,200,4.75,6983348000,6708244500,37514630,4227803,0.01214851379315216,510000,275614000,Biotechnology,"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd."
FOLD,14.34,"Amicus Therapeutics, Inc.",Rare/Orphan Diseases,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE3,Yes,8,12,"NCT03911505, NCT04020055, NCT04252066, NCT04808505, NCT06121011, NCT06904261, NCT06906367",United States,5.51,14.38,3,4509050400,4657877000,314000700,326652839,0.007861989842338477,442363000,293536000,Biotechnology,"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey."
DNLI,22.29,Denali Therapeutics Inc.,Rare/Orphan Diseases,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,Yes,8,10,"NCT04251026, NCT05262023, NCT05348785, NCT05371613, NCT06181136, NCT06602193, NCT07328451, NCT07354724",United States,10.57,23.77,4.84,3346473700,2518046700,156158370,152521608,0.04243453945803113,44480000,848204000,Biotechnology,"Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California."
IRON,66.89,"Disc Medicine, Inc.",Rare/Orphan Diseases,"Gastroenterology, Hematology, Rare/Orphan Diseases",PHASE3,No,3,6,"NCT05320198, NCT05745883, NCT06910358, NCT06985147, NCT07187973, NCT07368972",United States,30.82,99.5,4.92,2499060700,1914117800,37750160,37364585,0.01137007426023246,30977000,615920000,Biotechnology,"Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts."
NPPNY,37.75,"Nippon Shinyaku Co., Ltd.",Rare/Orphan Diseases,"Immunology/Autoimmune, Musculoskeletal, Rare/Orphan Diseases",PHASE3,Yes,4,5,"NCT04768062, NCT05135663, NCT05996003, NCT06046222, NCT06053814",Japan,21,41.82,-,2160164900,1788689900,67400950,34856354,0.001956945739740252,16261356,387993283.4915628,Drug Manufacturers - Specialty & Generic,"Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan."
SLNO,41.01,"Soleno Therapeutics, Inc.",Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE3,No,1,1,NCT05701774,United States,36.67,90.3199,4.84,2103284600,1599865600,53710024,62922212,0.01269037096395811,52663000,498934000,Biotechnology,"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California."
BCRX,7.55,"BioCryst Pharmaceuticals, Inc.",Rare/Orphan Diseases,"Dermatology, Immunology/Autoimmune, Metabolic/Endocrinology, Ophthalmology, Rare/Orphan Diseases",PHASE3,Yes,3,3,"NCT05453968, NCT06539507, NCT07228559",United States,6,11.31,4.7,1886086900,2356322800,247843230,179610448,0.009866350027790148,683109000,212873000,Drug Manufacturers - Specialty & Generic,"BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina."
AGIO,29.96,"Agios Pharmaceuticals, Inc.",Rare/Orphan Diseases,"Hematology, Others, Rare/Orphan Diseases",PHASE3,No,9,18,"NCT03692052, NCT04278781, NCT04770753, NCT04770779, NCT05031780, NCT05144256, NCT05175105, NCT05490446, NCT06286046, NCT06924970, NCT07055243, NCT07075640, NCT07241234",United States,22.24,46,4.4,1780616100,656385100,58592172,53415867,0.01627295149671033,40207000,854425000,Biotechnology,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
HRMY,28.19,"Harmony Biosciences Holdings, Inc.",Rare/Orphan Diseases,"Neurology/CNS, Psychiatry, Rare/Orphan Diseases",PHASE3,Yes,6,7,"NCT04257929, NCT04462770, NCT05066217, NCT05536011, NCT06366464",United States,25.52,40.87,3.81,1623641300,1011964350,57596360,52300102,0.014374406977469669,163663000,775340000,Biotechnology,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania."
CAPR,28.35,"Capricor Therapeutics, Inc.",Rare/Orphan Diseases,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT04428476, NCT05126758",United States,4.3,40.37,4.8,1443462700,1359439500,51718476,27207591,0.01141006187827464,14542789,98565971,Biotechnology,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California."
PVLA,128.6,"Palvella Therapeutics, Inc.",Rare/Orphan Diseases,"Dermatology, Rare/Orphan Diseases",PHASE3,No,3,3,"NCT05643872, NCT06239480, NCT06653842",United States,18.225,129.32,5,1425231700,1377685800,11836490,8028039,0.1518170480970827,16021000,63567000,Biotechnology,"Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania"
GERNW,0.05,Geron Corporation WT EXP 123125,Rare/Orphan Diseases,"Hematology, Rare/Orphan Diseases",PHASE3,Yes,12,15,"NCT02598661, NCT04576156, NCT05371964, NCT05583552, NCT06247787, NCT07320235",United States,0.05,0.455875,-,1244792800,947113800,638355260,382515490,0.0009340691983785989,121916000,359799000,,
DAWN,10.93,"Day One Biopharmaceuticals, Inc.",Rare/Orphan Diseases,"Neurology/CNS, Oncology/Hematology, Rare/Orphan Diseases",PHASE3,No,3,5,"NCT04775485, NCT05465174, NCT05566795, NCT06752681",United States,5.635,13.2,4.44,1234159500,785472500,102675500,70282943,0.043363469506095036,2893000,441113000,Biotechnology,"Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California."
PHAR,16.8,Pharming Group N.V.,Rare/Orphan Diseases,"Immunology/Autoimmune, Rare/Orphan Diseases",PHASE3,Yes,1,3,"NCT05438407, NCT05693129, NCT06990529",Netherlands,7.5018,21.34,5,1159530200,1124151400,685147600,147813721,0.02770361245437598,130922000,166168000,Biotechnology,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands."
NURPF,8.525,Neuren Pharmaceuticals Limited,Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE3,No,1,1,NCT07281079,Australia,6.6,14.7965,-,1094448800,882956160,126639530,29059704,0.0390606642036863,-,197141634.8558642,Biotechnology,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia."
KKPCF,26,"Kaken Pharmaceutical Co., Ltd.",Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE3,No,1,1,NCT07285005,Japan,23.65,28.121,-,1045798200,776444000,37868340,11157368,0.05012630603823669,24580378,292653340.0583544,Drug Manufacturers - Specialty & Generic,"Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan."
KALV,15.76,"KalVista Pharmaceuticals, Inc.",Rare/Orphan Diseases,"Immunology/Autoimmune, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT05505916, NCT05511922",United States,9.235,19,4.77,797115000,770536060,50546292,46091349,0.015116053338125619,138462000,191465000,Biotechnology,"KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts."
FDMT,9.92,"4D Molecular Therapeutics, Inc.",Rare/Orphan Diseases,"Ophthalmology, Rare/Orphan Diseases, Respiratory",PHASE3,Yes,8,13,"NCT04483440, NCT04517149, NCT04519749, NCT05197270, NCT05248230, NCT05629559, NCT05930561, NCT06864988, NCT07064759",United States,2.235,12.34,4.45,513649280,163684290,51007870,39882063,0.03335125256430374,22263000,305063000,Biotechnology,"4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California."
CLVLY,8.45,Clinuvel Pharmaceuticals Limited,Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE3,No,1,1,NCT06109649,Australia,6.81,8.6,-,397692800,239832580,50200740,10643167,0.10259464302717451,347853.1,147496341.9770962,Biotechnology,"Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia."
HNSBF,2.9,Hansa Biopharma AB (publ),Rare/Orphan Diseases,"Immunology/Autoimmune, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,6,9,"NCT05369975, NCT05679401, NCT05714514, NCT05753930, NCT05937750, NCT06518005",Sweden,2.73,4.58,-,364459870,390170000,101763224,20913165,0.06214520212420161,101428310,76149548.26180178,Biotechnology,"Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden."
XFORW,-,"X4 Pharmaceuticals, Inc. WT EXP A 041624",Rare/Orphan Diseases,"Hematology, Rare/Orphan Diseases",PHASE3,No,1,3,"NCT03995108, NCT06056297, NCT06858696",United States,-,-,-,296410370,251573380,87436690,55878166,0.0026751585101210612,77357000,122194000,,
ABEO,5.3,Abeona Therapeutics Inc.,Rare/Orphan Diseases,"Dermatology, Rare/Orphan Diseases",PHASE3,No,5,5,"NCT02716246, NCT05725018",United States,3.9328,7.5401,5,292633340,109623350,54191360,34047878,0.12225254870421139,24107000,207117000,Biotechnology,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio."
AARD,12.38,"Aardvark Therapeutics, Inc.",Rare/Orphan Diseases,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE3,No,1,2,"NCT06828861, NCT07197034",United States,4.88,17.94,4.81,276085100,150280100,21773272,5602607,0.1473812020536004,545000,126350000,Biotechnology,"Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California."
SLGL,90.12,Sol-Gel Technologies Ltd.,Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE3,No,2,2,NCT06050122,Israel,4.018,92,5,244118510,224358510,2785787,350524,0.670768435948078,1083000,20843000,Biotechnology,"Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel."
ACB,3.83,Aurora Cannabis Inc.,Rare/Orphan Diseases,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,Yes,2,2,"NCT03936361, NCT06513533",Canada,3.28,6.665,4.2,215197180,232719360,56709424,6802276,0.005165931503730315,73580940,79012363.66815536,Drug Manufacturers - Specialty & Generic,"Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants. It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada."
PLYX,2.77,"Polaryx Therapeutics, Inc.",Rare/Orphan Diseases,"Neurology/CNS, Rare/Orphan Diseases",PHASE3,No,1,1,NCT04637282,United States,2.201,48.91,-,132561230,126816230,47343296,85281,0.2164571470381541,-,5745000,Biotechnology,"Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey."
CANSF,0.119,Atlas Energy Corp.,Rare/Orphan Diseases,"Gastroenterology, Rare/Orphan Diseases",PHASE3,Yes,2,2,"NCT06226857, NCT07024316",Canada,0.0135,0.25,-,71197310,50688964,629439360,84209695,0.09432068653273307,-,20196916.88526357,Oil & Gas Midstream,"Atlas Energy Corp., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. The company was formerly known as Willow Biosciences Inc. and changed its name to Atlas Energy Corp. in June 2025. Atlas Energy Corp. was founded in 2019 and is headquartered in Calgary, Canada."
WVE,14.54,Wave Life Sciences Ltd.,Rare/Orphan Diseases,"Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE2,No,3,4,"NCT04906460, NCT06405633, NCT06842186, NCT07209332",Singapore,5.28,21.73,4.87,2565614300,2397042400,182996750,128054661,0.030099107859328077,19772000,196218000,Biotechnology,"Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore."
SION,38.03,"Sionna Therapeutics, Inc.",Rare/Orphan Diseases,"Rare/Orphan Diseases, Respiratory",PHASE2,No,8,8,"NCT07035990, NCT07108153",United States,7.255,45,4.55,1665546400,1349514400,44628788,17447642,0.01316482765410611,8968000,248329000,Biotechnology,"Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts."
QURE,24.87,uniQure N.V.,Rare/Orphan Diseases,"Neurology/CNS, Rare/Orphan Diseases",PHASE2,No,2,2,"NCT06100276, NCT06270316",Netherlands,7.76,71.5,4.35,1496868600,1334285700,62291664,52981848,0.01586907176217855,531662000,694245000,Biotechnology,"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands."
TSHA,4.67,"Taysha Gene Therapies, Inc.",Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE2,No,1,1,NCT04798235,United States,1.05,6.02,4.78,1339465700,1111204700,273919360,203967208,0.08894185886121525,69083000,297344000,Biotechnology,"Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas."
ZVRA,8.93,"Zevra Therapeutics, Inc.",Rare/Orphan Diseases,"Metabolic/Endocrinology, Rare/Orphan Diseases",PHASE2,No,1,1,NCT06773026,United States,6.19,13.16,4.75,504988900,368196900,56297536,34941093,0.01372962421889342,62717000,199509000,Biotechnology,"Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida."
RCKT,4.33,"Rocket Pharmaceuticals, Inc.",Rare/Orphan Diseases,"Hematology, Rare/Orphan Diseases",PHASE2,No,2,3,"NCT04069533, NCT04248439, NCT06422351",United States,2.19,9.805,3.64,459944480,262231470,108222220,75461762,0.03520737902383603,25045000,222758000,Biotechnology,"Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey."
IMMX,8.75,"Immix Biopharma, Inc.",Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE2,No,1,1,NCT06097832,United States,1.34,8.97,5,447384960,432543970,52695520,22936802,0.129031255959354,1106335,15947308,Biotechnology,"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California."
ARCT,8.3,Arcturus Therapeutics Holdings Inc.,Rare/Orphan Diseases,"Hematology, Metabolic/Endocrinology, Rare/Orphan Diseases, Respiratory",PHASE2,No,4,4,"NCT06488313, NCT06747858, NCT07390968",United States,5.85,24.17,4.33,232428800,78055800,28414280,21994708,0.07529298913408994,25987000,180360000,Biotechnology,"Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California."
MSLE,11.63,Satellos Bioscience Inc.,Rare/Orphan Diseases,Rare/Orphan Diseases,PHASE2,No,1,1,NCT07287189,Canada,4.5288,12.5,5,231810530,196626420,20626922,1273833,0.06877536066699627,-,34614000,Biotechnology,"Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada."
CPRX,24.86,"Catalyst Pharmaceuticals, Inc.",Rare/Orphan Diseases,Rare/Orphan Diseases,,No,1,1,NCT06564974,United States,19.05,26.58,5,2973250600,2286247700,122912380,106315928,0.061452780995946324,2889000,689892000,Biotechnology,"Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida."
CSLLY,51.79,CSL Limited,Respiratory,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
CONI.F,-,"Celltrion, Inc.",Respiratory,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Neurology/CNS, Others, Respiratory",PHASE4,Yes,37,39,"NCT03474744, NCT04627753, NCT05866614, NCT05906992, NCT06059989, NCT06113913, NCT06274294, NCT06571591, NCT06627322, NCT06630559, NCT06687928, NCT06738719, NCT06939595, NCT06952478, NCT06989723, NCT06997055, NCT07093476, NCT07200986, NCT07367958, NCT07425639",South Korea,-,-,-,37728227000,39172616000,218884430,41423436,0.05060953647783066,2060202800,679338237.0666933,,
UTHR,535.1,United Therapeutics Corporation,Respiratory,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
BMRN,61.44,BioMarin Pharmaceutical Inc.,Respiratory,"Cardiovascular, Hematology, Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE4,Yes,17,25,"NCT02724228, NCT03424018, NCT03989947, NCT04404530, NCT04476862, NCT04480567, NCT04554940, NCT04684940, NCT04800692, NCT05270837, NCT05579548, NCT05813678, NCT06224907, NCT06280209, NCT06305234, NCT06382155, NCT06455059, NCT06668805, NCT06738017, NCT06780332, NCT07126262",United States,50.76,73.51,4.33,12041831000,11078399000,192300100,189568438,0.003668880219094644,597176000,1560609000,Biotechnology,"BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Respiratory,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
AGYTF,0.11,Allergy Therapeutics plc,Respiratory,"Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Respiratory",PHASE4,Yes,19,19,"NCT05186025, NCT05476497, NCT06031272, NCT06205589, NCT06205602, NCT06856174, NCT07103746, NCT07412990",United Kingdom,0.052,0.11,-,1000048500,1063891100,6332529700,267020796,0.001447716418472931,82476390,17555177.33611508,Drug Manufacturers - Specialty & Generic,"Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom."
TBPH,19.06,"Theravance Biopharma, Inc.",Respiratory,"Neurology/CNS, Respiratory",PHASE4,Yes,6,6,"NCT05696717, NCT07133880",United States,7.9,21.03,4.42,965816500,677702500,50672430,26158733,0.06249226999959969,44595000,329680000,Biotechnology,"Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California."
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Respiratory,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
INSM,148.61,Insmed Incorporated,Respiratory,"Cardiovascular, Dermatology, Respiratory",PHASE3,Yes,3,5,"NCT05649722, NCT05649748, NCT06685835, NCT07179380, NCT07234032",United States,60.4,212.75,4.8,34190842000,33510330000,215551900,194243386,0.006452118253281625,749536000,1430047000,Biotechnology,"Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey."
ARWR,61.615,"Arrowhead Pharmaceuticals, Inc.",Respiratory,"Cardiovascular, Metabolic/Endocrinology, Neurology/CNS, Respiratory, Urology/Nephrology",PHASE3,Yes,17,21,"NCT05089084, NCT05217667, NCT06131983, NCT06138743, NCT06209177, NCT06347003, NCT06347016, NCT06347133, NCT06672445, NCT06700538, NCT06822790, NCT06880770, NCT06937203, NCT07037771, NCT07221344, NCT07223658, NCT07241546",United States,9.57,76.76,4.33,8915849000,8693578000,140032200,105803368,0.03328908874452367,698163000,914710000,Biotechnology,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California."
AKBLF,35.8,ALK-Abelló A/S,Respiratory,"Immunology/Autoimmune, Respiratory",PHASE3,Yes,4,4,"NCT05440643, NCT07013123, NCT07060885",Denmark,19.9,36.1425,-,7507449300,7377901600,221562640,38642330,0.0003883190828785812,65771460,195111512.5233268,Biotechnology,"ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark."
PBH,69.38,Prestige Consumer Healthcare Inc.,Respiratory,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,9,"NCT03390686, NCT05108259, NCT05141149",United States,57.25,90.04,4.57,3255055400,4271972400,47318730,52198761,0.01049667581388105,1079290000,62373000,Drug Manufacturers - Specialty & Generic,"Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York."
YIHCF,0.55,"Sunshine Lake Pharma Co., Ltd.",Respiratory,"Gastroenterology, Hematology, Oncology, Others, Respiratory",PHASE3,Yes,22,23,"NCT04415853, NCT05048368, NCT05133882, NCT05139719, NCT05451602, NCT05586074, NCT07082842, NCT07099118, NCT07102251, NCT07341672, NCT07376200",China,0.55,0.55,-,3182218000,3294738200,576032260,16305667,5.9675478550075e-05,306183700,-,,
LQDA,30,Liquidia Corporation,Respiratory,"Cardiovascular, Respiratory",PHASE3,Yes,3,3,"NCT03992755, NCT06129240, NCT07285655",United States,11.26,46.67,4.37,2920438300,2962124300,86995480,49336935,0.09368697912741056,199182000,157496000,Biotechnology,"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina."
MNKD,3.5,MannKind Corporation,Respiratory,"Metabolic/Endocrinology, Others, Respiratory",PHASE3,No,6,6,"NCT06532942, NCT06535789, NCT07224321, NCT07344558",United States,3.29,6.51,4.88,1701169400,1666565400,307070270,181097310,0.01777247860726711,225431000,260035000,Biotechnology,"MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut."
CLDX,30.82,"Celldex Therapeutics, Inc.",Respiratory,"Dermatology, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Oncology, Oncology/Hematology, Others, Respiratory",PHASE3,Yes,18,28,"NCT03688178, NCT03804944, NCT04930783, NCT05029999, NCT05231122, NCT05349890, NCT06366750, NCT06445023, NCT06455202, NCT06650761, NCT06727552, NCT07256392, NCT07266402, NCT07330778",United States,14.4,31,4.5,1650604800,1070002900,66449470,68469673,0.002753586481797145,2621000,583223000,Biotechnology,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey."
SVRA,5.84,Savara Inc.,Respiratory,"Immunology/Autoimmune, Respiratory",PHASE3,No,2,3,"NCT04544293, NCT06431776",United States,1.89,7.005,4.75,1393588900,1298500900,247090220,120188585,0.02029247851132077,29830000,124918000,Biotechnology,"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania."
GNIIF,15.5,GNI Group Ltd.,Respiratory,"Cardiovascular, Gastroenterology, Immunology/Autoimmune, Respiratory, Urology/Nephrology",PHASE3,Yes,20,25,"NCT05288179, NCT05689645, NCT05704166, NCT05905172, NCT06899815, NCT07262333, NCT07262346, NCT07263152, NCT07295873, NCT07343778, NCT07364448, NCT07388680, NCT07394309, NCT07412236, NCT07417553",Japan,12.02,19.88,-,1027117600,935934400,55671490,4905922,0.030491587740266182,34252916,134719624.079832,Biotechnology,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan."
FDMT,9.92,"4D Molecular Therapeutics, Inc.",Respiratory,"Ophthalmology, Rare/Orphan Diseases, Respiratory",PHASE3,Yes,8,13,"NCT04483440, NCT04517149, NCT04519749, NCT05197270, NCT05248230, NCT05629559, NCT05930561, NCT06864988, NCT07064759",United States,2.235,12.34,4.45,513649280,163684290,51007870,39882063,0.03335125256430374,22263000,305063000,Biotechnology,"4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California."
PRTC,17.54,PureTech Health plc,Respiratory,"Hematology, Respiratory",PHASE3,Yes,7,8,"NCT05321420, NCT05829226, NCT07284602",United States,13.3,20,-,405813340,233739540,241684030,189705572,0.03581391254311962,163574000,331284000,Biotechnology,"PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts."
AKBA,1.21,"Akebia Therapeutics, Inc.",Respiratory,"Hematology, Others, Respiratory, Urology/Nephrology",PHASE3,No,5,7,"NCT06520826, NCT06901505, NCT07086755, NCT07268638, NCT07429006",United States,1.14,4.0787,4.8,329053820,361617820,265366000,125640985,0.0211219415744805,199008000,166444000,Drug Manufacturers - Specialty & Generic,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
ORPOF,-,OSE Immunotherapeutics SA,Respiratory,"Gastroenterology, Oncology, Others, Respiratory",PHASE3,Yes,9,11,"NCT03806309, NCT04713514, NCT05751798, NCT06472245",France,-,-,-,112222850,121470290,22420804,710501,0.2413535999264969,41892624,32667998.12030075,,
IXHL,0.1586,Incannex Healthcare Inc.,Respiratory,Respiratory,PHASE3,Yes,5,5,NCT06146101,Australia,0.156,0.9229,-,98182250,29445246,358329380,15453541,0.12100830373468019,163000,68900000,,
ATYR,1.02,"aTyr Pharma, Inc.",Respiratory,"Immunology/Autoimmune, Respiratory",PHASE3,No,2,2,"NCT05415137, NCT05892614",United States,0.64,7.2904,3.4,96889180,18855184,97986630,54500219,0.025047691708646708,12359000,90202000,Biotechnology,"aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California."
GOSS,0.3801,"Gossamer Bio, Inc.",Respiratory,"Cardiovascular, Respiratory",PHASE3,No,2,3,"NCT04816604, NCT06274801, NCT07181382",United States,0.3312,3.87,3.75,96146930,118798930,231456240,153406014,0.03628875482457814,202876000,180224000,Biotechnology,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California."
APGE,70.89,"Apogee Therapeutics, Inc.",Respiratory,"Dermatology, Respiratory",PHASE2,Yes,3,6,"NCT06395948, NCT06920901, NCT07003425, NCT07027527",United States,26.2,84.56,4.75,4809886700,4230811000,67488240,59986671,0.01941189456261128,9853000,527289000,Biotechnology,"Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts."
BEAM,29.61,Beam Therapeutics Inc.,Respiratory,"Hematology, Metabolic/Endocrinology, Oncology, Others, Respiratory",PHASE2,No,8,8,"NCT05456880, NCT05885464, NCT06389877, NCT06735755, NCT06934382, NCT07304791, NCT07373639",United States,13.525,36.44,4.7,3186798800,2095711900,98693060,95256420,0.01137591112436375,151420000,1245210000,Biotechnology,"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts."
WVE,14.54,Wave Life Sciences Ltd.,Respiratory,"Metabolic/Endocrinology, Musculoskeletal, Rare/Orphan Diseases, Respiratory",PHASE2,No,3,4,"NCT04906460, NCT06405633, NCT06842186, NCT07209332",Singapore,5.28,21.73,4.87,2565614300,2397042400,182996750,128054661,0.030099107859328077,19772000,196218000,Biotechnology,"Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore."
SION,38.03,"Sionna Therapeutics, Inc.",Respiratory,"Rare/Orphan Diseases, Respiratory",PHASE2,No,8,8,"NCT07035990, NCT07108153",United States,7.255,45,4.55,1665546400,1349514400,44628788,17447642,0.01316482765410611,8968000,248329000,Biotechnology,"Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts."
AGMB,16.11,AgomAb Therapeutics NV,Respiratory,"Gastroenterology, Respiratory",PHASE2,No,2,2,"NCT05843578, NCT06181370",Belgium,12.66,16.65,-,779301100,980431000,48736780,7871872,0.0009277798190151219,1557877.4,152130781.8736793,Biotechnology,"AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium."
CTNM,15.78,"Contineum Therapeutics, Inc.",Respiratory,"Pain/Analgesia, Respiratory",PHASE2,No,3,3,"NCT06810245, NCT07284459",United States,3.35,16.33,4.57,581914100,405000130,36529450,20804204,0.0087932615682213,5493000,182407000,Biotechnology,"Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California."
UPB,7.74,"Upstream Bio, Inc.",Respiratory,Respiratory,PHASE2,No,2,3,"NCT06196879, NCT06966479, NCT06981078",United States,5.14,33.68,4.75,427985630,56977640,54038590,39326379,0.0007403521761455895,1419000,372427000,Biotechnology,"Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts."
ARCT,8.3,Arcturus Therapeutics Holdings Inc.,Respiratory,"Hematology, Metabolic/Endocrinology, Rare/Orphan Diseases, Respiratory",PHASE2,No,4,4,"NCT06488313, NCT06747858, NCT07390968",United States,5.85,24.17,4.33,232428800,78055800,28414280,21994708,0.07529298913408994,25987000,180360000,Biotechnology,"Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California."
CNTB,2.59,Connect Biopharma Holdings Limited,Respiratory,"Neurology/CNS, Respiratory",PHASE2,Yes,2,3,"NCT04937062, NCT06940141, NCT06940154",United States,0.51,3.28,5,136963600,82963610,55903510,7037949,0.2045582895658096,781000,54781000,Biotechnology,"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California."
KRRO,12.14,"Korro Bio, Inc.",Respiratory,Respiratory,PHASE2,No,1,1,NCT06677307,United States,5.2044,55.89,4.22,112348330,54523330,9417295,5122310,0.061577342538382845,44668000,92479000,Biotechnology,"Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts."
RNTX,1.23,Rein Therapeutics Inc.,Respiratory,Respiratory,PHASE2,No,1,1,NCT06968845,United States,1.02,2.4999,4,32857976,73814980,26286382,5112567,0.004887778013725891,-,4048000,Biotechnology,"Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas."
TRVI,11.36,"Trevi Therapeutics, Inc.",Respiratory,Respiratory,PHASE1,No,1,1,NCT07036029,United States,4.17,14.39,4.81,1446436000,1252331900,128230136,107804351,0.0074630715687488865,823000,194927000,Biotechnology,"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut."
UCBJY,310.6125,UCB SA,Rheumatology,"Dermatology, Immunology/Autoimmune, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Rheumatology",PHASE4,Yes,28,41,"NCT03845712, NCT04009499, NCT04123795, NCT04225871, NCT04436640, NCT04658199, NCT04666610, NCT04715646, NCT04901195, NCT05063162, NCT05064878, NCT05077904, NCT06055959, NCT06118255, NCT06149559, NCT06315322, NCT06336343, NCT06380816, NCT06425549, NCT06506916, NCT06598449, NCT06617325, NCT06624228, NCT06668181, NCT06754098, NCT06888193, NCT06921850, NCT06961747, NCT06970301, NCT07215949, NCT07219420, NCT07246564, NCT07277660, NCT07286682, NCT07290036",Belgium,150.7,345.39,-,60617093000,62109260000,189996210,60756375,0,3389870300,1897526501.766784,Biotechnology,"UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium."
PLNH,0.177265,Planet 13 Holdings Inc.,Unclassified,Unclassified,,Yes,1,1,NCT05642715,United States,0.148,0.5,2,59871196,102214610,328170780,607380,0.2848949710632084,58838370,17181080,Drug Manufacturers - Specialty & Generic,"Planet 13 Holdings Inc., together with its subsidiaries, cultivates and provides cannabis and cannabis-infused products for medical and retail cannabis markets in the United States. It owns, manufactures, and sells cannabis products in the form of gummies and beverages, chocolates, vapes and concentrates, and flowers under the TRENDI, Leaf and Vine, Dreamland, HaHa, and Medizin brand names. The company also owns and operates lounge and cannabis dispensaries; and non-cannabis retail merchandise store and event space, as well as Trece Eatery + Spirits, a coffee shop and pizzeria restaurant. In addition, it provides consultation, education, and convenience services. The company is headquartered in Las Vegas, Nevada."
NVO,38.16,Novo Nordisk A/S,Urology/Nephrology,"Cardiovascular, Gastroenterology, Hematology, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,100,177,"NCT01239550, NCT03496883, NCT03811561, NCT03878446, NCT04042402, NCT04082429, NCT04083781, NCT04121780, NCT04580420, NCT04624659, NCT04639414, NCT04775082, NCT04777396, NCT04777409, NCT04822181, NCT04873050, NCT05021835, NCT05135559, NCT05330325, NCT05350592, NCT05424003, NCT05441267, NCT05567796, NCT05621746, NCT05636176, NCT05669755, NCT05685238, NCT05689372, NCT05714683, NCT05723835, NCT05725902, NCT05726227, NCT05780905, NCT05953584, NCT06018467, NCT06118281, NCT06198712, NCT06200207, NCT06221969, NCT06260709, NCT06269120, NCT06388187, NCT06403761, NCT06411210, NCT06449625, NCT06504368, NCT06534411, NCT06571383, NCT06574984, NCT06577766, NCT06609226, NCT06612268, NCT06649630, NCT06685185, NCT06717698, NCT06718998, NCT06719011, NCT06780449, NCT06789900, NCT06797869, NCT06807190, NCT06859073, NCT06891365, NCT06977438, NCT06979362, NCT06979375, NCT07004322, NCT07010432, NCT07011667, NCT07035769, NCT07068295, NCT07076199, NCT07087795, NCT07112339, NCT07153172, NCT07157423, NCT07160816, NCT07184086, NCT07184632, NCT07207811, NCT07214870, NCT07218627, NCT07220564, NCT07220642, NCT07220759, NCT07225816, NCT07227246, NCT07238816, NCT07253285, NCT07270731, NCT07271251, NCT07276282, NCT07282613, NCT07301034, NCT07302802, NCT07305805, NCT07339423, NCT07357740, NCT07357766, NCT07379684, NCT07395687, NCT07400107, NCT07405229, NCT07411560, NCT07415954",Denmark,37.65,91.9,3.84,170679730000,187069550000,4444860400,1267076844,0.00023698180648359162,20605979000,4242416613.430595,Drug Manufacturers - General,"Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark."
CSLLY,51.79,CSL Limited,Urology/Nephrology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Neurology/CNS, Others, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,20,20,"NCT03684018, NCT03805789, NCT04672733, NCT05485155, NCT05485961, NCT05727384, NCT06008938, NCT06399289, NCT06617897, NCT06699849, NCT06738485, NCT06806657, NCT07048262, NCT07076446, NCT07094087, NCT07224360, NCT07326592, NCT07332091",Australia,50.85,89.71,3,49307427000,61792820000,481614530,179904105,0.0006447521302923125,11138000000,1145000000,Biotechnology,"CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia."
UTHR,535.1,United Therapeutics Corporation,Urology/Nephrology,"Cardiovascular, Hematology, Metabolic/Endocrinology, Neurology/CNS, Oncology, Others, Psychiatry, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,49,52,"NCT02573896, NCT03045029, NCT03804944, NCT04005469, NCT05203510, NCT05231122, NCT05245006, NCT05421897, NCT05848687, NCT05943535, NCT06059118, NCT06335407, NCT06374459, NCT06450041, NCT06580444, NCT06814717, NCT06878560, NCT06964009, NCT07037836, NCT07116681, NCT07224763, NCT07261241, NCT07391215",United States,266.98,537.19,4.35,20384285000,16049385000,43056600,39991728,0.01761143424743304,-,2920300000,Drug Manufacturers - Specialty & Generic,"United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland."
TVTX,29.34,"Travere Therapeutics, Inc.",Urology/Nephrology,"Immunology/Autoimmune, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,7,13,"NCT03406611, NCT03493685, NCT03762850, NCT04663204, NCT05003986, NCT05630612, NCT06247085, NCT07219121, NCT07224776",United States,12.91,42.13,4.66,2848419000,2854356000,92241550,104986700,0.009636140446103184,328733000,322796000,Biotechnology,"Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California."
CHIZF,0.2734,China Traditional Chinese Medicine Holdings Co. Limited,Urology/Nephrology,"Cardiovascular, Gastroenterology, Hematology, Immunology/Autoimmune, Infectious Diseases, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Oncology, Oncology/Hematology, Others, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE4,Yes,57,57,"NCT04370925, NCT05540938, NCT05709249, NCT05834413, NCT05914272, NCT05937178, NCT06093932, NCT06375824, NCT06514339, NCT06647940, NCT06709885, NCT06713421, NCT06743867, NCT06770296, NCT06874738, NCT06890143, NCT06898723, NCT07003191, NCT07020429, NCT07034326, NCT07099157, NCT07115641, NCT07153744, NCT07162870, NCT07295938, NCT07296614, NCT07309705, NCT07321535, NCT07338396, NCT07353749, NCT07360002, NCT07361783",Hong Kong,0.2399,0.3454,-,1325971600,1481892700,5035801600,1374483333,0.0,502164740,722156646.519354,Drug Manufacturers - Specialty & Generic,"China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong."
HITI,2.57,High Tide Inc.,Urology/Nephrology,"Gastroenterology, Neurology/CNS, Pain/Analgesia, Urology/Nephrology",PHASE4,Yes,9,10,"NCT04793932, NCT05226117, NCT05487417, NCT06222645, NCT06845306, NCT07412522, NCT07420712",Canada,1.64,4.0554,5,224996690,281240480,87839736,11283642,0.08707990751565906,78315210,34185590.53153186,Pharmaceutical Retailers,"High Tide Inc. engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Bricks and Mortar, E-commerce, and Medical Cannabis Distribution segments. It manufactures and distributes consumption accessories; cannabis; and hemp derived products. The company also engages in data analytics; advertising; product sourcing and imports; event-based cannabis retail; medical cannabis distribution; accessories retail; and other related services. It provides its products under the Daily High Club, DankStop, FAB CBD, GC, Nuleaf Naturals, Smoke Cartel, Blessed CBD, Fastendr, Famous Brandz, Queen of Bud, Canna Cabana, Grasscity, Daily High Club, and Valiant Distribution brands. The company sells its products through a network of retail stores, e-commerce platforms, and the wholesale distribution arm. The company was formerly known as High Tide Ventures Inc. and changed its name to High Tide Inc. in October 2018. The company was founded in 2009 and is headquartered in Calgary, Canada."
ILPLF,-,Island Pharmaceuticals Limited,Urology/Nephrology,"Cardiovascular, Dermatology, Gastroenterology, Hematology, Infectious Diseases, Musculoskeletal, Neurology/CNS, Oncology, Others, Pain/Analgesia, Psychiatry, Rare/Orphan Diseases, Urology/Nephrology",PHASE4,Yes,41,43,"NCT02656706, NCT03355976, NCT03374332, NCT03936361, NCT04005469, NCT04205916, NCT04253262, NCT04828083, NCT05347238, NCT05462704, NCT05625373, NCT05806164, NCT05990881, NCT06135636, NCT06316830, NCT06332781, NCT06439953, NCT06885996, NCT06931158, NCT06943404, NCT06953271, NCT06969326, NCT06974604, NCT06998069, NCT07222852, NCT07316166",Australia,-,-,-,73884184,68763860,294766700,13604034,0.40500044031435,-,4583643.157403083,,
ETST,0.11,"Earth Science Tech, Inc.",Urology/Nephrology,Urology/Nephrology,PHASE4,Yes,1,1,NCT05722925,United States,0.001,0.237,-,34067500,32723602,291324600,-,0.6800219934734177,178874,1599637,Drug Manufacturers - Specialty & Generic,"Earth Science Tech, Inc., together with its subsidies, focuses on health and wellness industry. It engages in compounding pharmaceuticals, telemedicine, and real estate development activities. The company also operates Peaks, a telemedicine referral platform focused on health and wellness for men and women; and pharmacies under the RxCompound and Mister Meds name. In addition, it is involved in the development and management of real estate assets. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida."
VRTX,483.05,Vertex Pharmaceuticals Incorporated,Urology/Nephrology,"Gastroenterology, Hematology, Immunology/Autoimmune, Metabolic/Endocrinology, Musculoskeletal, Neurology/CNS, Pain/Analgesia, Rare/Orphan Diseases, Respiratory, Urology/Nephrology",PHASE3,Yes,35,50,"NCT04786262, NCT05153317, NCT05312879, NCT05329649, NCT05331183, NCT05356195, NCT05422222, NCT05444257, NCT05477563, NCT05668741, NCT05791201, NCT05951205, NCT06154447, NCT06185764, NCT06460506, NCT06619860, NCT06628908, NCT06696443, NCT06794996, NCT06832410, NCT07022119, NCT07074327, NCT07161037, NCT07204275, NCT07231419, NCT07283770, NCT07349394, NCT07378865",United States,362.5,519.68,4.34,123823880000,113539480000,254034190,240867224,0.0020613406408011457,2036000000,6608100000,Biotechnology,"Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."
ARWR,61.615,"Arrowhead Pharmaceuticals, Inc.",Urology/Nephrology,"Cardiovascular, Metabolic/Endocrinology, Neurology/CNS, Respiratory, Urology/Nephrology",PHASE3,Yes,17,21,"NCT05089084, NCT05217667, NCT06131983, NCT06138743, NCT06209177, NCT06347003, NCT06347016, NCT06347133, NCT06672445, NCT06700538, NCT06822790, NCT06880770, NCT06937203, NCT07037771, NCT07221344, NCT07223658, NCT07241546",United States,9.57,76.76,4.33,8915849000,8693578000,140032200,105803368,0.03328908874452367,698163000,914710000,Biotechnology,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California."
CLBPF,-,"Caliway Biopharmaceuticals Co., Ltd.",Urology/Nephrology,"Pain/Analgesia, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,3,3,"NCT06303570, NCT07140939",Taiwan,-,-,-,8071872500,7864480000,1549997000,110195912,0.243680529704251,171713.53,213790033.1353958,,
ZLDPF,57.08,Zealand Pharma A/S,Urology/Nephrology,"Gastroenterology, Metabolic/Endocrinology, Oncology, Others, Urology/Nephrology",PHASE3,Yes,10,14,"NCT02446405, NCT03905707, NCT03941236, NCT04419402, NCT04881825, NCT05788601, NCT06662539, NCT06682975, NCT06926842, NCT07197944, NCT07338214",Denmark,49.98,101.2925,-,4063842000,1746636300,70607140,26243554,0.003573958667636162,63846624,2377340630.084307,Biotechnology,"Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark."
VERA,41.68,"Vera Therapeutics, Inc.",Urology/Nephrology,"Hematology, Urology/Nephrology",PHASE3,No,1,3,"NCT04716231, NCT06983028, NCT07020923",United States,18.53,56.05,4.64,3007714600,2587541500,70986890,64499175,0.007698153402152939,77216000,497389000,Biotechnology,"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California."
APLS,21.42,"Apellis Pharmaceuticals, Inc.",Urology/Nephrology,"Hematology, Ophthalmology, Urology/Nephrology",PHASE3,No,4,9,"NCT03531255, NCT04572854, NCT04901936, NCT05809531, NCT06161584, NCT07020832, NCT07213960, NCT07215390",United States,16.1,30.48,4.04,2800003000,2808130000,126525220,107419884,0.02693274909537906,474360000,467786000,Biotechnology,"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts."
GNIIF,15.5,GNI Group Ltd.,Urology/Nephrology,"Cardiovascular, Gastroenterology, Immunology/Autoimmune, Respiratory, Urology/Nephrology",PHASE3,Yes,20,25,"NCT05288179, NCT05689645, NCT05704166, NCT05905172, NCT06899815, NCT07262333, NCT07262346, NCT07263152, NCT07295873, NCT07343778, NCT07364448, NCT07388680, NCT07394309, NCT07412236, NCT07417553",Japan,12.02,19.88,-,1027117600,935934400,55671490,4905922,0.030491587740266182,34252916,134719624.079832,Biotechnology,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan."
PROK,2.26,ProKidney Corp.,Urology/Nephrology,"Metabolic/Endocrinology, Urology/Nephrology",PHASE3,No,1,2,"NCT05099770, NCT05918523",United States,0.4603,7.13,4,673869000,1375930800,141545440,30598687,0.1780790930132914,4236000,271725000,Biotechnology,"ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina."
HNSBF,2.9,Hansa Biopharma AB (publ),Urology/Nephrology,"Immunology/Autoimmune, Others, Rare/Orphan Diseases, Urology/Nephrology",PHASE3,Yes,6,9,"NCT05369975, NCT05679401, NCT05714514, NCT05753930, NCT05937750, NCT06518005",Sweden,2.73,4.58,-,364459870,390170000,101763224,20913165,0.06214520212420161,101428310,76149548.26180178,Biotechnology,"Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden."
AKBA,1.21,"Akebia Therapeutics, Inc.",Urology/Nephrology,"Hematology, Others, Respiratory, Urology/Nephrology",PHASE3,No,5,7,"NCT06520826, NCT06901505, NCT07086755, NCT07268638, NCT07429006",United States,1.14,4.0787,4.8,329053820,361617820,265366000,125640985,0.0211219415744805,199008000,166444000,Drug Manufacturers - Specialty & Generic,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts."
HUMA,1.16,"Humacyte, Inc.",Urology/Nephrology,"Cardiovascular, Urology/Nephrology",PHASE3,No,2,2,"NCT03005418, NCT05908084",United States,0.88,3.94,4.57,216156100,247639090,192996510,56679688,0.0490037822497216,50971000,19488000,Biotechnology,"Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina."
MAZE,47.23,"Maze Therapeutics, Inc.",Urology/Nephrology,Urology/Nephrology,PHASE2,No,1,1,NCT06830629,United States,6.71,49.25,4.9,2179810800,1820058800,48119444,30437208,0.01215643749222486,24183000,383935000,Biotechnology,"Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California."
OMER,11.38,Omeros Corporation,Urology/Nephrology,"Hematology, Urology/Nephrology",PHASE2,No,2,3,"NCT05855083, NCT06209736, NCT06298955",United States,2.95,17.65,4,818900300,1146254300,70900456,33206323,0.03765682250378661,363439000,36085000,Biotechnology,"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington."
CLYM,7.09,"Climb Bio, Inc.",Urology/Nephrology,"Hematology, Immunology/Autoimmune, Others, Urology/Nephrology",PHASE2,No,3,5,"NCT07011043, NCT07043946, NCT07090655, NCT07096843, NCT07248865",United States,1.05,7.09,4.87,303654600,128403610,47744436,17264769,0.01580150650018164,580000,86901000,Biotechnology,"Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts."
ELDN,2.47,"Eledon Pharmaceuticals, Inc.",Urology/Nephrology,"Immunology/Autoimmune, Urology/Nephrology",PHASE2,Yes,5,5,"NCT05027906, NCT06972069",United States,1.35,4.6,5,194413700,101734700,79352530,41048976,0.0005762260995024078,722000,93401000,Biotechnology,"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California."
TNXP,14.84,Tonix Pharmaceuticals Holding Corp.,Urology/Nephrology,"Metabolic/Endocrinology, Others, Psychiatry, Urology/Nephrology",PHASE2,Yes,4,4,"NCT04789148, NCT06636786, NCT07204080, NCT07413367",United States,6.76,69.97,5,182825570,-6804426,12793952,3780812,0.0004202767057434638,425000,190055000,Biotechnology,"Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is used for the treatment of fibromyalgia. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey."
SGMO,0.47,"Sangamo Therapeutics, Inc.",Urology/Nephrology,Urology/Nephrology,PHASE2,No,6,6,"NCT04628871, NCT04817774, NCT05145062",United States,0.345,1.06,4,175621060,171429060,371684770,62580623,0.011065736910008159,25424000,29616000,Biotechnology,"Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California."
CPHGF,1.65,Consun Pharmaceutical Group Limited,Urology/Nephrology,Urology/Nephrology,PHASE1,No,2,2,"NCT07021157, NCT07267026",China,1.0434,2,-,1980811100,1492322200,841308100,153620186,0.4051981082112734,35364256,563564259.6909505,Drug Manufacturers - Specialty & Generic,"Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, an irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology medicines, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China."
